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ABSTRACT  25 
Mycoplasma bovis is the most pathogenic bovine mycoplasma in Europe and North America. It 26 
forms an important component in the bovine respiratory disease (BRD) complex, a multifactorial 27 
disease of feedlot cattle that causes major economic loss. Naturally occurring M. bovis persist in a 28 
herd over an extended period and can be consistently identified not only in lesions but also 29 
commonly in healthy lungs and those with pneumonia indicating that M. bovis is capable of 30 
persisting in lungs of recovered animals. This suggests that M. bovis can modulate alveolar 31 
macrophage effector functions, although the mechanisms employed by M. bovis are not well 32 
understood. In this thesis, I determined how M. bovis modulates bovine alveolar macrophage 33 
(BAM) effector functions. I used primary alveolar macrophages infected with M. bovis Mb1 to 34 
demonstrate that the production of nitric oxide and cytokines was impaired. I observed a 35 
reduction in the production of nitric oxide but not a decrease in gene transcription of iNOS; and 36 
no stimulation of the pro-inflammatory cytokine TNF-α coupled with an increase of IL-10 37 
expression in infected BAMs. These results suggest modulation of the immune response by M. 38 
bovis. To better understand other strategies of immune suppression by M. bovis to evade the host 39 
immune responses, I focused on the ability of M. bovis to modulate macrophage apoptosis during 40 
infection. Previously, studies on M. bovis infection have reported it to exert both pro- and anti- 41 
apoptotic effects on a diversity of cell types, including neutrophils, lymphocytes, monocytes and 42 
macrophages. In this thesis, I sought to understand the mechanism of inhibition of apoptosis 43 
using a BoMac bovine macrophage cell line to identify the apoptosis pathways modulated by M. 44 
bovis infection. The results indicate that M. bovis strain Mb1 is able to delay STS-induced 45 
apoptosis in BoMac cells, activate the NF-kβ pathway and induce up-regulation of the pro- 46 
survival genes Bcl-2 and Bcl-XL. Additionally, upon infection M. bovis inhibits the activity of 47 
caspases 3, 6, and 9, reduces ROS production and inhibits DNA fragmentation. These results 48 
support the observation that M. bovis inhibit apoptosis for survival and potentially facilitate 49 
bacterial survival, replication and transmission. 50 
The results presented in this thesis taken together detail how M. bovis modulates the macrophages 51 
effector functions and apoptosis to survive within the bovine host. The studies also improve the 52 
understanding of factors that contribute to virulence; dissemination and immune evasion of a 53 
pathogen is critical knowledge to contemplating new vaccines and therapeutics. 54 
55 
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CHAPTER 1. Introduction and literature review 
1.1. Mycoplasmas 
Classification 
Mycoplasma bacteria belong to the class Mollicutes in the phylum Firmicutes consisting of the 
genus Mycoplasma, Phytoplasma and Ureaplasma. Phylogenetic analysis of 16S RNA 
oligonucleotide sequences indicates that the Mollicutes evolved by reductive evolution from 
Gram-positive eubacteria, as reflected by their low genetic guanine-plus-cytosine content (G+C) 
content of 23-40 mol% (Woese et al., 1980). 
Structure 
Mycoplasmas are the simplest smallest independently replicating bacteria. They are minimalist 
cells with a few ribosomes, soluble proteins, a plasma membrane and a double-stranded circular 
deoxyribonucleic acid (Dudek et al.) molecule. Some mycoplasmas have capsules that are 
essential for survival (Razin et al., 1998). Mycoplasmas lack a cell wall and their plasma 
membrane is composed of membrane proteins, phospholipids, lipoproteins, glycolipids and 
lipoglycans. The lack of a cell wall confers unique characteristics: Staining with the Gram stain is 
not effective, and they are resistant to antibiotics that target the peptidoglycan synthesis such as 
beta-lactams. Moreover, they are also intrinsically resistant to Rifampin, an antimicrobial that 
targets ribonucleic acid (RNA) synthesis (Razin and Hayflick, 2010). 
Mycoplasmas encode surface exposed lipoproteins that are good antigenic determinants and this 
property is explored for diagnostics of infections. Mycoplasmas are pleomorphic as they can 
change their shapes due to lack of an internal cytoskeleton. The majority are circular in nature 
with a diameter of about 0.2 to 0.8µm, while others are pear-shaped, flask-shaped or rod-like, 
occurring in coccus and filamentous forms (Razin and Hayflick, 2010). The small sizes of 
mycoplasmas allow them to pass through 0.45µm sterilization filters making it a nuisance 
laboratory contaminant of cell cultures. 
Most mycoplasmas are non-motile and have no flagella. However, some of the flask-shaped 
mycoplasma species, including the human and animal pathogens (M. pneumoniae, M. genitalium, 
M. gallisepticum, M. pulmonis, and M. mobile) glide on liquid-covered surfaces without the aid 
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of extracellular structures (Jaffe et al., 2004; Pich et al., 2006). Due to lack of locomotive 
structures and a cell wall, it is reasonable to conclude that the cell membrane is involved in 
attachment and gliding. The gliding mechanism is always toward the terminal organelle head-like 
protrusions with the involvement of adhesin proteins. In M. pneumoniae, the protein P1 (Feldner 
et al., 1982), GapA of M. gallisepticum (Goh et al., 1998), MgPa of M. genitalium (Inamine et al., 
1989), and Gli349 of M. mobile (Uenoyama et al., 2004) are involved in gliding. 
Habitat 
As reviewed by Pitcher et al., mycoplasmas cause disease in plants, human, and animals. In 
animals, they have been isolated from mammals, birds, reptiles, amphibians, and fish revealing 
unique species (Pitcher and Nicholas, 2005). 
Multiplication and cell invasion 
Mycoplasmas possess a circular chromosome ranging in size between 0.58 to 2.20Mb. Due to 
their small genomes, they lack essential genes for biosynthesis of numerous compounds and rely 
on the host biosynthetic activity and metabolism for survival (Rottem, 2003). The lack of certain 
metabolic genes and reliance on host nutrients also makes them fastidious organisms that are 
difficult to cultivate in a laboratory setting and grow very slowly. Mycoplasma culture medium 
must contain serum to provide sterols and cholesterol for plasma membrane synthesis (Dahl, 
1993). Mycoplasmas also use the universal stop codon, UGA as a tryptophan codon (Razin et al., 
1998). In general, the presence of the UGA codon in mycoplasma genes hinders expression of 
proteins in commonly used Escherichia coli expression systems leading to premature truncation 
of the target proteins. 
Some mycoplasmas invade cells using adhesins. These are mostly surface proteins that facilitate 
adhesion and have an effect on invasion (Razin and Jacobs, 1992; Rottem, 2003; Sachse et al., 
1996). They enter the cell through a site-receptor mediated event or phagocytized. The complex 
interaction between mycoplasmas and the host immune system induces both pathogen-specific 
and non-specific immune responses. Their ability to display antigenic variation and host immune 
system antibody modulation contribute to disease pathogenesis and avoidance of clearance by the 
host (Razin and Jacobs, 1992). 
  3 
Other virulence factors involved include competition for and depletion of nutrients in host cells. 
Some mycoplasma species hydrolyse arginine to citrulline as a major energy source depriving the 
host cell of an essential amino acid for host maintenance and a substrate for NOS for 
antimicrobial function. Infection of host cells by mycoplasmas also leads to stimulation of pro-
inflammatory cytokines, cytotoxicity and activation of immune cells through secretion of toxins, 
and surface antigens contribute to the disease pathogenesis (Rottem, 2003). 
As reviewed by Christodoulides et al., mycoplasma surface lipoproteins play a role in in the 
immune modulation of the host (Christodoulides et al., 2018). In M. fermentans, the MALP 
(Macrophage-activating lipopeptide) lipoprotein elicited a strong inflammatory response in 
macrophages through the activation of toll like receptors, TLR-2 and 6 (Muhlradt and Frisch, 
1994; Muhlradt et al., 1997). The production of Community-Acquired Respiratory Distress 
Syndrome (CARDS) toxin an ADP-ribosylating and vacuolating protein by M. pneumoniae and 
M. penetrans cause severe cytopathology in mammalian cells (Johnson et al., 2009; Kannan and 
Baseman, 2006). Other virulence factors described include hemolysins (Kannan and Baseman, 
2000; Somerson et al., 1965) and endonucleases (Bendjennat et al., 1997). 
Human mycoplasmas 
Human mycoplasmas cause a variety of diseases and are mostly opportunistic pathogens. The 
most common pathogen is M. pneumoniae that causes atypical pneumonia and tracheobronchitis 
a disease of the upper respiratory tract (Cassell et al., 1987). In contrast, Ureaplasma spp., M. 
genitalium, M. hominis, and M. penetrans are sexually transmitted mycoplasmas that cause pelvic 
inflammatory disease, pyelonephritis, and nongonococcal urethritis often, though not always, in 
immune compromised patients infected with human immunodeficiency virus (Blanchard and 
Montagnier, 1994; Cassell et al., 1987). Other mycoplasmas that are found in the mouth and 
throat as normal flora include M. orale, M. salivarium, and M. buccale. 
Animal mycoplasmas  
The range of animal hosts that are infected by mycoplasmas vary from domesticated animals, 
wildlife, birds, and fish (Nicolet, 1996). It has long been appreciated that most Mycoplasma spp. 
exhibit extreme host specificity except for a few documented cases of crossover between related 
host such as ruminants (Pitcher and Nicholas, 2005). In animals, mycoplasmas are mostly found 
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as commensals on the mucous membrane of the respiratory tract, gastro intestinal tract (GIT), 
urinary tract (UT), joint surfaces, and in bovine mammary glands. They are mostly opportunistic 
pathogens that cause infections and diseases in immune-compromised host (Razin et al., 1998). 
The majority of the pathogenic mycoplasmas in livestock cause chronic diseases with high 
morbidity causing massive losses in the food production industry as summarised in the table 1.1 
below. 
 
Table 1. 1: Selected mycoplasma species of veterinary importance. 
Host 
Organism Disease Reference 
Cattle 
M. mycoides subsp. 
mycoides (Mmm) 
CBPP (contagious 
bovine 
pleuropneumonia) 
(Cottew and Yeats, 
1978) 
M. bovis 
Polyarthritis, mastitis, 
abortion, sterility, 
pneumonia, 
kerotoconjunctivitis, 
(Pfutzner, 1990) 
M. dispar Pneumonia 
(Gourlay and 
Leach, 1970) 
M. leachii Arthritis, mastitis 
(Manso-Silvan et 
al., 2009) 
Bison M. bovis 
Pneumonia, abortions, 
necrotic pharyngitis 
(Dyer et al., 2008) 
Sheep 
M. agalactiae 
Contagious agalactia 
 
(Manso-Silvan et 
al., 2012) 
M. ovipneumoniae Pneumonia (Alley et al., 1975) 
Goat 
M. capricolum subsp. 
capripneumoniae 
Contagious caprine 
pleuropneumonia 
(Thiaucourt and 
Bolske, 1996) 
M. mycoides subsp. 
capri (Mmc) 
Contagious 
agalactiae/pneumonia 
(Manso-Silvan et 
al., 2009) 
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M. capricolum subsp. 
capricolum 
Contagious 
agalactiae/pneumonia 
(Thiaucourt and 
Bolske, 1996) 
Swine 
M. hyopneumoniae 
Porcine enzootic 
pneumonia 
(Vasconcelos et al., 
2005) 
M. suis Hemolytic anemia (Ross, 1973) 
M. hyorhinis Pneumonia, arthritis (Ross, 1973) 
Poultry 
M. synoviae 
Pneumonia 
Synovitis 
(Vasconcelos et al., 
2005) 
M. gallisepticum 
Chronic Respiratory 
disease 
(Ley et al., 1993) 
 
Table compiled by the author.  
1.2 Mycoplasma bovis 
The genome size of M. bovis is approximately 948 kbp (Li et al., 2011) to 1,038 kbp (GenBank: 
LT578453.1), and has a G+C ratio of 27.29% (Chen et al., 2017; Razin et al., 1998). Mycoplasma 
bovis is an important pathogen that causes various diseases in animals that include pneumonia 
(Caswell and Archambault, 2007; Gagea et al., 2006a), mastitis (Jasper et al., 1987), arthritis 
(Gagea et al., 2006a; Kumar et al., 2011), infertility (Hermeyer et al., 2012b), and 
keratoconjunctivitis (Alberti et al., 2006). It is also becoming clear that M. bovis is a key player in 
the BRD complex worldwide (Caswell et al., 2010; Maunsell and Donovan, 2009; Nicholas et al., 
2008). M. bovis is considered the most pathogenic bovine mycoplasma in Europe and North 
America (Nicholas, 2011), and if not treated early enough, M. bovis infection might be fatal 
especially in calves that have a weak immune system. Even further, the pathogen is known to 
affect the productivity of beef cattle with the challenges being prevalent in various parts of the 
world (Kumar et al., 2011; Nicholas, 2011). Notably, the infection is also hard to identify due to 
lack of consistent manifestation of the disease, which can require specific diagnosis approaches 
to determine, which might impact farmers, particularly those with large herds. 
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Epidemiology 
M. bovis can be introduced into beef herds after co-mingling of asymptomatic infected animals 
into the herd (Nicholas and Ayling, 2003). Bovine mycoplasmosis is prevalent in most parts of 
the world. In the feedlot industry M. bovis is estimated to cost across Europe €144 million per 
year (Nicholas and Ayling, 2003), and in the US $32 million per year in feedlot cattle and $108 
million per year in dairy cattle due to mastitis (Maunsell et al., 2011). M. bovis occurs both as 
normal flora and opportunistic pathogen in cattle (Maunsell et al., 2011). In Ontario, Allen et al. 
examined broncho-alveolar lavage fluid (BAL) samples and reported 48% recovery of M. bovis 
in the control group (calves that started the study with a clinical score of zero) with no BRD and 
60% of recovery in BRD cases on day one at the research facility and after 12 days, they 
observed that a high proportion of feedlot calves were exposed to M. bovis with 80% recovery 
from the control group (calves that started with a clinical score zero) and 100% from the BRD 
cases (Allen et al., 1991). In another study in 3 Canadian feedlots, 28% of the necropsied cattle 
had CPPS (chronic pneumonia and polyarthritis syndrome), a disease mainly attributed to M. 
bovis (Maunsell et al., 2011). In North American bison, M. bovis was reported to cause up to 45% 
morbidity and case mortality (Sweeney et al., 2013). In addition, cases of pneumonia (Dyer et al., 
2008), abortions (Register et al., 2013) and necrotic pharyngitis (Dyer et al., 2013) have been 
recently described caused by M. bovis in bison. The pathogen is known to colonize its hosts and 
can survive without the host expressing any symptoms making observation of sickness a 
challenge (Nicholas and Ayling, 2003; Pfutzner, 1990). Infected animals shed the pathogen via 
the nasal secretions, nose-to-nose contact (Maunsell et al., 2011); contaminated milk (Aebi et al., 
2012), and infected semen (Pfutzner, 1990). Moreover, M. bovis is spread from farm to farm 
through borrowing of bulls, poor boundary fence, shared grazing or housing, which indicates the 
prevalence rates are high and tends to increase during transportation of animals from one region 
to the other, thus leading to high infection rates (Castillo-Alcala et al., 2012; Nicholas and 
Ayling, 2003; Timsit et al., 2012). 
Pathogenesis and virulence 
Some mycoplasma biological characteristics are of great importance in their clinical role in the 
disease. A small genome means that mycoplasmas relay on the host for its metabolic requirement 
sand the lack of a cell wall makes them resistant to beta-lactam antimicrobials (Caswell et al., 
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2010). The respiratory tract and the mammary glands are the most affected parts that result in 
shedding and persistence of M. bovis. Clinical studies of BRD show that naturally and 
experimentally infected calves had pulmonary lesions with characteristic coagulative necrosis 
(Thomas et al., 1986) surrounded by inflammatory cells such as macrophages and neutrophils 
(Rodriguez et al., 1996). The lesions found in the lungs are bilateral and involve 20-90% of the 
lung with characteristic multiple round foci of caseous necrosis. The affected lungs are deep red 
and consolidated (Caswell et al., 2010). Once transmitted, entry into the body leads to 
colonization that lead to disease progression if left untreated. We still have a limited 
understanding of the M. bovis virulence factors and the mechanisms of pathogenicity as disease 
development often is due to synergism to co-infection with other pathogens. For a long time, 
limited research techniques and lack of genetic tools hindered host-pathogen interaction studies. 
Tools such as random transposon mutagenesis have been used recently to create M. bovis mutants 
(Sharma et al., 2014) and this will allow future studies of host-pathogen interactions. A number 
of pathogenic mechanisms of M. bovis have been identified that have an effect on the infected 
host. 
Variable surface proteins 
Due to lack of a cell wall, lipoproteins are readily exposed on the mycoplasma membrane and act 
as key antigens (Behrens et al., 1994; Lysnyansky et al., 1996). As argued by Behrens et al., 
mycoplasmas posses cell surface lipoproteins that play a key role in inducing pro-inflammatory 
cytokines and, hence contributing to the disease pathogenesis (Behrens et al., 1994). Like other 
mycoplasma species (Razin et al., 1998) size variation and phase variation (ON-OFF) of surface 
lipoproteins occur in M. bovis. Variable surface proteins (Vsps) found on the cell surface are 
subject to modification, presenting different antigenic mosaic repertoires due to high-frequency 
DNA-rearrangement in a population (Lysnyansky et al., 1996; Lysnyansky et al., 1999; Sachse et 
al., 2000). This switching was also demonstrated in vivo in experimentally infected calves 
(Buchenau et al., 2010). Thirteen single copies of vsp genes have been identified in M. bovis 
strain PG45 with a conserved N-terminal domain for membrane attachment and a variable C-
region that is exposed. Mycoplasmas use DNA recombination to produce a mosaic of Vsps 
(Lysnyansky et al., 1999). The Vsps are used for colonization, adhesion, and immune evasion 
from the host immune system (Behrens et al., 1994). M. bovis successfully uses high-frequency 
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antigenic switching strategy to maintain strain population diversity in an attempt to evade the 
host immune system hence, contributing to the chronic presentation of the disease (Buchenau et 
al., 2010). Other studies are required to determine more roles of the variable surface antigens in 
the disease. 
Adhesion  
Once transmitted, entry into the host cells requires adherence, a critical step to facilitate 
colonization and infection of the lung (Sachse et al., 1996). In M. pneumoniae, a tip like structure 
containing adhesin P1 is used for attachment (Razin and Jacobs, 1992). On the contrary, there is 
no tip-like structure in M. bovis (Behrens et al., 1996) but the surface membrane proteins are 
thought to be involved in adhesion (Behrens et al., 1996; Razin and Jacobs, 1992). In a Western 
blot adhesion assay using embryonic bovine lung cells (LeBlanc et al.), the surface membrane 
protein p26 was demonstrated to be an adhesin of M. bovis (Sachse et al., 1996) and some 
members of the Vsps, VspA, VspB, VspE, and VspF (Sachse et al., 2000). In another study, 
primary bovine bronchial epithelial cells were used to characterise the cytoadherence properties 
of M. bovis strain PG45 (Thomas et al., 2003b). Significant variation in the cytoadherence among 
different host cells tested and different pathogenic strains were also observed (Thomas et al., 
2003a; Thomas et al., 2003b), with the less pathogenic strains having lower adherence rates. 
Cell invasion 
Using immunohistochemistry (IHC) and electron microscopy M. bovis antigens were detected in 
different host cells such as macrophages, neutrophils, bronchiolar epithelial cells, monocytes, and 
lymph nodes of infected calves (Adegboye et al., 1995; Kleinschmidt et al., 2013; Maeda et al., 
2003; Rodriguez et al., 1996). In primary embryonic calf turbinate cells, an intracellular stage of 
M. bovis was demonstrated using electron microscopy (Burki et al., 2015). Moreover, Van der 
Merwe et al., also reported intracellular M. bovis in peripheral blood mononuclear cell (PBMC) 
and red blood cells (RBCs) and this was later followed by reports of invasion in embryonic 
bovine tracheal cells (EBTr) and embryonic bovine lung (Burki et al., 2015) cell lines, primary 
alveolar macrophages, and the BoMac cell line using the gentamicin protection assay (Burgi et 
al., 2018; Burki et al., 2015; Maina et al., 2019; Suleman et al., 2016a; van der Merwe et al., 
2010).  
  9 
The ability of M. bovis to invade and persist in both phagocytic and non-phagocytic cells may 
play a major role in the dissemination of the pathogen to different sites, escape from elimination 
by the host immune system and antimicrobial therapy and overall contributing to the 
pathogenesis of the bacteria and progression of bovine mycoplasmosis. 
Biofilm formation and production of secondary metabolites  
Biofilm are known to harbour pathogens and aid in persisting infections leading to the chronic 
manifestation of the disease (Mah and O'Toole, 2001). In mycoplasmas, biofilm formation occurs 
independently of their pathogenicity and their capacity to form biofilms is reliant on their ability 
to adhere the host cells. Due to the presence of highly variable Vsps and their involvement in 
adherence, there is also a variable ability to form biofilms depending on the Vsp patterns 
(McAuliffe et al., 2006; Sachse et al., 1996). Even though most mycoplasmas do not posses 
biofilm formation genes found in other bacterial species McAuliffe et al., showed that M. bovis 
was resistant to heat and desiccation, Further studies are necessary to investigate the formation of 
biofilms in vivo (McAuliffe et al., 2006). 
Previous reports show that production of hydrogen peroxide (H2O2) is an important virulence 
factor in different mycoplasma spp. such as Mycoplasma mycoides subsp. mycoides (Pilo et al., 
2005). Similarly, mycoplasma H2O2 production was observed in all the M. bovis isolates used in 
another study (Schott et al., 2014) and in vitro passage studies showed a decrease in H2O2 
production with an increase in passage attributed to the loss of a 32-kDa protein during passage 
(Khan et al., 2005). Unlike M. pneumoniae where glycerol metabolism plays a key factor in 
cytotoxicity, there was no indication of glycerol metabolism in any of the M. bovis strains tested 
as there was no L-α-glycerophosphate oxidation (Hames et al., 2009; Khan et al., 2005). 
Modulation of immune responses to M. bovis 
Introduction 
Previous reports infer that elements of both innate immunity as well as adaptive responses play a 
significant role to M. bovis infections and pathology (Bennett and Jasper, 1977; Howard et al., 
1986). It has been reported that after M. bovis immune responses, infection are skewed toward a 
TH2 phenotype (moderated interferon gamma (IFN-γ) and high interleukin, IL-4 levels in T-cells, 
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high IgG1, low IgG2a titres in the serum, and high IL-10 levels in monocytes) (Mulongo et al., 
2014; Vanden Bush and Rosenbusch, 2003). Moreover the alteration of surface antigens is also 
an important aspect of the immune modulation by M. bovis infection (Rosengarten et al., 1994). 
However, despite all of this information the immune response that confers protection are still 
largely unknown. 
Innate immunity responses to M. bovis 
During invasion of the respiratory tract, mycoplasmas encounter non-specific immune responses 
from the host immune cells. Jungi et al., suggests that alveolar macrophages effector functions 
are modulated upon infection with mycoplasmas and their inappropriate activation can promote 
an excessive inflammatory response (Jungi et al., 1996). They also demonstrated that induction of 
NO, TNF-α, and procoagulant activity was strain-specific giving variable differential induction 
profiles (Jungi et al., 1996). Activation of macrophages leads to the recruitment of neutrophils to 
the site of infection (Gagea et al., 2006b). In vitro studies of bovine neutrophils, infection with M. 
bovis strain Mb1 reported an increase in elastase release, inhibition of NO production, along with 
stimulation of pro-inflammatory cytokines TNF-α and IL-12 (Jimbo et al., 2017). Similarly, M. 
bovis inhibited neutrophil respiratory burst (Thomas et al., 1991). In monocytes, infection with 
M. bovis strain Mb1 caused an immune suppression of IFN-γ and TNF-α, pro-inflammatory 
cytokines and an up-regulation of anti-inflammatory cytokine IL-10 (Mulongo et al., 2014). 
The TLRs are expressed on phagocytic cells such as dendritic cells, neutrophils and macrophages 
in the lungs and are a vital component of the innate immune responses at these sites. They 
recognise pathogen-associated molecular patterns (PAMPs) derived from pathogens. To date, 10 
TLR bovine genes are characterized (Menzies and Ingham, 2006). Evidence in human 
mycoplasmas shows that surface lipoproteins are involved in the induction of TLR-2 and 6 
during mycoplasma invasion of monocytes (Into et al., 2004a), and mRNA levels of TLR-2 and 4 
in bovine mammary epithelial cells stimulated with heat-killed M. bovis were significantly 
increased (Gondaira et al., 2018). 
Humoral immune responses against M. bovis 
Since M. bovis is considered an extracellular respiratory pathogen, local antibodies responses 
play a significant role in attempting to inhibit the attachment and growth of the pathogen, in the 
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host cells. A previous study characterized serum antibody responses against surface-exposed 
Vsps lipoproteins of M. bovis (Rosengarten et al., 1994). Different experimental infection studies 
of calves reported a strong production of antigen-specific IgG responses to M. bovis (Howard et 
al., 1986; Vanden Bush and Rosenbusch, 2003) and predominantly IgG1 (Hermeyer et al., 2012a; 
Vanden Bush and Rosenbusch, 2003). The low IgG2 response is thought to contribute to 
pathogenesis, as there is less opsonisation and poor immunity (Vanden Bush and Rosenbusch, 
2003). Other investigators have described opsonisation of M. bovis in bovine alveolar 
macrophage as crucial in the killing of the pathogen (Howard et al., 1976). 
Cell-mediated immune responses to M. bovis 
M. bovis infection induces cell-mediated immune responses (Bennett and Jasper, 1977) and using 
an IL2R-α subunit (CD25) as an indicator of T-cell activation, Vanden Bush reported the 
different subsets of T-cells (CD4 and γδ-T cells) that were activated during the recall along with 
production of moderate IFN-γ and high IL-4 (Vanden Bush and Rosenbusch, 2003). Down-
regulation of lymphocyte proliferation is another important immunosuppression strategy of M. 
bovis infection (Mulongo et al., 2013; Prysliak et al., 2013; van der Merwe et al., 2010; Vanden 
Bush and Rosenbusch, 2003). We suggested that the expression of programmed cell death protein 
1 (PD-1) and its ligand PD-L1 played a role in the impairment of antigen-specific T-cell 
responses (Suleman et al., 2018). The PD-1 receptor is expressed on activated T-cells and 
recognizes its ligand, PD-L1 expressed on activated dendritic and macrophages cells and 
engagement of both leads to poor immune responses (Keir et al., 2008). In the study, we used 
EBTr cells, EBL cells, and BAMs cells to report an increase of PD-L1 after M. bovis infection 
and demonstrated restoration of M. bovis infected PBMC proliferation using blocking anti-PD-1 
antibodies. These data can inform vaccine strategies to overcome the PD-1-related immune 
exhaustion of T-cells during M. bovis infection (Suleman et al., 2018). 
Diagnostics 
Since most M. bovis infections are multifactorial, clinical and pathological signs cannot be used 
for diagnostics, and the sample choice depends on the disease suspected. In BRD and pneumonia, 
nasal swabs, BAL, serum and affected lungs can be collected. A study by Thomas et al., showed 
that BAL was a better choice of clinical samples in suspected lower respiratory tract infections 
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(Thomas et al., 2002) than nasal swabs. The diagnosis of the disease is performed using various 
methods that include testing for antibodies using the indirect enzyme-linked immunosorbent 
assay (ELISA). Serology is particularly important in cases where extensive antibiotic use in the 
herd is practiced as this severely hinders isolation of viable mycoplasma by culture (Parker et al., 
2018). However, the disease is difficult to detect in natural infections since studies have shown 
that the individual titres do not correlate with infection (Le Grand et al., 2002). Nonetheless, the 
use of ELISA is useful in group testing since the rate of seroconversion is high which is 
indicative of the presence of the pathogen among the affected herd (Kumar et al., 2011). 
Traditionally, in clinical samples, the diagnostic process is usually complicated since it required 
isolation of culture with M. bovis growth generally occurring within 2-6 days at 37°C and 5% 
CO2 before the sample is determined as negative. It is a fastidious organism and requires 
supplementation of its medium with cholesterol, serum, and DNA and appearance of ‘fried egg’ 
morphology of the colonies under a microscope is confirmatory of mycoplasma growth on solid 
medium (Razin and Jacobs, 1992). 
Immunohistochemistry can also be used to detect M. bovis antigens in frozen, fresh or formalin-
fixed paraffin-embedded tissues. Localised antigens close to the necrotic tissues suggest 
causation of the infection (Adegboye et al., 1995; Gagea et al., 2006a; Yilmaz et al., 2016). 
Molecular diagnosis of M. bovis is more efficient, specific, and sensitive from various clinical 
samples compared to culture methods (Sachse et al., 1993). Currently, polymerase chain reaction 
(PCR) assays that are designed to detect M. bovis target the 16S Ribosomal ribonucleic acid 
(rRNA) genes followed by separation of the PCR products using denaturing gradient gel 
electrophoresis (DGGE), this approach is useful in detecting mixed cultures (Jozefova et al., 
2014). The disadvantage of targeting the 16S rRNA genes of M. bovis is the cross-amplification 
seen with closely related mycoplasmas such as M. agalactiae (Gonzalez et al., 1995). Other 
target genes have been used as quantitative PCR (qPCR) fluorescent reporter probe for greater 
specificity that allows multiplexing in a single reaction such as, the use of the uvrC gene 
(Clothier et al., 2010; Rossetti et al., 2010) and oppD/F genes (Sachse et al., 2010) for M. bovis 
diagnostics. 
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The challenges of using PCR and culture methods in diagnostics is that they both rely on 
shedding of the organism at the time of sampling, hence the sensitivity of the clinical samples is 
quite low due to uneven distribution of M. bovis in the diseased samples, the intermittent and 
shedding nature of the disease in the affected animal and mishandling of the sample (Parker et al., 
2018). ELISA can prove to be complementary as it can measure past exposure to pathogen. 
The tools for molecular typing of mycoplasmas include pulsed-field gel electrophoresis (PFGE), 
multiple locus variable number tandem repeat analysis (MLVA), and multilocus sequence typing 
(MLST). In PFGE, the chromosomal DNA is digested using restriction enzymes and the resulting 
DNA fragments are separated in an agarose gel producing band patterns specific to different 
strains of M. bovis (Arcangioli et al., 2012). In MLST, analysis for sequence uniqueness using 
multiple housekeeping genes within the genome is performed and based on the differences, the 
relatedness of the isolate is determined (Rosales et al., 2015), however, in MLVA the analysis is 
based on differences in the number of tandem repeats at a selected gene (Register et al., 
2014,Spergser, 2013 #5413).  
To date the completed whole genome sequences of eleven M. bovis isolates are available with 
five M. bovis isolates being used in comparative genomics analysis (Chen et al., 2017; Li et al., 
2011; Qi et al., 2012; Sun et al., 2018; Wise et al., 2011). Although mostly conserved, the 
genomes have varied restriction-modification genes, variable numbers and copies of IS and 
invasion of different integrative conjugative element (ICE) that are important for traceability. 
Using comparative genomics, these sequences can be further used to identify conserved candidate 
antigens for vaccine candidates, disease surveillance and diagnostics. 
Treatment 
The treatment and control of M. bovis are challenging since they lack a cell wall making beta-
lactam antimicrobials not effective. Similarly, they are intrinsically resistant to rifampicin and 
sulphonamides, as mycoplasma does not synthesise folic acid. In contrast, mycoplasmas are 
generally susceptible to antimicrobials that affect the integrity of the cell membrane: ionophores; 
protein synthesis: tetracycline, macrolides, and DNA synthesis: fluoroquinolones. There have 
been studies of unresponsive antimicrobial treatment in cattle with BRD (Haines et al., 2001a) 
along with 80% isolation of M. bovis in the lungs and joints of the unresponsive feedlot cattle. In 
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Europe drugs such as oxytetracyclines, tilmicosin, and spectinomycin have also started showing 
resistance (Ayling et al., 2000). 
There are other antibiotics that can be used to manage the disease. In the United States 
tulathromycin and florfenicol are the only two antimicrobials approved (Godinho et al., 2005). 
Experimental trials conducted on affected calves have shown that the animals showed low 
temperatures and lower lung lesions, demonstrating the effectiveness of these antibiotics. 
Nonetheless, the efficacy of the drugs is not 100% requiring the adoption of other methods to 
ensure that affected animals recover fully (Maunsell et al., 2011). A Western Canadian bison 
study reported higher MIC values for tetracyclines and spectinomycin in clinical bison isolates 
compared to Canadian beef feedlots or dairy cattle herds isolates. Also, all the bison isolates 
tested in the study were resistant to tilmicosin and resistant to tulathromycin (Suleman et al., 
2016b). This study described marked differences between clinical bison isolate susceptibility 
profiles to other cattle isolate studies performed (Suleman et al., 2016b). 
Control 
The management of M. bovis infection is undertaken using various approaches that include close 
herding where the herds are managed more strictly without buying and borrowing bulls from 
other farms, proper fencing and lack of community grazing, which limits the spread of the 
disease. Further, the screening of newly purchased animals is critical to the prevention spread 
since affected animals can be quarantined, thus ensuring the healthier ones are not affected 
(Maunsell et al., 2011). In particular, the farmer should assess the health records of calves to 
establish if incidences of otitis media were present before the acquired animal is mixed with the 
rest of the herd. Even further, the farmer should partition the farm into various sections that can 
limit the spread of the disease in case of an outbreak. Continuous monitoring of the livestock is 
vital since it enables the farmer to identify the disease early on, which is essential in managing 
the spread of the disease. Pre-vaccination of calves against the viral pathogens before entering the 
feedlot, or vaccination upon arrival at the feedlot should be carried out to reduce morbidity by 
BRD (Howard et al., 1987; Nicholas and Ayling, 2003; Timsit et al., 2012) 
Currently, there are few commercial and autogenous vaccines available and these are not 
effective in limiting the spread of M. bovis disease in animals. One of the challenges for vaccine 
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development is the lack of a consistent, reproducible experimental infection model for respiratory 
disease vaccine testing, the understanding of the role of other pathogens in the disease 
manifestation, the age of the animals involved, and the challenge dose used (Perez-Casal et al., 
2017). Contradicting reports of successful disease models are available with studies using M. 
bovis only (Nicholas et al., 2002) and co-infection models using BHV-1 (Prysliak et al., 2011) 
during the challenge. Prysliak et al., also reported no disease after co-infection with BVDV-2 and 
M. bovis only infected animals (Prysliak et al., 2011). The discrepancies in the disease 
progression by M. bovis alone may be attributed to the age of the calves used in the respective 
studies. 
We have reviewed the status of different vaccines used in M. bovis control (Perez-Casal et al., 
2017). In dairy cattle, mastitis infected cattle vaccinated with a M. bovis bacterin did not confer 
any protection despite a high IgG1 and IgG2 titres response in the serum and they also observed 
no milk or circulating lymphocytes proliferation after infection (Boothby et al., 1986, 1987; 
Boothby et al., 1988). In the US there are only two licensed vaccines for the prevention of M. 
bovis infection (Soehnlen et al., 2011) in BRD. In an experimental vaccine trial a saponin-
inactivated vaccine was shown to be safe and protective as when given to young calves on arrival 
to the farm reduced cost treatment and mortality. (Nicholas et al., 2002) In another study, a 
saponin inactivated M. bovis with EmulsigenTM induced protection (Dudek et al., 2016). Use of 
live attenuated vaccines has also been explored with a multiple passaged Chinese M. bovis strain 
HB0101 that reduced the lung lesion scores (Zhang et al., 2014) but this is commercialised only 
in China. Commercially available live-attenuated vaccines in bovine, poultry, and swine have 
been used in control of mycoplasmosis in other countries other than those in Europe and North 
America (Perez-Casal et al., 2017). 
 In M. mycoides subsp. mycoides the current vaccine strategies include a killed vaccine that has 
poor efficacy and live vaccine that has issues with stability and safety (Mbulu et al., 2004) and 
only protects for 6-12 months (Wesonga and Thiaucourt, 2000). The live vaccines approved by 
FAO include 2 freeze-dried vaccines (T1SR and T1/44), (Thiaucourt et al., 2004). Hence the 
need for an improved vaccine that is affordable, stable, and easy to produce and provides better 
immunity, such as a subunit vaccine. This can be aided by reverse vaccinology (Rappuoli, 2000; 
Vivona et al., 2008). Using two Mmm genome sequences of strains PG1 (Westberg et al., 2004) 
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and Gladysdale (Wise et al., 2011) we identified several possible vaccine candidates (Perez-Casal 
et al., 2015) using reverse vaccinology. The potential surface exposed protein vaccine candidates 
were used to study their capacity to induce protection against an experimental CBPP infection. In 
the study, there was 80% reduction in lung pathology score and a correlation of high antibody 
titres to low pathology score index in two groups was reported. The antibodies may be playing a 
role in steric hindrance of Mmm attachment hence high titres of antibodies is a requisite for good 
immunity which explains why the live vaccine is short lived with decline in antibody titres 
(Nkando et al., 2016). In M. bovis multiples studies with protein vaccine candidates show no 
protection; in previous studies using recombinant proteins (Prysliak et al., 2013; van der Merwe 
et al., 2011) and membrane proteins (Mulongo et al., 2013). Further studies using 
immunoproteomics analysis and reverse vaccinology should be used to determine potential 
protective antigens as vaccine candidates and comparative genomics can be used to identify the 
ones conserved in all M. bovis isolates. 
1.3. Bovine respiratory disease complex 
Introduction  
The bovine respiratory disease (BRD) complex can be described as a disease that affects the 
lower or upper respiratory tract of beef cattle. BRD is a multifactorial disease in which bacteria 
such as Mannheimia haemolytica, M. bovis, Histophilus somni, and Pasteurella multocida; and 
sometimes parasites like lung worms (Cusack et al., 2003) co-infect with viruses such as bovine 
herpes virus (BHV), parainfluenza virus (PI-3), bovine respiratory syncytial virus (BRSV), and 
bovine viral diarrhea virus (BVDV). The consequences of the viral infections are to compromise 
the immune system allowing the normal bacterial flora of the respiratory tract to cause secondary 
infections (Booker et al., 2008; Booker et al., 1999). Environmental factors such as transportation 
and housing of feedlot cattle also play a key role in the development of BRD and host factors 
such as the age of the cattle, immune status and previous health history of the animals cannot be 
ignored (Taylor et al., 2010). The treatment and control for BRD includes vaccination of viruses 
and the bacteria, antibiotics, and stress management during housing and transportation for control 
(Perez-Casal et al., 2017). BRD is known to resist antimicrobial medication, which poses a 
challenge in the treatment or management of the disease in animals and requires stronger 
antibiotics to mitigate (DeDonder and Apley, 2015). 
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1.4. Macrophages  
Functions 
Phagocytic cells such as macrophages or monocytes are important lines of defense against 
mycoplasmas in the respiratory tract. They play a crucial role in the orchestration and execution 
of the innate and adaptive arms of the immune response to bacterial infection. Macrophage 
effector functions are: phagocytosis mediated by a receptor, antigen presentation to other immune 
cells and production of cytokines (Gordon, 2007). Alveolar macrophages in particular, are 
important in the early clearance of mycoplasmas from the lungs. Previous evidence suggests a 
role of M. bovis in modulating alveolar macrophages activities although the mechanisms 
employed by M. bovis are not well understood (Maunsell et al., 2011). 
Macrophage activation 
In response to distinct external signals macrophages differentiate into three populations: 
classically activated, alternatively activated and regulatory macrophages. Upon polarization, 
macrophages differentiate in terms of cytokine production, surface receptor expression, effector 
function and chemokine repertoires and acquire different functional properties; host defense, 
wound healing and immune regulation respectively (Mosser and Edwards, 2008). The scheme in 
figure 1.1 shows the canonical macrophage activation pathways. 
Classically activated macrophages are formed during cell-mediated immune responses. They 
produce pro-inflammatory cytokines (IL-1, IL-6, and IL-23) that are important components of 
host defense but can also cause extensive host tissue damage (Mosser and Edwards, 2008) as well 
as up-regulate major histocompatibility complex (MHC)-II surface receptor most of which can be 
detected by fluorescence-activated cell sorting (FACS) or qPCR assays. They protect the host 
from intracellular bacterial and viral infections. A combination of two signals is needed to 
produce classically activated macrophages in vitro; a primer IFN-γ produced by natural killer 
(NK) cells and TH1 cells and interaction with Toll-like receptors ligands that induce production 
of TNFα, which in return stimulates macrophages. Classically activated macrophages are the only 
macrophage class able to metabolize arginine into NO for microbial killing by expressing 
inducible inducible nitric oxide synthase (iNOS) enzyme. In addition to iNOS activity, classically 
activated macrophages are associated with a shift towards increased glucose uptake (O'Neill et 
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al., 2013). Thus, by determining iNOS activity, increased glucose uptake, production of 
cytokines, and expression of the MHC-II receptor, we can identify classically activated 
macrophages. 
Macrophages activated by the alternate pathway are associated with a TH-2 type immune 
response and the indicator cytokine involved is IL-4 (Gordon, 2003; Stein et al., 1992). This 
phenotype produces less toxic oxygen and nitrogen radicals and is deficient in killing intracellular 
pathogens. Hölscher and his group suggested that they are more susceptible to intracellular 
infections (Holscher et al., 2006). Alternatively activated macrophages are characterized by an 
alteration in their metabolism of arginine and a reduction in the uptake of glucose (O'Neill and 
Hardie, 2013). Arginine is converted to ornithine and proline, a collagen precursor by the 
arginase I enzyme whose activity is induced by IL-4. Thus, measuring the increase of 
macrophage arginase I activity in the presence of IL-4, combined with glucose uptake assays will 
allow the identification of alternatively activated macrophages. 
Even though in different studies regulatory macrophages have been developed using different 
methods in vitro, in all cases they secrete high levels of IL-10. They are also known to down-
regulate the production of IL-12 as they shut off the production of the p40 subunit of IL-12/23. 
Currently, there is no proven reliable surface or biological markers hence the ratio of IL-10 to IL-
12 and IL-23 cytokines could be used to define regulatory macrophages using an ELISA (Mosser, 
2003; Sica et al., 2008). 
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Figure 1. 1: Macrophage activation. Likened to the Star Wars movies and the battle between the forces, 
macrophages are activated to a classically activated phenotype (M1) and like soldiers of the Dark Side of 
the force releases pro-inflammatory mediators, cytotoxicity and contribute to pathogen clearance and if 
left unchecked, lead to tissue damage. The alternatively activated (M2) macrophages activities like the 
soldiers of the Order of Jedi counter the M1 activities (dark side) and dampen the immune responses and 
produce mediators involved in wound healing. Disease outcome depends on the balance between these 2 
opposing forces. Adapted from (Laskin, 2009). 
1.5. Use of cells lines as an approach to study host-pathogen interactions 
The intracellular phase of M. bovis represents a protective niche for avoiding clearance by host 
immune cells as demonstrated by Kleinschmidt et al., in alveolar macrophages (Kleinschmidt et 
al., 2013). Host-pathogen interactions have been investigated over the past decades using a wide 
range of primary cell-dependent and -independent techniques using immortalized cell lines. A 
cell line that has been validated in experimental studies as models for in vitro survival, growth 
and as a co-infection model with other pathogens is needed. The dilemma for investigators to 
choose an in vitro cell model of either primary cells and/or cell lines is real as both are useful and 
have advantages and disadvantages. 
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Primary cells closely resemble the tissue from which they are derived (hence a better choice) but 
are isolated from different individual animals hence significant variability between samples is 
commonly encountered. The cells are often difficult to obtain, their isolation is time consuming 
and they are often poorly characterized. In contrast, immortalized cell lines are better 
characterized, show less variation, and are easy to grow (MacDonald, 1990). 
The bovine macrophage cell line (BoMac) is an in vitro differentiated bovine peritoneal 
macrophage cell line (Stabel and Stabel, 1995). In particular, the development of the BoMac cell 
line has greatly facilitated the investigation of host-pathogen interactions as proved by an array of 
laboratory procedures in studies of M. bovis host-pathogen interaction. It has also been used to 
study BHV-4 (Donofrio and van Santen, 2001) and Map (Langelaar et al., 2005; Souza et al., 
2007; Woo et al., 2006). In these different studies the cell line has shown the ability to develop 
macrophage functions including the ability to phagocytize bacteria with and without 
opsonization, generate ROS, produce different cytokines (IL6, TGFβ-1, TNFα-2, IFN-γ, IL1-α), 
and express genes related to apoptosis, the B-cell lymphoma 2 (BCL2-1) following activation and 
infection (Stabel and Stabel, 1995; Tooker et al., 2002). In a different study, Abendano and group 
showed an increased level of expression of the apoptotic inhibitor BCL2-1 and increased TGF-β 
after infection with Map (Abendano et al., 2013). In M. bovis, BoMac cells were used to test their 
potential use as an in vitro infection model for M. bovis with BVDV to be used in the future for 
synergism studies of M. bovis with other microorganisms (Burgi et al., 2018). M. bovis-host cell 
interactions seem to be dependent on the cell type, but the immune modulation of macrophage 
effector function in bovine mycoplasmosis by M. bovis is largely unknown. In this thesis work, I 
demonstrate the potential of BoMac cells for studies involving the mechanism of cell death after 
infection with M. bovis. 
1.6. Cell death mechanisms 
Introduction 
Regulated cell death is essential in maintaining multicellular organisms during embryonic 
development, normal cell turnover in healthy adult tissue, immune responses, and clearance of 
infected cells (Tait et al., 2014). Any defect in cell death (too little or too much) contributes to 
different pathologies including cancer, autoimmunity, injury, and inflammation (Hotchkiss et al., 
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2009). There are different highly regulated cell death mechanisms that are recognized for their 
morphologically and specific molecular differences and can be induced passively or actively by 
the cell itself (Green, 2011; Green and Llambi, 2015; Green and Victor, 2012). According to 
Galluzzi et al., the field continually expands; researchers unveil novel cell death mechanisms and 
pathways. Still, the fundamentals of cell death classification remain unchanged, encompassing 
the following types: necrosis, pyroptosis, necroptosis, autophagy, and apoptosis (Galluzzi et al., 
2018). 
Different cell death mechanism  
Necrosis is referred to as the premature cell death through autolysis due to injury or response to 
lack of blood supply, infections, chemicals, and others (Banoth and Sutterwala, 2017). It is 
induced by external factors such as toxins, infections or unregulated cell digestion (Chang et al., 
2017), but it does not however inform how the cell died (Schwartz and Bennett, 1995). It is 
characterised by high levels of cytosol Ca2+ accumulation, activation of calcium-activated 
proteases (calpains), and phospholipases (Fawthrop et al., 1991; Furuse et al., 2015; Vanden 
Berghe et al., 2014), chromatin condensation and DNA fragmentation is lacking (Edinger and 
Thompson, 2004). 
Necroptosis, on the other hand, is a genetically regulated necrosis and a defence mechanism that 
helps the cell to execute suicide in the presence of an inhibitor of cysteinyl aspartic acid-protease 
(caspase) in a caspase-independent way (Pasparakis and Vandenabeele, 2015). It is induced by 
stimuli such as radiation, pathological or endogenous factors, chemical or viral exposure and 
others (Legarda et al. 2016). It is dependent on death receptor ligands such as TNF and fatty acid 
synthetase (Fas) ligands (Matsumura et al., 2000), and also through pattern recognition receptors 
(PRRs) such as TLRs (Galluzzi et al., 2017; Gonzalez-Juarbe et al., 2017). Necroptosis requires 
sequential activation of receptor-interacting serine/threonine-protein kinases, RIPK1 and RIPK3, 
and its substrate mixed lineage kinase domain (MLKL). It is characterized by swelling of 
organelles (Moujalled et al. 2014), and once phosphorylated, the pMLKL disrupts the cellular 
membrane that leads to random degradation of DNA, acidosis, along with leakage of cellular 
content leading to a programmed cell death (PCD) (Lalaoui et al. 2015). 
Pyroptosis is referred to as an inherent inflammatory form of PCD, which frequently occurs when 
infection happens with intracellular pathogens and is likely to take part in the antimicrobial 
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response (Doitsh et al. 2014). Pyroptosis resembles apoptosis in cell lysis, swelling, pore 
formation, and DNA fragmentation (Shi et al. 2017) but is dependent on inflammatory caspases; 
caspase 1 (Cookson and Brennan, 2001), caspase 3, murine caspase 11 (Case et al., 2013; 
Kayagaki et al., 2011), and its human homologs caspases 4 and 5 (Aachoui et al., 2013; 
Fernandez and Lamkanfi, 2015). The inflammatory caspases induce the cleavage of members of 
the gasdermin D protein family, releasing the gasdermin-N domain that is often involved in the 
formation of plasma membrane pores that lead to leaking of cellular content that causes 
inflammation (Ruhl and Broz, 2016; Shi et al., 2017; Wang et al., 2017). Pyroptosis is often (if 
not always) followed by IL-1β and IL18 secretion, and hence mediates robust pro-inflammatory 
effects and fever (Galluzzi et al., 2018). The changes in cell death by pyroptosis include the 
release of alarmins and DAMPs (Jorgensen and Miao, 2015). 
Autophagy is referred to as the natural physiological process which involves cell destruction in 
the host that is done to maintain homeostasis or normal protein degradation; clearance of 
defective organelles (Galluzzi et al., 2017), and the recycling of new information from destroyed 
organelles. (Diaz et al., 2005). Autophagy of the cells is induced by hypoxia, starvation, growth 
factor deprivation, and chemotherapy. The observable changes in the autophagy cells include 
mass degradation of proteins and organelles along with double membrane vacuolization in the 
cytosol, autophagosomes (Su et al. 2015). The molecular changes in the cells include lysosomal 
activity, fusion of autophagosomes with the lysosome (Galluzzi et al., 2017). During clearance, 
the cells are cannibalized, and the contents present in the cell are recycled to survive the tissues 
(Zhuang et al., 2016). 
Apoptosis 
Apoptosis, “controlled suicide’, is a programmed cell death which occurs in all multicellular 
organisms during embryonic development, regeneration of healthy cells in adult tissue, and 
cellular stress-related signals including the presence of toxins and withdrawal of hormones (Kerr 
et al., 1972). As mentioned by Renehan et al., cells that undergo apoptosis are seen to shrink and 
developed bubble-like projections on the cell surface. The DNA present in the nucleus of the 
apoptotic cell is fragmented into smaller pieces along with fragmentation of the cellular 
organelles. The cell at the end then splits into smaller apoptotic bodies in the form of cellular 
debris, which are engulfed by the macrophages but with no inflammatory response (Fulda et al., 
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2010; Hotchkiss et al., 2009; Renehan et al., 2001). As postulated by Hochreiter-Hufford et al., 
apoptosis leads to the clearance of damaged, cancerous or infected cells. This helps in protecting 
the body from infections and disease and can also be used by the pathogen to evade the host 
immune response (Hochreiter-Hufford and Ravichandran, 2013). Apoptosis is also seen to play a 
key part in the maintenance and development of an effective immune system. This is because 
when T- and B-cells are produced they are then put to the test if they act against their body’s own 
defence system. The cells that act against the defence system are instantly eliminated through the 
help of apoptosis (Mariño et al. 2014). Moreover, during detection of a pathogen in the body 
huge numbers of pathogen-specific immune cells are released into the body for the destruction of 
the pathogeṇ. However, after the pathogen is removed the pathogen-specific immune cells are 
removed by apoptosis to help the body maintain homeostasis (Hochreiter-Hufford and 
Ravichandran, 2013). There are two major apoptosis pathways; the intrinsic pathway also 
referred to as the mitochondrial pathway; is induced by growth factors, radiation, toxins, and 
hypoxia (Wang and Youle, 2009), while the extrinsic pathways also known as the death receptor 
pathway is activated by transmembrane receptor-mediated interactions like activation of TNF 
(Teng and Hardwick, 2014). Both pathways result in activation of caspases (Duprez et al., 2009; 
Teng and Hardwick, 2014) and can be blocked by inhibitor of apoptosis proteins (IAPs) allowing 
for cell survival (Elmore, 2007; Riedl and Shi, 2004; Shi, 2002).  
Intrinsic pathway 
The intrinsic pathway is initiated by non-receptor induced stimuli such as during radiotherapy or 
chemotherapy. Thus, it is activated when a range of endogenous as well as exogenous stimuli like 
DNA damage, oxidative stress, ischemia are experienced by the host and these leads to the loss of 
mitochondrial membrane potential via opening of the mitochondrial permeability transition pore 
(Joo et al. 2015). Reactive oxygen species (ROS) also play a significant role as a stimulus for the 
intrinsic pathway. Once the mitochondrial membrane integrity is lost it leads to leakage of 
sequestered pro-apoptotic proteins cytochrome C (Saelens et al., 2004) and second mitochondrial 
activator of caspases/direct (Smac/DIABLO) protein, (Du et al., 2000) into the cytosol. Once in 
the cytosol cytochrome C binds to apoptotic protease activating factor (Apaf-1) and procaspase 9 
to form an apoptosome. The complex formed is seen to hydrolyse Adenosine triphosphate (ATP) 
for cleavage and activation of caspase 9. The initiator caspase 9 is then involved in activating and 
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cleavage of the executioner caspases 3, 6, and 7 that eventually lead the cell to undergo apoptosis 
(Park et al. 2016). The intrinsic pathway activation also includes activation of Bcl-2 homologs 
(Redza-Dutordoir and Averill-Bates, 2016; Wang and Youle, 2009; Wang, 2001) that can either 
promote or inhibit apoptosis. This family of proteins includes the anti-apoptotic Bcl-2-family 
proteins such as BCL2 related protein long isoform (Bcl-XL), myeloid leukemia cell 
differentiation protein (Mcl-1), and Bcl-2), and pro-apoptotic family of proteins such as BCL2 
associated X protein, Bax and BCL2 antagonist of cell death, Bad (Elmore, 2007; Riedl and Shi, 
2004; Shi, 2002). The pro-apoptotic Bcl-2 family proteins are found in the cytosol (Yee et al. 
2014) and the anti-apoptotic proteins are localized in the outer mitochondrial membrane as 
heterodimers with apoptotic proteins (Bax and Bad) thus inhibiting their apoptotic functions 
(Cory and Adams, 2002) or by controlling the cleavage and activation of the caspases (Czabotar 
et al. 2014). Smac/DIABLO pro-apoptotic proteins released in the cytosol are thought to also 
induce apoptosis by interacting with the inhibitor of apoptosis proteins to inhibit their activity 
(Wu et al., 2000). IAPs are a structural and functional family of proteins which execute their 
function as negative regulators of apoptosis and caspases (Silke and Meier, 2013). All the IAPs 
have a common feature that is the presence of one or more copies of the baculovirus IAP repeat 
motifs (BIR) (Birnbaum et al., 1994). The BIR found in IAPs bind to IAP-binding motifs (IBMs) 
present in caspases inhibiting their protease activity (Riedl and Shi, 2004), and Smac/DIABLO an 
IAP-antagonist, inhibiting apoptosis (Wu et al., 2000). The IAPs that are usually found in 
mammals include XIAP, cIAP1, and cIAP2, NAIP, Survivin, and others (Srinivasula and 
Ashwell, 2008). The third group of pro-apoptotic proteins released from the mitochondria 
includes endonuclease G that occurs in the late stage of apoptosis when the cell has already 
committed to PCD. The endonuclease translocates to the nucleus where it causes DNA 
fragmentation (Li et al., 2001). 
Extrinsic pathway 
The extrinsic pathway is stimulated by external death-induced signals for apoptosis and each of 
the cells possesses receptors in the plasma membrane which are specific for each stimulus and 
therefore the extrinsic pathway is also called the receptor-mediated programmed cell death 
pathway. In most cases, tumor necrosis factor alpha (TNF-α) is the cytokine that is responsible 
for the external stimuli in initiating the extrinsic pathway of apoptosis. TNF is an inflammatory 
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cytokine mostly provoked in the body when the body is exposed to toxic substances and infection 
(Teng and Hardwick, 2014). The extrinsic pathway of apoptosis involves binding of the TNF to 
the tumor necrosis factor receptor-1 (TNFR-1) on the plasma membrane of the cell (Locksley et 
al., 2001). The TNFR-1 belongs to a member of the death receptor family that activates the 
apoptotic signal process. The TNFR-1 is a transmembrane receptor which has the external 
domain for bonding of ligand along with a cytosol domain (Nair et al., 2014), the cytosolic 
domain present in each subunit of TNFR-1 contains a 70 amino acid segment known as the death 
domain (Chattopadhyay et al. 2014). The binding of the TNF to the TNFR-1 causes a change in 
the death domain, which results to recruit many apoptotic-related adaptor proteins factors. To 
further activate the death domain, the cytosolic adapter proteins; TNF receptor-associated death 
domain (TRADD) and Fas-associated death domain (Rahman and McFadden) along with 
procaspase 8 residue are bound in forming a multi-protein, death-inducing signalling complex 
(DISC) which interacts in generating an activated caspase 8 (Elmore, 2007). This activated 
caspase 8 acts as an initiator in activation of the extrinsic pathway of apoptosis which in turn 
activates caspase 3 which is the key apoptotic executioner creating self-destruction of the cell 
(Richardson et al. 2017). The Fas-ligand is also seen to cause extrinsic apoptosis by activating 
procaspase 8, which in turn activates the downstream executioner caspase 3 for inducing 
apoptosis (Ahmed et al. 2015).  
Caspases  
Caspases belong to enzymes of the cysteine protease family which have an essential role in 
executing programmed cell death and inflammation (Kumar, 2007). The caspases are divided into 
three groups that include initiator caspases (caspases 8, 2, 9 and 10), executioner caspases 
(caspases 7, 3, and 6), and inflammatory caspases (caspases 1, 4, 5, 11 and 12) (Cohen, 1997; 
Fernandez and Lamkanfi, 2015). The initiator caspases act to initiate the apoptotic process 
whereas the executioner caspases execute the proteolysis that leads to the cleavage of cellular 
proteins. The caspases are initially synthesized in the form of inactive procaspases which are later 
cleaved as well as activated to respond to death receptors, granzyme B, and apoptosome stimuli 
depending on the stimuli (McIlwain et al., 2013). The activated caspases then go to cleave 
various substrates that include nuclear proteins, downstream caspases, and plasma membrane 
proteins that lead ultimately to execute cell death (Slee et al., 2001).  
  26 
Nuclear Factor kappa beta (NF-kβ) pathway role in apoptosis 
NF-kβ is a form of transcription factor composed of c-Rel, RelA, RelB, p105/NF-kβ1 and p100/ 
NF-kβ2 proteins, that are involved in different pathways including immune and inflammatory 
responses (Hayden et al., 2006). The canonical NF-kβ pathway that plays a role in apoptosis is 
activated by cellular stress either from within the cell, the environment, toxins, medications or 
infections. Usually, RelA/p65 is stored in an inactive form in the cytoplasm as part of the p65-
p50 (NF-κβ) complex bound to the inhibitory protein IκBα. On activation, IκBα is 
phosphorylated by the IκB kinase leading to ubiquitination and release of the inhibitory protein 
from the NF-kβ complex (Scheidereit, 2006). This in turn, exposes nuclear import factors that 
target p65 to the nucleus where it binds to regulatory elements and leads to changes in cellular 
gene transcription (Rahman and McFadden, 2011). Upon activation, NF-κβ leads to expression of 
apoptotic or anti-apoptotic genes of the Bcl-2 family, the IAPs, and the IAP antagonists (Into et 
al., 2004a; Kucharczak et al., 2003). 
Apoptosis programmed cell death (PCD) and infection 
While apoptosis is considered a defence mechanism for the host during pathogen invasion, by 
clearance of infected cells without inflammation, bacterial pathogens have also evolved strategies 
to manipulate host cell death mechanisms for their survival, multiplication as well as 
dissemination (Renehan et al., 2001). Using different virulence factors, pathogenic bacteria are 
known to either inhibit apoptosis of the host cells to allow proliferation and dissemination or 
induce apoptosis to eliminate the different types of immune cells. 
Mycobacteria are intracellular pathogens that are taken up through receptor-mediated 
phagocytosis by macrophages and modulates their effector functions; their virulence largely 
depends on intracellular survival in the macrophages (Basu et al., 2012). Virulent Mycobacteria 
are known to use either of the two key apoptotic pathways and possess both apoptotic inducing 
and inhibiting components (Briken and Miller, 2008). In Mycobacterium avium the MAV2052 
protein is known to induce apoptosis through TLR-4 in murine macrophages through the intrinsic 
pathway activated by the production of ROS that leads to loss of mitochondrial membrane 
potential (ΔΨm), the release of pro-apoptotic protein Bax and cytochrome C and activation of 
caspases (Lee et al., 2016). In Mycobacterium tuberculosis (Mtb), other proteins have been 
  27 
implicated in the induction of TLR-2-dependent activation that results in activation of the NF-kβ 
pathway and release of pro-apoptotic activity of TNF-α (Basu et al., 2007). Moreover, a 
glycolipid component released from the mycobacterial wall, lipoarabinomannan (LAM) induce 
apoptosis (Guerardel et al., 2003) or inhibit apoptosis through phosphorylation of Bad, which 
prevents the binding with the anti-apoptotic proteins Bcl-xl and Bcl-2 (Halder et al., 2015; Maiti 
et al., 2001) or by neutralising the pro-apoptotic activity of TNF-α (Srinivasan et al. 2014).  
Neisseria gonorrhoeae induces apoptosis by releasing a membrane protein porin (PorB) 
associated with loss of membrane potential, the release of cytochrome C, and activation of 
caspases (Deo et al. 2018). Moreover, Neisseria meningitidis possesses lipopolysaccharide (LPS) 
and LPO that induce apoptosis in epithelial cells (Deghmane et al., 2009) and the porin PorB that 
inhibits apoptosis in epithelial and lymphoid cell lines (Massari et al., 2000). Similarly, 
Salmonella spp. directly injects effector SopB through a type III secretion system resulting in 
activation of the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway. The pathway reacts to 
prevent the release of cytochrome C resulting in inhibition of apoptosis (Robinson and Aw, 
2016). While in Anaplasma phagocytophilum the PI3/Akt pathway is activated along with 
activation of the NF-kβ pathway and are also seen to prevent the release of cytochrome C along 
with activation of the IAPs (Ayllón et al. 2015) and secretion of Ats-1 protein to block pro-
apoptotic Bax to inhibit apoptosis (Niu et al., 2010). 
As discussed, different pathogenic bacteria modulate apoptosis by either, protecting the 
mitochondria integrity preventing release of cytochrome C and caspase activation as described in 
Chlamydia and Neisseria spp. (Greene et al., 2006), or activating cell survival pathways by up-
regulating inhibitors of apoptosis (e.g. Bcl-x proteins) as described for Rickettsia rickettsii 
(Lancellotti et al., 2006). The discrepancies of the same bacteria possessing ability to induce or 
inhibit apoptosis are attributed to the different cell types, different strains, and the different 
antigens/virulence factors used in the studies. The overlapping effects of both induction and 
inhibition of apoptosis are likely to play a role in the pathogenesis of the disease. Like other 
pathogens, M. bovis has evolved to use apoptosis to modulate the immune system of the host as 
shown by Mulongo et al., using high-throughput bovine peptide kinome arrays as one of the 
pathways modulated during infection of bovine monocytes (Mulongo et al., 2014). We have 
shown that M. bovis strain Mb1 delays apoptosis in bovine monocytes, PBMCs, and primary 
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alveolar macrophages for survival (Van der Merwe et al., 2010; Mulongo et al., 2014; Suleman et 
al., 2016); and induces apoptosis in bovine neutrophils to enhance release of bacteria for 
colonization of new cells to assist in dissemination (Jimbo et al., 2017). In another study with 
lymphocytes, Vanden Bush reported that M. bovis induced apoptosis after observing 
lymphotoxicity post-M. bovis infection (Vanden Bush and Rosenbusch, 2002) while in the 
BoMac cell line, the M. bovis strain JF4278 caused slight apoptosis and delay in STS-induced 
apoptosis was not observed. These discrepancies may also reflect the diversity that exists within 
M. bovis strains as previously described in adherence to various host cell lines that influence 
virulence (Burgi et al., 2018; Thomas et al., 2003a). Moreover, Wiggins’ research group 
demonstrated that the ability to reduce ROS and cellular metabolism in leucocytes varies within 
different strains therefore suggesting, "research that examines the effect of a single M. bovis 
isolate may not yield information broadly relevant to all M. bovis isolates” (Wiggins et al., 2011). 
In Mycobacterium spp. after two decades of research, there are many studies that associate 
different virulence genes/antigens as the drivers of apoptosis inhibition in macrophages 
(Parandhaman and Narayanan, 2014). In M. bovis no genes have been identified responsible for 
apoptosis and this highlights the large knowledge gap in the field of mycoplasmas. In Mtb, 
Mycobacterium bovis and Mycobacterium kansasii, it has been suggested that only virulent 
strains inhibit apoptosis in macrophages as attenuated strains like the BCG-strain enhanced 
apoptosis (Keane et al., 2000). This has led to several studies where researchers knocked-out 
different virulence genes and reported an increase in macrophage apoptosis (Velmurugan et al., 
2007). Hence, if the genetic formation of a bacterium influences the mechanism of apoptosis 
then, this would make a huge contribution in creating attenuated vaccine strains. Such key 
information is missing in the M. bovis-host interaction field and there is a need for further 
investigations to find out if both pathogenic and non-pathogenic strains of M. bovis inhibit 
apoptosis of primary alveolar macrophages. From a basic research point of view, the discovery of 
genes responsible for apoptosis provides an opportunity to understand the host-pathogen 
interaction further and inform the pathogenesis of the disease. In this thesis, I will explore the 
molecular mechanisms employed by M. bovis to modulate macrophage apoptosis as currently 
there is limited understanding of the strategies used. 
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HYPOTHESIS  
Immune modulation by Mycoplasma bovis and its interaction with host cells continues to be 
investigated to generate insights into disease pathogenesis outcomes. Mycoplasmas interact with 
host immune cells to create a favourable niche for their replication and thus, avoid clearance. To 
understand disease progression and how to combat it, it is necessary to study mycoplasma-host 
interactions. I hypothesize that Mycoplasma bovis strain Mb1 invades and modulates bovine 
alveolar macrophage (BAM) activity and apoptosis, while avoiding clearance by the host immune 
system. 
 
OBJECTIVES 
1. Characterize the heterogeneity of activated M. bovis infected primary bovine alveolar 
macrophages based on their cytokine and nitric oxide production. 
2. Determine the antigen-presentation capacity of primary BAMs infected by M. bovis in 
vivo using ova-albumin and characterise the immune responses. 
3. Determine the mechanism of BoMac cell apoptosis induced by the cattle isolate M. bovis 
strain Mb1 and the bison isolate strain Mb304. 
4. Study the role of the NF-κβ-signalling pathway on apoptosis of BoMac cells infected with 
M. bovis strains Mb1 or Mb304 by detecting the translocation of the p65 subunit of NF-κβ 
to the nucleus and the differential gene expression of anti- and pro-apoptotic genes. 
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CHAPTER 2. Understanding the heterogeneity of responses in primary bovine alveolar 
macrophages activated by the M. bovis strain Mb1  
 2.1. Introduction 
The importance and prevalence of M. bovis among other pathological agents implicated in bovine 
respiratory disease (BRD) complex, a multifactorial disease of feedlot cattle, has been shown 
(Arcangioli et al., 2008). It is also the most pathogenic bovine mycoplasma in Europe and North 
America causing substantial economic losses (Maunsell et al., 2011). A significant line of 
defense against mycoplasmas in the respiratory tract is macrophages. They are responsible for 
initiating both the innate and adaptive arm of the immune response to bacterial infection. 
Pathogens are known to exploit the different polarized phenotypes of macrophages to the 
disadvantage of the host (MacMicking et al., 1997a; Odegaard and Chawla, 2011). A study on 
experimental challenge models for M. bovis in feedlot cattle indicate that M. bovis is capable of 
persisting in lungs of recovered animals (Prysliak et al., 2011; Rodriguez et al., 2015). Naturally 
occurring M. bovis persist in a herd over an extended period and can be consistently identified not 
only in lesions but also commonly in healthy lungs and those with pneumonia (Gagea et al., 
2006b). This suggests that M. bovis can evade alveolar macrophage functions although the 
mechanisms employed are not well understood. Hence, I sought to investigate the phenotype of 
BAMs activated in response to an in vitro infection with the M. bovis strain Mb1. Alveolar 
macrophages were isolated and infected with Mb1. The supernatant and cells were harvested at 
different time points post-infection and assayed for nitric oxide production, cytokine profile and 
expression of surface markers associated with APCs. I observed a reduction in the production of 
nitric oxide and the pro-inflammatory cytokine TNF-α coupled with a reduction in gene 
transcription of iNOS, the nitric oxide synthase gene. These results suggest modulation of the 
immune response by the M. bovis skewed to an anti-inflammatory immune response. 
2.2. Materials and Methods: 
Bacteria strains and culture conditions 
The experiments were conducted using M. bovis strain Mb1, which was previously isolated from 
the synovial fluid of a calf exhibiting signs of arthritis (Perez-Casal and Prysliak, 2007). Cultures 
were grown in modified Hayflick’s medium at 37°C in a 5% CO2 atmosphere. Bacterial cells 
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were collected by centrifugation (5,500 x g for 15min) at the exponential phase of growth and 
then washed with minimum essential medium (MEM; Invitrogen, Burlington, ON, Canada). 
Bacteria were suspended to a cell density of 108 cfu/ml in MEM supplemented with 30% glycerol 
and stored at -70°C until use. 
Isolation of bovine alveolar macrophages (BAMs) 
The lungs of recently euthanized animals were gradually filled via the trachea with sterile Hanks 
balanced salt solution (HBSS) supplemented with 2X antibiotic-antimycotic cocktail (penicillin, 
streptomycin, and amphotericin B) and 1X gentamicin. The lungs were gently massaged, and the 
lavage decanted into sterile bottles to harvest the BAMs suspension. Washing of the lungs 
required 3 to 4L of HBSS (dependent on the lung size) and about one-half of this volume could 
be recovered. The macrophage suspension was centrifuged at 400 × g for 10min at 4°C and the 
cell pellet was collected and washed with cold PBS supplemented with 2X antibiotic-antimycotic 
and suspended in Dulbecco’s modified eagle medium (D-MEM). The cells were then counted in 
a Coulter counter and the suspension diluted to the required working concentration of BAMs. D-
MEM containing 10% fetal bovine serum (FBS), 0.05 mM 2-mercaptoethanol, 1 mM sodium 
pyruvate, 0.1 mM nonessential amino acids (NEAA), and 10mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer was used to culture BAMs for all subsequent 
assays. Trypan blue 0.4% and flow cytometry was used to assess the viability of the BAMs. 
Infection of BAMs with M. bovis 
Alveolar macrophages from individual animals were seeded (5 x 106/per well) in flat-bottom 6-
well tissue culture plates (Nunc™, Thermo Fisher Scientific, Massachusetts, USA). The cells 
were incubated at 37°C in 5% CO2 atmosphere for 3h. The supernatant was discarded and 
replaced with 2ml of fresh D-MEM medium and the cells were incubated overnight at 37°C in 
5% CO2 atmosphere. Infection with Mb1 was carried out using 2.5 x 107 cfu/ml of M. bovis at a 
multiplicity of infection (MOI) of 0.1:1 and 5:1. The cultures were incubated at 37°C in a 5% 
CO2 atmosphere. The supernatants were collected at different time points (3h, 6h, and 24h) and 
assayed for the presence of the following cytokines: IL-1, IL-6, IL-10, IL-12, IL-13, IFN-γ, IFN-
α, TNF-α, and TGF-β using a BioRad BioPlex® 200 reader (BioRad, CA, USA). Eight 
independent experiments with two technical replicates of each treatment were performed. 
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Bio-Plex® cytokine ELISA 
Different colour-coded BioRad MaxPlex-® microsphere beads (BioRad, CA, USA) were coated 
with antibodies to the target cytokines. The cytokines coupled colour-coded beads (Appendix, 
table 6.1.) were added at 1200 beads/well at a final volume of 50µl/well, to a 96-well plate, and 
washed with PBS-BN (PBS, 1% bovine serum albumin (BSA), 0.05% Na azide, pH 7.4) using 
the Bio-Plex Pro™ Wash Station (BioRad, CA, USA). The cytokine standards, samples, and 
PBS-BN as a blank were added to the beads at 50µl/well and incubated at 750rpm at room 
temperature (RT) for 30min on a shaker (IKA MTS 2/4 digital microtiter shaker, NC, USA) 
followed by washing with PBS using an automatic plate washer. Detection of cytokines was 
performed using biotinylated antibodies at 50µl/well diluted in PBS-BN. The plates were 
incubated as above and washed with PBS before adding Strepatavidin-Phycoerythrin (SA-PE; 
Cedarlane, ON, Canada) at 5µg/ml in PBS-BN (50ul/well) and the plates were incubated at RT 
for 10min on the plate shaker at 750rpm. The plates were then washed with PBS. Finally, 125µl 
of TE buffer was added to each well and the plates incubated at 750rpm at RT for 3min before 
reading the cytokine concentrations on the Bio-Plex® at 45sec timeout, 50 beads/region, 100µl 
volume following the manufacturer’s instructions. During all the shaking the plates were sealed 
and wrapped in foil to avoid light. 
Nitric oxide (NO) concentration in BAMs supernatant 
Nitric oxide concentration was determined by measuring nitrite levels in supernatants of 
macrophage cultures using a modification of the Griess reaction a colorimetric assay, (R&D 
Systems, Minneapolis, USA), that detects nitrite formed by the spontaneous oxidation of NO 
under physiological conditions. Alveolar macrophages isolated as before were seeded, (5 x 
106/per well) in flat-bottom 6-well tissue culture plates (Nunc™, Thermo Fisher Scientific, 
Massachusetts, USA). The cells were incubated at 37°C in a 5% CO2 atmosphere for 3h. The 
supernatant was discarded and replaced with 2.5ml of fresh D-MEM medium and incubated 
overnight at 37°C in 5% CO2 atmosphere. Infection with Mb1 was carried out using 2.5 x 107 
cfu/ml of M. bovis at a multiplicity of infection (MOI) of 5:1. The cultures were incubated at 
37°C in a 5% CO2 atmosphere and the supernatant collected at different time points (0h, 3h, 6h, 
12h, and 24h) and assayed for the presence of nitrites. In a 96-well microplate (Nunc™, Thermo 
Fisher Scientific, Massachusetts, USA), 20µl of Griess reagent (equal volumes of N-(1-
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naphthyl)ethylenediamine and sulfanilic acid) was added to 150µl of the nitrite-containing 
sample and 130µl water and incubated for 30min at RT. The absorbance of the nitrite-containing 
samples relative to the reference sample (Griess reagent and water), was measured at 548nm 
using a Bio-Rad Xmax spectrophotometric microplate reader. The absorbance readings were 
converted to nitrite concentrations using a standard curve of nitrite (NO2−) solutions with 
concentrations between 1-100µM. Eight independent experiments with two technical replicates of 
each treatment were performed. 
Flow cytometry 
Alveolar macrophages were isolated from three animals as indicated previously and seeded, (5 x 
106/per well) in flat-bottom 6-well tissue culture plates (Nunc™, Thermo Fisher Scientific, 
Massachusetts, USA). The cells were incubated at 37°C in a 5% CO2 atmosphere for 3h. The 
supernatants were discarded and replaced with 2ml of fresh D-MEM medium and plates 
incubated overnight at 37°C in 5% CO2 atmosphere. Infection with Mb1 was carried out using 2.5 
x 107 cfu/ml of M. bovis at a multiplicity of infection (MOI) of 5:1. The cultures were incubated 
at 37°C in 5% CO2 atmosphere for 24h. The adherent cells were washed with PBSA and 1ml of 
pre-warmed Accutase™ (Sigma Inc, St. Louis, MO, USA) was added to cover the entire surface 
of the tissue culture and incubated for 30min to allow cells to detach. Cells were transferred into 
a centrifuge tube and collected by centrifugation at 400-x g for 5min at 4oC. The supernatants 
were discarded and the cell pellets saved for the assays. The cells were counted and blocked in 
PBSA with 2% BSA for 30min. Different fluorophore-conjugated antibodies were added to the 
sample in appropriate dilutions (Appendix, table 6.1) and stained for 15min in an orbital shaker in 
the dark followed by incubation with a secondary antibody where necessary, with washes in 
between. The fluorophore-conjugated antibodies used were, anti macrophage-APC, CD40-RPE, 
CD80-PE, CD163-PE, CD86-FITC, CD205-FITC, MHC ΙΙ-None (secondary antibody IgG1-PE) 
and CD11b-FITC. Samples were stained with the secondary antibody only to control for non-
specific binding. The cells were washed and suspended in FACS buffer (PBS with 2% FBS and 
0.1% Na azide) for flow cytometry analysis. Samples were analysed with (BD FACSCaliburTM, 
San Jose, CA) and data analysed with Kaluza® software (Beckman Coulter, Indianapolis, US). 
Minimum of 10,000 events were captured for each sample with data collected in list-mode and 
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cells gated according to size (FS: forward scatter) and granularity (SS: side scatter). PI was used 
to measure the viability of cells. 
Quantitative real-time PCR 
Total RNA was extracted using Trizol® (Molecular probes, Life technologies®, USA) from 
BAMs infected with M. bovis, cells treated with lipopolysaccharide (LPS) for 24h, and un-
infected BAMs as control from three independent experiments. RNA quantity was determined 
using a Nanodrop spectrophotometer and integrity was assessed using denaturing agarose gel 
electrophoresis. Reverse transcription was performed using primers in Table 2.1; they all had a 
primer efficiency of above 90%. qPCR was carried out using the RT² SYBR Green Fluor 
(Qiagen, CA, USA) fast method performed on an iCycler i5 system (BioRad, CA, USA). The 
reactions were carried out in duplicate on 5µl of cDNA diluted tenfold with H2O. The melting 
curve analysis indicated a single amplicon product for each primer pair. The data are expressed as 
fold changes as calculated using the 2-ΔΔCT method relative to GAPDH, a stable housekeeping 
gene. 
Table 2. 1: Primers used in this study. 
Gene name Primer sequence 
Product 
length 
(bp) 
Reference 
Glyceraldehyde 3-
phosphate 
dehydrogenase 
(GAPDH) 
F: TTCAACGGCACAGTCAAGG 
R: ACATACTCAGCACCAGCATCAC 
119 This thesis 
Beta-actin 
(β-Actin) 
F: AGGCATCCTGACCCTCAAGTA 
R: GCTCGTTGTAGAAGGTGTGGT 
95 This thesis 
Toll-like receptor 
2 
(TLR-2) 
F: CTGTGTGCGTCTTCCTCAGA 
R: TCAGGGAGCAGAGTAACCAGA 
113 This thesis 
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Toll-like receptor 
6 
(TLR-6) 
F: CGACATTGAAGGCACTGAAA 
R: TCCTGAGGACAAAGCATGTG 
110 This thesis 
Ribosomal protein 
S15a 
(RPS15a) 
F: GAATGGTGCGCATGAATGTC 
R: GACTTTGGAGCACGGCCTAA 
101 
(Kishore et al., 
2013; Sodhi et al., 
2013) 
Ribosomal protein 
S9 
(RPS9) 
F: CCTCGACCAAGAGCTGAAG 
R: CCTCCAGACCTCACGTTTGTTC 
54 
(Kishore et al., 
2013; Sodhi et al., 
2013) 
Inducible nitric 
oxide synthase 
enzyme 
(iNOS) 
F: GGTGGAAGCAGTAACAAAGGA 
R: GACCTGATGTTGCCGTTGTTG 
115 This thesis 
Tyrosine 3-
monooxygenase/ 
Tryptophan 5-
monooxygenase 
activation protein, 
zeta polypeptide 
(YHZ) 
F: GAGCTGGTACAGAAGGCCAAAC 
R: ATGACCTACGGGCTCCTACAAC 
160 This thesis 
The sequences of housekeeping and TLR genes primers used in the study. F: Forward primer and R: 
Reverse primer. 
Statistical Analysis 
Prism 7.0c (GraphPad Software, Mac OS X, La Jolla, CA, USA) was used for data analysis. I 
used one-way analysis of variance (ANOVA, Friedman or Kruskal-Wallis tests) to analyse the 
cytokines, nitric oxide production, surface receptors, and differential gene expression data 
followed by multiple-groups analysis to compare the different treatments. Differences were 
considered significant at a P value of ≤0.05. 
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2.3. Results 
BAMs recovery and viability 
BAL is widely accepted as a clinical sample for lower respiratory infections (Thomas et al., 
2002) and the BAL cells composition includes alveolar macrophages, lymphocytes, eosinophils, 
epithelial cells and neutrophils. I sought to determine the percentage of BAMs recovered from the 
lavage and their viability before using them for different assays and after infection or treatment 
and the results are shown in figure 2.1. Following overnight culture and removal of non-adherent 
cells, the cell viability on the day of BAMs harvesting from BAL was greater than 96% of the 
adherent cells as assessed by trypan blue from each of the animals (not shown). The viability of 
the BAMs was also demonstrated by flow cytometry to be more than 93% even after 24h 
incubation with or without treatment (Fig. 2.1a). Cells were stained with propidium iodide (PI), a 
DNA binding dye used to check if the integrity of the membrane is compromised, the amount of 
PI detected is inversely proportional to the percentage of viable BAMs cells. 
 
 
 
Figure 2. 1a: Representative plot of flow cytometry analysis demonstrating cell viability. Cell 
viability after 24h incubation of unlabelled BAMs, untreated BAMs and LPS-treated BAMs were all 
above 93% with the fluorescence dot graphs and the scatter box plots show PI positive (nonviable) cells. 
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To assess the population of BAM cells in BAL fluid, the cell suspension was stained with a 
mouse anti-human macrophage APC antibody (Serotec, CA, USA). The forward scatter height 
(FSC-H) vs. forward scatter area (FSC-A) (R1) and FSC-A vs. side scatter area (SSC-A) were 
used for gating on single cells to eliminate debris and clumped cells from the analysis. Single 
cells were then examined by CD expression, gating on anti-macrophage APC+ cells, which 
represent total alveolar macrophage present (Fig. 2.1b). 
 
 
Figure 2.1. b: Representative plot of flow cytometry analysis demonstrating the live population of 
BAMs in lavage fluid. Single-cell suspension BAL cells were gated using the forward scatter and side 
scatter based on size and granularity respectively, then followed by showing the fluorescence peak shifting 
of the BAMs before and after staining with a mouse anti-macrophage APC marker. 
The lung lavage fluid contained 98% of alveolar macrophage cells as shown by the anti-
macrophage APC+ cells where there was a shift in intensity between the negative control and 
stained cells (Fig. 2.1b).	
  38 
Lack of stimulation of BAMs TNF-α induced by M. bovis strain Mb1 
Since macrophage stimulation can be assayed by monitoring the release of cytokines, I tested 
whether infection of BAMs by M. bovis activates production of pro- or anti-inflammatory 
cytokines. Using Bio-Plex® ELISA, I measured the secretion levels of IL-1, IL-6, IL-10, IL-12, 
IL-13, IFN-γ, IFN-α, TNF-α, and TGF-β after 3h, 6h, and 24h of incubation of BAMs with M. 
bovis, and the results are shown in figure 2.2. Although untreated and M. bovis-treated BAMs had 
no stimulation of the pro-inflammatory TNF-α cytokine, LPS treatment of BAMs induced 
significant production at 3h and 6h (P ≤ 0.01 and P ≤ 0.001), with the levels dropping at 24h. On 
the other hand, BAMs infected with Mb1 significantly induced production of IL-10 at 6h. There 
was a slight drop at 24h compared to un-infected BAMs and LPS-infected BAMs. There was no 
detectable production of IL-1, IL-6, IL-13, IFN-γ, IFN-α, and IL-12 (data not shown). I also 
observed large data dispersion in the results. Our data indicate that the infection of BAMs leads 
to cytokine production skewed towards an anti-inflammatory profile. 
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Figure 2. 2: Cytokine ELISA. The quantification of TNF-α and IL-10 in supernatants from bovine 
alveolar macrophages collected from eight animals after different hours of incubation with M. bovis Mb1 
is shown. Cytokines were quantified from undiluted supernatants. The left Y-axis is units in ng/ml. 
Results are presented as median of the values and differences between treatments were determined by one-
way ANOVA (Kruskal–Wallis test analysis). Significant differences between the treatments and untreated 
cells are indicated by * = P<0.05, ** = P<0.01. Black symbols represent untreated BAMs; blue represents 
Mb1-infected BAMs; and red represents LPS-treated BAMs. 
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M. bovis strain Mb1 decreases production of NO in BAMs 
Nitric oxide is part of the antimicrobial arsenal for polarized macrophages that leads to 
inactivation of key enzymes of the target pathogens. NO is produced after metabolism of L-
arginine by the iNOS/NOS-2 enzyme to NO and citrulline (MacMicking et al., 1997a). To 
investigate whether M. bovis infection of BAMs modulates their ability to produce NO by iNOS, 
I examined 24h post-infection the production of NO using the Griess reagent and the results are 
shown in figure 2.3. Compared to the untreated BAMs, incubation of BAMs with M. bovis strain 
Mb1 resulted in low production of NO although the level of this inhibition was not significant. 
LPS-treated cells showed significant NO levels at 3h (P ≤ 0.05). Finally, compared to untreated 
BAMs, incubation with LPS and infection with Mb1 at 24h resulted in less NO production but 
this difference was not significant. The results suggest that Mb1 may decrease NO generation by 
BAMs. Although a control with LPS+Mb1 should have been included. 
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Figure 2. 3: Nitric oxide production. NO quantification was carried out in undiluted supernatants from 
alveolar macrophages collected from eleven animals after incubation with M. bovis for 3 and 24h. The 
results are presented as median of the NO concentration. LPS was used as a positive control. (LPS: 
Lipopolysaccharide, M. bovis: M. bovis strain Mb1). Each dot represents BAMs from an animal. Black 
symbols represent untreated BAMs; blue represents Mb1-infected BAMs; and red represents LPS-treated 
BAMs and differences between treatments were determined by one-way ANOVA (Kruskal–Wallis test 
analysis). Values of P < 0.05 were considered significant. Black symbols represent untreated BAMs; blue 
represents Mb1-infected BAMs; and red represents LPS-treated BAMs. 
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There was a basal production of NO by the untreated BAMs. This finding is not surprising since 
NO has an array of functions depending on level and site of production of the cells in the lungs; it 
can act as a vasodilator, a bronchodilator, a pro-inflammatory and an antimicrobial molecule 
(Bogdan, 2001). 
I further decided to use qPCR to confirm the NO production results observed above (Fig. 2.3). To 
choose a reference gene for qPCR, the most important factor to consider is the stability of the 
reference gene. I used the Normfinder™ software to score and rank different reference genes. For 
cattle, the suggested reference genes were RPS9, RPS15a, YHZ, GAPDH and β-Actin (Kishore 
et al., 2013). As indicated in the now standardized MIQE guidelines, five untreated and five 
treated samples were used to run qPCR for all reference gene candidates for each sample (Bustin 
et al., 2009). The quantification cycle (Cq) was used to calculate a theoretical quantity based on a 
theoretical standard curve with 100% efficiency with a value of 1 copy at 35 Cq of target RNA in 
the samples by using the efficiency of each reaction (Equation 1) and the Normfinder™ 
algorithm was used to calculate sample variation and to produce stability scores. GAPDH and β-
Actin were found to have the highest stability score as shown in table 2.1, as they had the lowest 
stability value in Normfinder™. 
 I tested for iNOS gene expression changes after each treatment. Also, I tested for expression of 
TLR-2 and 6 genes, as involved in the invasion of other mycoplasmas in macrophages (Muhlradt 
and Frisch, 1994; Muhlradt et al., 1997). The results are shown in figure 2.4. 
Equation: Theoretical copy number= 10^((Cq-35)/slope of target standard 
curve)………………………………………………………………………….(2.1) 
Table 2. 2: Estimation of the stability of reference genes using NormFinder™ algorithm. In 
NormFinder™ a low value indicates a more stable gene. 
Gene name Stability value 
GAPDH 0.586 
β-Actin 0.810 
RPS15a 1.203 
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RPS9 1.263 
YHZ 1.730 
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Figure 2. 4: Differential expression of iNOS, TLR-2 and TLR-6 genes in infected BAMs. The 
expression of these genes was measured by qPCR on untreated BAMs, treated with LPS, M. bovis, and 
LPS + M. bovis. Specific primers to iNOS, TLR-2 and 6 were used. The comparative threshold cycle (2-
ΔΔCT) method was utilized to calculate fold change (mean± SD) between different treatments compared to 
the untreated control. Data were normalized using GAPDH as the reference gene. Each dot represents a 
different animal. Black symbols represent TLR-6; blue represents iNOS; and red represents TLR-2. The 
experiment was conducted with 2 technical replicates. Significant differences between the treatments and 
Mb1 treated cells are indicated by * = P<0.05, ** = P<0.01. 
There was an increase in the iNOS gene expression after infection with M. bovis, LPS and 
Mb1+LPS compared to untreated cells (Fig. 2.4). Expression of the TLR-2 and TLR-6 genes in 
BAMs was not changed after the different treatments.  
Effect of M. bovis strain Mb1 infection on BAMs cell surface receptors associated with 
antigen presentation 
I sought to see if in vitro infection with M. bovis strain Mb1 would modulate expression of 
different receptors involved in antigen presentation mechanisms. I used FACS to evaluate the 
relative expression of various relevant cell surface markers: MHCΙΙ; CD163: a scavenger 
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receptor on macrophages; CD80/86: co-stimulatory signal necessary for T-cell activation; and 
CD40: a co-stimulatory signal important in APC cells. The results are shown in figure 2.5. 
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Figure 2. 5: Expression of surface receptors on infected BAMs. Expression of receptors associated 
with antigen presentation and other macrophage receptors was detected using FACS. Each data point 
represents a different animal and the experiment was conducted with two technical replicates. Black 
symbols represent untreated BAMs; blue represent Mb1-infected BAMs, while red represents LPS-treated 
BAMs. The data are presented as mean and differences between treatments. Significant differences 
between the treatments and untreated cells are indicated by * = P<0.05, *** = P<0.001. 
The results indicated that there were no statistically significant differences in expression of the 
APCs surface receptors, CD86, CD40, CD163, CD205, and MHC class II except for the 
significant overexpression of one of the B7 co-stimulatory molecule, CD80 after Mb1 infection 
(Fig. 2.5). 
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2.4. Discussion  
During mycoplasma infection, invasion of the respiratory tract results in activation of the innate 
response as the first line of defense and primes the adaptive immune response against the 
bacteria. Jungi et al., suggested that alveolar macrophage effector functions are modulated upon 
Mycoplasma spp. infections and their inappropriate activation can promote an excessive 
inflammatory response (Jungi et al., 1996). Several studies have shown that M. bovis invades and 
persists in alveolar macrophages (Burgi et al., 2018; Maina et al., 2018; Suleman et al., 2016a) 
circumventing their effector functions. The intracellular phase of M. bovis represents a protective 
niche for avoiding clearance by host immune cells as demonstrated by Kleinschmidt et al., in 
alveolar macrophages (Kleinschmidt et al., 2013). To date, the mechanisms of evading 
macrophage effector functions by M. bovis are not well elucidated. I used primary alveolar 
macrophages infected with Mb1 to demonstrate that the production of NO and cytokines was not 
stimulated. These experiments aimed to determine whether M. bovis modulated host macrophage 
effector functions and the results from these studies represent pathogen-host interactions that 
occur between M. bovis and cattle alveolar macrophages. Here I report no stimulation of TNF-α 
and an increase of IL-10 expression in macrophages infected with the M. bovis strain Mb1. 
Macrophages are an important line of defense against mycoplasmas in the respiratory tract 
(Caswell, 2014; Maunsell et al., 2011), exerting their protective effects principally through 
phagocytosis, production of ROS, NO, and inflammatory cytokines (Lai et al., 2010; Lohmann-
Matthes et al., 1994; MacMicking et al., 1997b). Disruption of these macrophage functions could 
lead to persistence and survival of M. bovis. 
The secretion profile of M. bovis in infected primary BAMs indicates basal levels of pro-
inflammatory TNF-α and up-regulation of anti-inflammatory IL-10 (Fig. 2.2). Consistent with 
these findings, there are previous reports of low IFN-γ and TNF-α and high IL-10 cytokines 
expression in monocytes (Mulongo et al., 2014). TNF-α plays a key role in inflammatory, 
infectious, and malignant conditions while IL-10 plays a role in suppression of inflammation and 
skews the immune response to a TH2 response dominated by antibodies (Couper et al., 2008a). 
These observations agree with reports of a TH2-skewed immune response after an M. bovis 
infection resulting in moderate IFN-γ, high IL-4 levels in T-cells; and high IgG1, low IgG2 titres 
in the serum (Vanden Bush and Rosenbusch, 2003). In contrast, Rodriguez and his group used 
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immunohistochemistry to identify increased in vivo levels of TNF-α, IL-4, and IFN-γ in 
experimentally infected lungs compared to un-infected controls. In M. bovis-infected neutrophils, 
there was stimulation of the pro-inflammatory cytokines TNF-α and IL-12 (Jimbo et al., 2017). 
Interestingly, just as I observed by ELISA tests, there was no significant production of IL-1α, IL-
1β, IL-2, IL-6, and IL-8 between the different treatments (Rodriguez et al., 2015). In our previous 
work, we show evidence that suggests that there was in vitro expression of IL-17 after incubation 
of PBMCs with M. bovis Mb1 proteins (Prysliak et al., 2018) however I found that there was no 
IL-17 production by infected primary BAMs. The different observations may be attributed to the 
specific cell types used in different studies. 
The pro-inflammatory cytokines IFN-γ and TNF-α are known to be stimulated by expression of 
iNOS (MacMicking et al., 1997a). The low NO levels secreted by infected primary BAMs could 
be explained by the low expression of TNF-α in these cells. Only a few papers have been 
published regarding inhibition of NO production by mycoplasma. Here I report a trend 
reduction of NO production (Fig. 2.3) and no reduced expression of the iNOS gene (Fig. 2.4) by 
infected primary macrophages at 3h compared to untreated cells. Similarly, there is evidence of 
host immune modulation of bovine neutrophils by M. bovis. In vitro studies revealed an increase 
in elastase release and inhibition NO production after infection of neutrophils with the M. bovis 
strain Mb1 (Jimbo et al., 2017). Additionally, M. bovis inhibited neutrophil respiratory burst 
(Thomas et al., 1991). As described below inhibition of NO production is not only observed in M. 
bovis.  
During infection of rat macrophages, Francisella tularensis uses phase variation to alter the host 
macrophage nitric oxide response and its antigenicity. A reverse phase shift reduces NO and 
restores intracellular growth perhaps to prolong the host-pathogen interaction during acute or to 
establish a chronic state. Given that M. bovis also has the phase-variation phenomenon I cannot 
rule out the likelihood of this survival strategy (Cowley et al., 1996). Similarly, infection of the 
macrophage cell lines, J774-A1 and RAW 264.7 with the parasite Toxoplasma gondii resulted in 
inhibition of NO production through up-regulation of arginase 1 (Arg1) which competes with 
iNOS for the substrate L-arginine. This effect on the cell lines was concluded to be a survival 
mechanism to avoid clearance (Cabral et al., 2018). There are very few studies on arginase 1 
activity during mycoplasma infection. A study carried out in sheep with contagious agalactia 
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demonstrated significant decreases in host erythrocyte arginase activity and significant increases 
in plasma NO compared to healthy sheep. The study further suggested that increase in plasma 
NO might contribute to the elimination of the pathogen (Hanedan et al., 2017). Other pathogens 
deploy their own arginases for immune suppression, such as, Helicobacter pylori arginase that 
inhibits nitric oxide production in the cell line RAW 264.7 (Gobert et al., 2001) and a parasite-
encoded arginase of Leishmania spp. that increases disease outcome of murine cutaneous 
leishmaniasis through decreased iNOS (Gaur et al., 2007). In another study in the J774 
macrophage-like cell line infection with BCG (Bacille Calmette-Guerin) suppressed NO 
production by induction of Arg1 (El Kasmi et al., 2008). Currently, there is no known 
information on the effects of bovine host macrophage Arg1 modulation with infection of 
mycoplasma or if there is a gene that encodes for Arg1 in any mycoplasma. 
In contrast, in vivo co-localization of M. bovis antigens and iNOS-producing macrophages was 
observed by IHC of lungs from infected calves compared to un-infected calves. The findings 
suggested that NO was also somewhat involved in the lung damage seen in severe chronic M. 
bovis infection. The discrepancies observed in the different M. bovis studies may be due to 
presence of other types of macrophages such as tissue macrophages and the fact that host-
protective functions of iNOS/NO are restricted to certain stages of the diseases. As such, in 
infections with mycobacteria, iNOS is critical in the late and not early stages of the infection 
(Cooper et al., 2000). 
 In other mycoplasmas, M. synoviae (Lavric et al., 2007), M. fermentans (Muhlradt and Frisch, 
1994) and M. hyopneumoniae (Bai et al., 2013) are known to induce NO production in 
macrophages leading to increased acute disease progression in their hosts. These differences with 
M. bovis may be a result of strain-specific differences and also due to the stage of infection. 
Additionally, high levels of NO production are found in healthy lung tissues of different species 
(sheep, human and rats), (Radi et al., 2001). Here, I also reported basal production of NO in 
untreated BAMs (Fig. 2.3). 
One could also argue that the presence of TLRs 2 and 6 (Fig. 2.4) genes transcripts on primary 
BAMs helps in recognition of PAMPs and leads to the transcription of genes involved in the 
activation of the innate host defense, mainly the production of pro-inflammatory cytokines such 
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as TNF-α, IL1β, and IL-12 and NO. Several studies on M. genitalium, M. fermentans, and M. 
pneumoniae indicate that following stimulation of TLR-2 and TLR-6, the NF-κB signalling 
pathway is activated to elicit inflammatory responses (Into et al., 2004b; McGowin et al., 2009; 
Shimizu et al., 2005, 2008). Expression of surface receptors on APCs is important in antigen 
presentation to the adaptive immune system. In this study, when comparing the surface markers 
expression on the primary BAMs populations (Fig. 2.5) there were no significant changes in the 
expression of MHC ΙΙ, CD163, CD86, CD40 markers on infected primary BAMs except for 
CD80 that was significantly up-regulated in infected primary BAMs. These results did not give 
us information on what modulates primary BAMs surface-receptors expression during antigen 
presentation to T-cells. Thus, in chapter 3, I investigate if there is in vivo modulation of 
presentation of the T-cell antigen OVA to T-cells after infection with M. bovis strain Mb1. 
2.5. Conclusion 
This chapter describes how M. bovis has successfully evolved different strategies to modulate 
BAMs effector functions for survival and persistence. As a result of this, I report modulation of 
pro-inflammatory cytokine production with a decrease trend in NO production and an increased 
expression of one of the B7 complex receptors, CD80 in M. bovis infected primary BAMs. This 
is one of the different strategies applied by M. bovis for survival and immune suppression of the 
host. The ability of the immune cells to move within the host also allows pathogens to 
disseminate systemically inside their host to various tissues such as, synovial membrane (Haines 
et al., 2001b), liver (Adegboye et al., 1995), and kidneys (Hermeyer et al., 2012b). Taken 
together, the findings provide evidence for the suppression of macrophage effector functions and 
have implications in disease pathogenesis. 
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Transition statement 
Modulation of protein activity by post-translational modification through cellular 
phosphorylation is an important regulatory mechanism that can be evaluated by using a high-
throughput fashion in a kinome arrays. Kinome arrays are a useful tool to identify biochemical 
pathways modulated by host-pathogen interactions. Elucidation of signal transduction pathways 
by kinome array is becoming popular because kinase-mediated phosphorylation is the 
predominant mechanism for regulation of protein function. (Manning et al., 2002). Bovine-
specific peptide kinome arrays is available (Jalal et al., 2009), and it was used in search of Toll-
like receptor signalling in bovine monocytes (Arsenault et al., 2009), and to unravel novel 
immune evasion mechanisms of Mycobacterium avium subsp. paratuberculosis in monocytes 
(Arsenault et al., 2012; 2013). In a related study, our research team investigated phosphorylation 
pathways modulated by the interaction of bovine alveolar macrophages and monocytes cells with 
M. bovis Mb1 using a kinome array (Mulongo et al., 2014). Among the pathways that were 
increased phosphorylated were: IFN-γ, apoptosis, and NF-κB, while the down-phosphorylated 
pathways were: caspases, T-cell receptor signalling, inhibition of cellular proliferation, and 
antigen processing. In this study, we sought to analyse in more detail the antigen presentation 
capacity of infected macrophage cells. 
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CHAPTER 3. Antigen presentation capacity of primary BAMs infected with Mycoplasma 
bovis strain Mb1 
3.1 Abstract 
A successful antigen presentation requires multiple molecular signals. Antigen-presenting cells 
(APCs) capture and process antigens into small peptides before displaying them on their surface 
in association with MHC class I and II molecules and thus allowing the naïve T-cells to recognize 
them and induce an immunological reaction. Other co-stimulatory molecules expressed on the 
APCs must bind to their respective receptors found on T-cells. CD40 receptors on APCs bind to 
the CD40L found on the T-cells. Only then, the host mounts an immune response to that antigen 
characterized by the production of IL-2 that induces T-cell proliferation followed by a cascade of 
events. I showed that the expression of several key BAM surface markers in vitro, (chapter 2) 
was not affected by infection with Mb1 except for CD80 and hence, I sought to determine if the 
ability of BAMs to present a known T-cell antigen (ovalbumin) was affected after infection with 
M. bovis. An animal trial was designed to test the humoral and cell-mediated immune responses 
to ovalbumin (OVA) followed by a challenge with M. bovis strain Mb1. The animals were 
vaccinated twice with OVA formulated in EmulsigenTM and CpG oligodeoxynucleotides. At the 
end of the trial, I pulsed the BAMs with OVA co-incubated with T-cells and collected 
supernatants and cells for cytokine and proliferation assays respectively to test the hypothesis that 
infection of the BAMs with M. bovis Mb1 would reduce/interfere with the presentation of OVA 
to PBMCs and T-cells. The study resulted in a marked humoral response in the two groups 
(infected and control), as judged by the steady increase of anti-ovalbumin antigen titers over the 
course of vaccination. Examination of haematoxylin and eosin (H&E)-stained lung tissues 
sections indicated that there were no differences in morphology and cell infiltration of the 
bronchiolar lumen with neutrophils or macrophage accumulation of cells between the two groups. 
There was also no effect on the T-cell proliferative responses to the antigen of either the infected 
nor the non-infected BAMs except for the cells stimulated with ConA. 
3.2 Materials and Methods 
Bacteria strains and culture conditions 
The experiments were conducted using M. bovis strain Mb1, which was previously isolated from 
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the synovial fluid of a calf exhibiting signs of arthritis (Perez-Casal and Prysliak, 2007). Cultures 
were grown in modified Hayflick’s medium at 37°C in a 5% CO2 atmosphere. Bacteria were 
collected by centrifugation at 10 000 × g and suspended in the same medium at the highest 
concentration as determined by counting the bacteria in a hemocytometer. Challenge doses were 
prepared by serial dilutions of the original suspension in the same medium to 5.00 × 1010 cfu/ml. 
Animal trial  
All animal experiments followed the guidelines of the Canadian Council on Animal Care and 
followed protocols approved by the University of Saskatchewan Animal Research Ethics Board. 
The trials were conducted at the VIDO-InterVac research farm. The trial consisted of 6 beef 
calves about 6 months old previously determined to be negative for respiratory mycoplasmas by 
nasal swab cultures. Six calves were assigned into 2 groups (infected and non-infected) of 3 
animals each using a random numbers table. The groups were separated for the duration of the 
study. All six animals were vaccinated with 1mg of OVA in 30% EmulsigenTM, 250µg/dose of 
CpG, and PBS intramuscularly as described in figure 3.1. On day 57 M. bovis strain Mb1 (5×1010 
cfu/ml) suspended in 4ml of culture medium was administered directly into the trachea of 
animals in one group of the calves (infected group). The control group was given an equal 
volume of sterile Hayflick's broth. Animals were observed daily for clinical signs of disease and 
euthanized on day 60. Investigators who were unaware of the status of the animals carried out all 
clinical and gross pathology assessments. Necropsy of all animals and collection of tissue 
samples was carried out as described before (Prysliak et al., 2011) on day 60. Serum antibody 
titres against the OVA antigen were determined at days 0, 21 (prior to boost), 41, (second boost), 
57 (pre-challenge), and 60 (post-challenge). 
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Figure 3. 1: Animal trial scheme. 
Sample collection and preparation: 
Recovery of M. bovis from tissue samples 
Nasal secretions were collected on day 0 and after the trial (D60) and lung sections after 
euthanizing the animals, after a 48h pre-enrichment in Hayflick’s medium, they were spread on 
plates for isolation of M. bovis. Colonies resembling M. bovis were isolated and their genomic 
DNA extracted by detergent lysis and proteinase K treatment. Using polymerase chain reaction 
(PCR) primer were specific of the M. bovis gene encoding glyceraldehyde 3-phosphate 
dehydrogenase, GAPDH was used to identify M. bovis strain Mb1 (Perez-Casal and Prysliak, 
2007). The primer pair used is shown in table 3.1. PCR reactions of 25 µl final volume were 
carried out using a commercial Taq-polymerase and buffer (GE-Healthcare Bio-Sciences Inc., 
Baie d’Urfe, QC) with 3mM MgCl2. PCR conditions used were 1 cycle of 2min at 94°C, 35 
cycles of 30s, 94°C, 30s annealing at the appropriate temperature for the primer combination 
used, 2min extension at 72°C and a final cycle of 5min at 72°C An aliquot of the sample was 
processed and bands resolved by gel electrophoresis on a 2% agarose gel stained with ethidium 
bromide and a positive control of M. bovis DNA was included on the gel. 
Genomic DNA isolation 
Briefly, M. bovis cells were harvested using trypsin/ ethylene diamine tetra acetic acid (EDTA) 
buffer. Cells were washed twice in phosphate-buffered saline and lysed with 0.5xTBE (25 mM 
TRIS, 25 mM boric acid and 0.5 mM EDTA) containing 0.25% (v/v) NP-40). RNase H 
(0.5 mg/ml, Sigma Inc, St. Louis, MO, USA) was added and samples incubated for 45min at 
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37°C followed by addition of Proteinase K (0.5 mg/ml, Sigma Inc, St. Louis, MO, USA) with 
continued incubation for another 45min at 37°C. The cell debris was removed by 
centrifugation at 14 000 rpm at 4°C for 10min. The supernatants were transferred into new 
EppendorfTM tubes and DNA extracted using 500 µl of buffered phenol (Sigma Inc, St Louis, 
MO, USA) and with chloroform/isoamyl alcohol (24:1, Sigma Inc, St. Louis, MO, USA). 
Addition of 5 M NaCl to a final concentration of 200 mM and 2 volumes of ice-cold 100% 
ethanol precipitated the DNA. The samples were mixed by inverting them and further 
precipitated at −80°C for 20min or −20°C overnight. The DNA was pelleted by centrifugation 
at 14 000 rpm at RT for 20min, washed with ice cold 70% ethanol and pelleted again and 
allowed to air-dry. The pellet was resuspended in 40µl of TE, pH 7.5 and used for the PCR 
reaction. 
Table 3. 1: Primers used in this study. 
Name Sequence 
Product 
size (bp) Reference 
M.b.gap7 
F: 
ATAGGAGGATCCAAAAGAGTCGCTATCAATGG
TTTTGGACG 
1018 
 
(Perez-
Casal and 
Prysliak, 
2007) 
M.b. gap8 
R: 
GGAAATGGTACCTTACTTAGTTAGTTTAGCAAA
GTATGTTAATG 
(Perez-
Casal and 
Prysliak, 
2007) 
The sequences of GAPDH primers used in the trial are shown. F: Forward primer and R: Reverse primer. 
Serum  
Blood was collected from all animals by jugular venipuncture on days 0, 21 (prior to boost), 41, 
(second boost), 57 (pre-challenge), and 60 (post-challenge). Serum was decanted following 
centrifugation at 1000 x g for 15min to remove clots, red blood cells and other cells. Serum was 
then aliquoted and stored at -20°C until analysis for OVA IgG antibody titres. 
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Isolation of bovine alveolar macrophages (BAMs) 
The lungs of the recently euthanized animals were gradually filled via the trachea with sterile 
Hanks balanced salt solution (HBSS) supplemented with 2X antibiotic-antimycotic cocktail 
(penicillin, streptomycin, and amphotericin B) and 1X gentamicin. The lungs were gently 
massaged and the lavage decanted into sterile bottles to harvest the BAMs suspension. Washing 
of the lungs required 3 to 4l of HBSS (dependent upon lung size) and about one-half of this 
volume could be recovered. The macrophage suspension was centrifuged at 400 × g for 10min at 
4°C and the cell pellet was collected and washed with cold PBS supplemented with 2X 
antibiotic-antimycotic and suspended in D-MEM medium. The cells were then counted in a 
Coulter counter and the suspension diluted to the required working concentration of BAMs. D-
MEM containing 10% FBS, 0.05 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 0.1mM 
nonessential amino acids, and 10mM HEPES buffer was used to culture BAMs for all subsequent 
assays. Trypan blue 0.4% and flow cytometry were used to assess the viability of the BAMs. 
Lung tissues samples for histological and immunohistological analysis 
Lung tissues of approximately 3cm3 were excised and immersed in 10% buffered formalin (10% 
formaldehyde in PBS; v/v) for transport to PDS (Prairie Diagnostics Lab, SK, Canada) for wax 
embedment. The formalin-fixed tissues were hand-trimmed and wax-embedded into labelled 
cassettes. Three-micron sections were then cut from the wax-embedded tissues using a 
microtome (Leica Microsystems, Milton Keynes, UK) and floated on the surface of a pre-heated 
(45-55oC) water bath. The floating sections were picked up using a microscope slide (VWR, 
West Sussex, UK) ready for IHC. 
PBMC purification 
Blood samples (60 ml from each animal) were collected in syringes containing sodium EDTA 
and the cells separated by centrifugation at 2500rpm for 20min at RT, with no brake. The buffy 
coat fraction (containing PBMC) was purified by Ficoll gradients (GE Healthcare, ON, Canada). 
The PBMCs isolated were washed thrice with PBSA (137 mM NaCl, 2.7 mM KCl, 7 mM 
Na3PO4, and 1.5 mM KH2PO4) containing EDTA and suspended in MEM medium in the 
working concentration. 
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T-cell isolation 
Isolated PMBCs were labelled with a cocktail of biotin-conjugated antibodies for 5min in the 
refrigerator (2-8°C). The cocktail contained antibodies against CD8, CD14, CD15, CD16, CD19, 
CD36, CD56, CD123, TCR γ/δ, and CD235a (Glycophorin A) (Miltenyi Biotec, Auburn, CA). 
CD4+ T-cell MicroBead cocktail was added to the cell suspension and further incubated for 
10min in the refrigerator (2-8°C). Next, the CD4+ T-cells were negatively selected for on LS 
columns using a magnetic isolated cell sorter (Miltenyi Biotec, Auburn, CA). The collected flow-
through containing unlabeled cells represented the enriched CD4+ T-cells. The cells were washed 
twice in PBSA and suspended in MEM medium in the correct concentration. 
Proliferation assay 
The isolated PBMC and T-cells were used for the proliferation assay with stimulation of the cells 
with concanavalin A (ConA; Sigma-Aldrich, Ontario, Canada), different OVA concentrations 
and/or M. bovis Mb1. 96-well tissue culture plates were seeded with PBMC or T-cells (5 x 
105/per well) and incubated at 37°C in 5% CO2 atmosphere in the presence of 1µg of ConA/ml 
and/or infection with M. bovis Mb1 using 2.5 x 106 cfu/ml at a MOI of 5:1 at 24h in triplicates. A 
solution containing 0.4 µCi of [3H] thymidine (GE Healthcare)/well was added, and the cells 
were incubated for 18h. The cells were harvested (Filtermate Harvester; Guelph, Ontario), the 
amount of incorporated [3H] thymidine was determined in a scintillation counter (Top Count 
NXT; Guelph, Ontario), and the stimulation index was determined by the formula: counts per 
minute of treated PBMCs/counts per minute of control or unstimulated PBMCs 
CFSE assay 
The enriched T-cell population was stained with CellTrace CFSE staining solution (Cell Trace 
CFSE, ThermoFisher, Massachusetts, USA), and incubated for 20min in a 37°C water bath. 
CFSE is a cell-permeant fluorescent intracellular labeling tool of live cells and monitors 
lymphocyte proliferation. Cells were collected by centrifugation and suspended in MEM medium 
and plated in a 96 well U-bottom plate for incubation with: ConA, live M. bovis Mb1 with, or 
without ConA, 0.5µg/ml, 1µg/ml, 5µg/ml, and 10µg/ml of OVA) and assessed proliferation with 
flow cytometry. Samples were analysed with (BD FACSCaliburTM, San Jose, CA) and data 
analysed with Kaluza® (Beckman Coulter, Indianapolis, US). 
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Humoral and cell mediated immune responses assay 
Serum antibodies responses (IgG) to OVA antigen were determined using a multiplex platform as 
previously described (Prysliak et al., 2018). Briefly, 96-well Immuno II plates were coated with 
5ng OVA per well in carbonated buffer overnight at 4°C. The plates were washed 4 times in 
PBS-T to prevent non-specific binding to the plastic surface and the wells were coated with 
PBST-G for 2h. After washing, serum samples from the 6 animals were serially diluted in PBST-
G (1/100 first and 4-fold further on) placed in the wells and incubated for 2h at RT and washed 
thrice. IgG was detected using alkaline phosphatase-conjugated goat anti-bovine IgG (KPL 
antibodies, MA, USA) followed by washes. Alkaline-phosphatase substrate NTA was added and 
the reaction incubated for 30min at RT and the A405 was read using a Bio-Rad Xmax 
spectrophotometric microplate reader. The titers were calculated by the intersection of least-
square regression of A405 versus the logarithm of the serum dilution. 
Purification of bovine PBMC and proliferation assay were also performed as described above on 
days 0 (Pre-vaccination), pre-boost, pre-challenge and post-challenge. T-cells were further 
purified from the PBMCs using MACS® cell separation kit (Miltenyi Biotec, CA, USA), as 
described above on day 60 (post-challenge) according to the manufacturers’ instructions. The 
purified T-cells were used in the in vitro antigen-presentation assay. 
In vitro antigen presenting assay 
The BAMs isolated from the 6 animals were pulsed with different concentrations of OVA for 4h 
and 8h then an equal number of T-cells from the same animals were added. The supernatants 
were collected after 24h, 48h, and 72h of incubation at 37°C in 5% CO2 atmosphere and used for 
determination of cytokine levels. The T-cell proliferation assay was used as readout for 
successful antigen presentation using a thymidine incorporation assay alongside a CFSE assay by 
flow cytometry. Samples were analysed with (BD FACSCaliburTM, San Jose, CA) and data 
analysed with Kaluza® 
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Haematoxylin and eosin (H&E) staining of tissues 
The Prairie Diagnostic Services Inc. (SK, CA) performed the H&E staining, and I collected the 
slides for subsequent microscopic examination and photography. 
Immunohistochemistry (IHC) of tissue sections 
Sections were immersed in 100% xylene (2 x 6min each) then immediately transferred to 100% 
ethanol (2 x 6min each) and finally placed in a 100o C water bath for 15min. Antigen retrieval 
was achieved by immersing the sections in pre-heated citrate buffer [0.25% (w/v) trisodium 
citrate hydrate (Na3C6H5O7) and 0.025% citric acid (C6H8O7); pH 6.1] in deionized water. The 
sections were heated at 800 watts in a microwave for 10min then left to cool in citrate buffer for a 
further 10min before transferring them into water for 2min. IHC was carried out on the samples 
using the VECTASTAIN®ABC-AP (alkaline phosphatase) detection kit according to the 
instructions of the manufacturer and stained at 1/500 dilution using M. bovis antibodies 
(procedure performed by PDS), mouse anti bovine TNF-α (in-house), mouse anti bovine MHC II 
(Serotec), and mouse anti bovine IFN-γ (in house). An isotype control (mouse IgG1) was used as 
a negative control. The sections were dehydrated by sequential immersion in 70%, 90%, and 
100% ethanol respectively and subsequent immersion in 100% xylene. Sections were then 
mounted with coverslips using VectaMount™ (Vector, CA, USA) and left overnight to dry and 
subsequently examined under a microscope and photographed. 
Statistical analysis 
Prism 7.0c (GraphPad Software, Mac OS X, La Jolla, CA, USA) was used for data analysis. I 
used one-way ANOVA (Friedman) to analyse the serum OVA IgG and Ag presentation assay 
data and two-way ANOVA to analyse the PBMC and T-cell proliferation data. This was followed 
by multiple-groups analysis using Dunn’s multiple comparison tests for the serum OVA IgG and 
Tukey’s multiple comparison tests for the proliferation data to compare the different treatments. 
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3.3. Results  
Isolation of M. bovis Mb1 
Nasal swabs from all the 6 animals were collected in saline and cultured in PPLO medium to 
detect M. bovis Mb1. I prepared genomic DNA from the cultures and used primers specific for M. 
bovis (Table 3.1). I was not able to isolate M. bovis Mb1 from the nasal swab cultures as judged 
by the negative results of the PCR reactions performed on samples collected before and after the 
M. bovis Mb1 challenge (data not shown). 
Lung pathology 
All the animals were vaccinated with OVA but only one group was infected with Mb1. 
Macroscopic examination of the lungs from the non-infected and infected group were performed 
and the results are shown in figure 3.2. No gross pathological characteristic of M. bovis infection 
such as the characteristic multifocal ‘marble cheese’ caseous necrosis effect and consolidation of 
the lungs was observed at necropsy of lungs of the infected group of calves; #186, #187, and 
#190. The pathological scores were determined by detecting the presence of lesions, multifocal 
white nodules containing caseous material, characteristic of M. bovis infections or consolidation 
of the lung tissues. There was only 1% pathology score on one of the lung tissue (261) in the non-
infected (control group). 
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Figure 3. 2: Figure 3.2: Lung pathology. Gross pathology of lungs from all the six animals vaccinated 
with OVA, 3 infected with M. bovis Mb1: #186, #187, and #190 and 3, control non-infected calves: #181, 
#185 and #246 in the trial. 
Haematoxylin and eosin (H&E) staining of the infected lung tissues 
H&E staining was also carried out for all the 6 animals and the results are shown in figure 3.3. 
There were no differences in morphology and cell infiltration of bronchiolar lumen with 
neutrophils and macrophages by either group. The results infer that the lungs in both groups 
(infected and un-infected) had the same basal cell infiltration. 
 
Figure 3. 3: H&E staining of tissue sections of infected and non-infected lungs. The H&E staining was 
from both non-infected: #181, #185, and #246 and infected cattle: #186, #187, and #190. 
Immunohistochemistry (IHC) of infected lung tissue sections 
IHC was performed on lung sections and the results are shown in figure 3.4. TNF-α and MHC II 
staining were positive for all the 6 animals and appeared as a brown deposit in BAMs that 
adhered to capillary endothelium (Figs. 3.4a and b). This brown deposit was absent in the isotype 
control stained sections. There were no differences in the intensity of the staining between the 
infected and non-infected groups. Staining for M. bovis and IFN-γ was negative in all the lungs 
(Fig. 3.4c). 
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Figure 3. 4: IHC staining of paraffin embedded lung tissues from representative lungs. Paraffin 
sections of lungs from infected and non-infected cattle were stained for TNF-α, IFN-γ, MHC II, and M. 
bovis. As shown in panel (a) and (b), there were cells that stained positive (brown deposit) for TNF-α for 
both infected and non-infected animals (190 and 246 respectively). In contrast to (c), the panel shows no 
positive stain for either Mb1 and IFN-γ. 
Humoral immune responses to OVA antigen 
I measured serum total IgG to OVA antigen and the results are shown in figure 3.5. As expected, 
there was a steady increase of titers over the course of vaccination, with the serum titers in both 
groups (infected and un-infected) higher after the 2nd vaccination boost and before the Mb1 
challenge compared to day 0 values. However, despite not been significant there was a slight 
increase in titres of the infected group after the challenge compared to the un-infected group. 
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Figure 3. 5: Serum immune responses to OVA antigen. The mean of the IgG titers against OVA is 
shown as a bar across the symbols. Blood samples were collected pre-vaccination (Day 0), after 
vaccination (Day 21), after the 2 boosts and prior to M. bovis challenge (Pre-challenge) and at the time of 
necropsy (post-challenge). The differences between treatments were determined by one-way ANOVA 
(Friedman test, Dunn’s multiple comparison tests). Significant differences between the treatments and day 
zero are indicated by ** = P<0.01, *** = P<0.001. 
Cellular-mediated immune responses to the recall antigens 
PBMC proliferation was monitored in response to recall antigens OVA and Mb1 over the course 
of the vaccination and infection and the results are shown in figure 3.6. Compared to day 0 (blue 
bar), stimulation indexes were higher after the first boost (Day 21, black bar) in both panels, (a) 
control un-infected and (b) infected samples (Fig. 3.6) pre- and post-vaccination samples. This 
trend was not seen after the second boost or post-challenge except in recall stimulation with 
10µg/ml OVA post-challenge (purple bar) in control un-infected samples where there was an 
increase in stimulation index even though not significant (Fig. 3.6a). 
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Figure 3. 6: PBMC proliferation assay in the course of the animal trial. 2 groups; control (a) and 
infected (b), 3 animals in each group. Compared to day 0 incubation of live, M. bovis Mb1 with or without 
ConA, 0.5µg/ml, 1µg/ml, 5µg/ml, and 10µg/ml of OVA with bovine PBMC from 6 cattle there was an 
increase after the 1st boost but not after the second and post-challenge except stimulation with 10µg/ml of 
OVA in the control un-infected group. The differences between treatments were determined by two-way 
ANOVA (Tukey’s multiple comparisons test). Blue: day 0, black: 1st boost, green: 2nd boost and purple: 
post challenge. 
Previous results have shown that the ability of Mb1 to suppress the host immune system could be 
accomplished by the down-regulation of lymphocyte proliferation and hence could explain the 
lack of proliferation seen in the infected animals even exposure to live Mb1 (Mulongo et al., 
2014). Post-challenge proliferation of purified T-cells was also performed by flow cytometry 
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using the CFSE staining to confirm the results observed in the thymidine incorporation assay and 
the results are shown in figure 3.7. As shown in proliferation of total purified T-cell post-
challenge (Fig. 3.7), there was no significant T-cell proliferation observed regardless of the recall 
OVA antigen concentration used to stimulate in either the control or challenged group compared 
to the untreated cells. There was significant proliferation in ConA and ConA+Mb1 T-cells 
compared to untreated cells and all treatments compared to ConA but no differences between the 
un-infected and infected samples in the trial. 
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Figure 3. 7: Post-challenge purified T-cell Proliferation (CFSE). This is a graph representative of the 
post-challenge purified T-cells proliferation. Compared to untreated cells, incubation of live, M. bovis 
Mb1 with or without ConA, 0.5µg/ml, 1µg/ml, 5µg/ml, and 10µg/ml of OVA with purified T-cells from 
the 6 calves there was no significant stimulation of proliferation. Significant differences between the 
treatments and untreated cells (medium) are indicated by * = P<0.05, *** = P<0.001 and between 
treatments and ConA are indicated by $$$$= P<0.0001. Black represents non-infected animals and red 
represents infected animals. 
M. bovis Mb1 modulates BAMs presentation of ovalbumin antigen to T-cells 
Macrophages and T-cells were co-cultured to investigate the stimulatory capacity of Mb1 
infected macrophages, to promote T lymphocyte proliferation. The results are shown in figure 
3.8. In the in vitro OVA antigen presentation assay where purified T-cells were co-incubated with 
OVA pulsed macrophages for 4h and 8h there was no T-cell proliferation by either OVA antigens 
and Mb1 compared to untreated cells. The results suggest an inhibitory proliferation mechanism 
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by Mb1compared to Mb1+OVA. There were significant stimulation indices by ConA compared 
to untreated cells showing that the cells were not dead during the assay (Fig. 3.8). 
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Figure 3. 8: OVA antigen presentation assay. BAMs incubated with different concentrations of OVA 
for 4h and 8h and mixed with an equal number of purified T-cells. Cells were incubated for 72h the cells 
and pulsed with thymidine for 18h. No stimulation was observed regardless of the stimulation except for 
ConA. Significant differences between the treatments and (untreated cells) medium are indicated by *** = 
P<0.001. Red represents infected animals and black represents non-infected animals. 
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3.4. Discussion 
Antigen presentation is a biological process where the APCs capture and process antigens into 
small peptides before displaying them on their surface in association with MHC class I and II 
molecules, and hence allow the T-cells to recognize them and induce an immunological reaction 
(Ten Broeke et al., 2013). 
MHC I molecules are expressed on all nucleated cells and present the endogenous proteins (self 
or from intracellular pathogens) to CD8+/cytotoxic T-cells. They are made of α and 
β2‐microglobulin chains of proteins. The antigens are processed by proteasomes into peptides (8-
10 residues) and transported across the ER by transporter proteins (Yaneva et al., 2010). The 
peptide fragments that fit the MHC I groove binds and the complex is expressed on the cell 
surface to be presented to cytotoxic T-cells (Yaneva et al., 2010). If the CD8+ T-cells recognize 
self they do not mount an immune response but if they recognize foreign peptides they will kill 
the infected cells (Li and Raghavan, 2010).  
MHC II molecules are expressed on activated macrophages, dendritic cells and activated B-cells. 
They are made up of α and β chains of protein produced in the cytoplasm and injected into the 
endoplasmic reticulum (ER) where they are loaded with an invariant chain protein in their groove 
to avoid binding to proteins in the ER. The invariant chain also guides the MHC II molecules to 
the endosomes within the Golgi apparatus where they are loaded with the antigen peptide and 
presented on the APCs surfaces (Yaneva et al., 2010). The antigen processing by APCs occurs 
when the antigen is enclosed in a phagosome that later merges with the endosome and specific 
endosomal and lysosomal enzymes present in the endosome (e.g. cathepsins), dice the exogenous 
proteins into small peptides (10-30 residues) and subsequently destroy the invariant chain which 
leads to peptide loading on to the MHC II groove. Eventually the MHC II plus the antigen 
complex are transported to the cell surface for display to CD4+ cells (Ten Broeke et al., 2013). 
Three steps are required for successful antigen presentation after processing of the antigen: first, 
the peptides bound to MHC molecules are presented to the TCR complex; second, the CD80/86 
complex on the APCs binds to CD28; and third, CD40 binds to the CD40 ligand (CD40-L) on the 
T-cells. Only then, the host mount an immune response to the antigen that is characteristic of the 
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production of IL-2 and T-cell proliferation followed by a cascade of events (Mantegazza et al., 
2013). 
T-cells express on their surface the T-cell receptor (TCR) that allows presentation of peptides, 
foreign or self bound to MHC by APCs such as macrophages. The recognition of processed 
antigen through MHC molecules to TCR is the most important step towards successful antigen 
presentation (Sundberg et al., 2007). TLR stimulation in macrophages has also been 
demonstrated to be important during microbial presentation on MHC II molecules (Iwasaki and 
Medzhitov, 2004). 
To determine whether antigen presentation of OVA was modulated by an M. bovis infection, an 
animal trial was designed to test the humoral and cell-mediated immune responses to OVA 
before and after a challenge with M. bovis strain Mb1 (Fig. 3.1). The experiments used freshly 
isolated primary BAMs, PBMCs, and T-cells from infected and non-infected calves that were 
vaccinated with OVA. The responses after stimulation of OVA-antigen-specific, or ConA-driven 
T-cells were compared. In chapter 2, I demonstrated that CD80 receptors were upregulated after 
infection with Mb1, while there were no differences in expression of MHC class II, CD163, 
CD86 or CD40 receptors on both infected and non-infected primary BAMs (Fig. 2.5) There was 
increased T-cell proliferation after incubation with ConA showing that the cells used were viable. 
On the other hand, there was no proliferation after incubating with the other recall antigens, OVA 
and Mb1 except for at the highest OVA concentration (10µg/ml), on the post-challenge samples 
in the three control un-infected samples (Fig. 3.6a). 
Several previous studies have shown that proliferation of lymphocytes is down-regulated after 
infection by M. bovis but not their ability to produce cytokines both in vitro (Suleman et al., 
2016a; Thomas et al., 1990; van der Merwe et al., 2010; Vanden Bush and Rosenbusch, 2002) 
and in vivo (Mulongo et al., 2013; Prysliak et al., 2013). Similarly, there are previous reports on 
the decreased proliferative capacity of lymphocytes in response to incubation with 
phytohemagglutinin, a mitogen, by various mycoplasma strains and species in vitro (Naot et al., 
1977). It remains to be discerned whether this is due to faulty antigen presentation, lack of co-
stimulation or T-cell exhaustion due to persistent antigen stimulation. 
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We also know that T-cell activation and proliferation is influenced by control of the PD-1/PD-L1 
immune checkpoint. The programmed death 1 (PD-1) receptors are expressed on activated T-
cells and their interaction with the PD ligand 1 (PD-L1) which is expressed on activated 
macrophages (Butte et al., 2007). Interaction of the PD-1/PD-L1 complex leads to T-cell 
signalling exhaustion inducing immunosuppression (Wherry, 2011). We previously demonstrated 
that there was intermediate and high expression of PD-1 in CD4+ and CD8+ on M. bovis infected 
cells compared to un-infected cells and that blocking the interaction of PD-1 with its ligand with 
an anti-PD-1 antibody restored normal T-cell proliferation (Suleman et al., 2018). These results 
indicate that M. bovis infection is involved in the PD-1/PD-L1 inhibitory pathway modulation 
and immune exhaustion causing impaired host immune responses. 
The animal trial resulted in significant increases of the IgG responses to OVA. Compared with 
day 0 titres, there were significant humoral responses to the OVA antigen in serum samples 
obtained from all animals (infected and non-infected) before and after challenge (Fig. 3.5). The 
current evidence also suggests that there was a failure to infect the three calves as judged by the 
negative result of the PCR reactions for M. bovis DNA post-challenge. 
To successfully test the Ag-presenting model there is need to reproduce the infection through 
challenge models. Previous, M. bovis intranasal challenge (5 × 108 cfu/ml) disease models 
established in our lab included a co-infection model with BHV-1 to reproduce the disease 
(Prysliak et al., 2011). I used the M. bovis strain Mb1 for an intratracheal challenge (5 × 1010 
cfu/ml) for this experiment to infect the calves. In my study, I did not report any lung gross 
pathology (Fig. 3.2) in the Mb1-infected claves nor did I detect M. bovis antigens in the lungs of 
any calves by IHC (Fig. 3.4c). A number of studies have previously reported a reproducible 
infection using a M. bovis alone challenge model with M. bovis doses ranging from 109 to 1010 
cfu/ml and 2-3 weeks infection period after the challenge (Dudek et al., 2016; Nicholas et al., 
2002; Zhang et al., 2014). Since the aim of the study was to investigate the modulation of BAMs’ 
ability to present antigens after infection by M. bovis strain Mb1, I did not use the co-challenge 
model of infection as studies have shown that previous exposure to viruses such as BHV-1 and 
BVDV were immunosuppressive to the host (Prysliak et al., 2011). I also used the adjuvant 
formulation with EmulsigenTM and CpG2007 used previously in M. bovis vaccine trials (Mulongo 
et al., 2013; Prysliak et al., 2013). 
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3.5. Conclusion 
Taken all together, these results suggest that although vaccination with OVA antigen was 
successful, the challenge using M. bovis Mb1 alone did not result in disease. The failure of the 
challenge could be explained by the small window between infection before euthanising (4 days) 
not being enough to observe infection and pathology. The antigen presentation capacity of the 
primary BAMs was also not successfully detected as there were no differences between the 
control un-infected and infected Mb1 samples. 
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Transition statement 
We have previously shown that Mb1 delays apoptosis in primary bovine PBMC subsets (van der 
Merwe et al., 2010), monocytes (Mulongo et al., 2014) and in primary bovine macrophages 
(Suleman et al., 2016a). Mulongo et al., has further shown that in bovine monocytes, Mb1 
decreases caspase 9 expressions and activates translocation of NF-κβ-p65 to the nucleus 
(Mulongo et al., 2014). In this present study, I sought to elucidate the macrophage apoptosis 
pathways that are modulated by M. bovis Mb1; for this, I chose to use BoMac, a bovine 
macrophage cell line (Stabel and Stabel, 1995). My decision to switch from using primary 
alveolar macrophages for the apoptosis assays to a cell line was based on the variability of the 
results obtained from BAMs isolated from abattoirs in the cytokine and NO assays. Commercial 
cattle are not inbred, and thus there are several factors including genetics, age, or previous 
exposure to bacteria or viruses that may influence the results. The advantage of the BoMac cell 
line is that it is genetically uniform and that a large number of cells can be readily grown. 
BoMac cells were a generous gift from Dr. Matthias Schweizer (Universität Bern, Switzerland). 
Before using the BoMac cells, I needed to confirm the results observed with primary alveolar 
macrophage cells that Mb1 delays STS-induced apoptosis. I tested for the survival of Mb1 in the 
cell line, cytokine profiles after infection and whether Mb1 affects STS-induced apoptosis. 
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CHAPTER 4. Modulation of apoptosis and activation of the NF-kappa beta-signalling 
pathway by Mycoplasma bovis Mb1  
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4.1. Abstract 
Mycoplasma bovis is a pathogen that causes various diseases including chronic 
bronchopneumonia, mastitis, otitis, keratoconjuctivitis, meningitis, infertility, and arthritis in 
cattle (Arcangioli et al., 2008; Caswell and Archambault, 2007; Caswell et al., 2010). The 
importance of M. bovis among other pathological agents implicated in bovine respiratory disease 
(BRD) complex has also been shown (Maunsell and Donovan, 2009; Maunsell et al., 2011). BRD 
is a multifactorial disease of feedlot cattle that is caused by M. bovis co-infection with bovine 
herpes virus (BHV-1); parainfluenza virus (PI-3); bovine respiratory syncytial virus (BRSV); 
bovine viral diarrhea virus (BVD), and Mannheimia haemolytica, and Pasteurella multocida 
(Arcangioli et al., 2008). It is also the most pathogenic bovine mycoplasma in Europe and North 
America (Nicholas and Ayling, 2003; Snowder et al., 2006). Although M. bovis is considered to 
be an extracellular pathogen, there is in vivo (Kleinschmidt et al., 2013; Prysliak et al., 2011) and 
in vitro evidence that indicates intracellular presence and survival in different subsets of the host 
immune cells (Burki et al., 2015; Maeda et al., 2003; van der Merwe et al., 2010). To date, the 
mechanisms by which M. bovis interacts with host cells to generate disease are poorly 
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understood. Naturally occurring M. bovis persists in a herd over an extended period and can be 
consistently identified not only in lesions but also commonly in healthy and pneumonic lungs 
(Gagea et al., 2006b). 
Apoptosis (Programmed cell death) is employed by host cells to limit pathogen survival and 
propagation. Apoptosis can also be exploited by the pathogen to evade the host immune response 
(Fulda et al., 2010; Hotchkiss et al., 2009; Renehan et al., 2001). M. bovis has been demonstrated 
to exert both pro and anti-apoptotic effects on a diversity of cell types, including neutrophils, 
lymphocytes, monocytes and macrophages (Jimbo et al., 2017; Mulongo et al., 2014; Suleman et 
al., 2016a; van der Merwe et al., 2010). In monocytes, M. bovis manipulates apoptotic signalling 
through inhibition of caspase 9 and activation of the NF-kβ pathway (Mulongo et al., 2014). M. 
bovis strain Mb1 exerts anti-apoptotic effects on macrophage STS-induced apoptosis (Suleman et 
al., 2016a) but the mechanisms are unknown. In this study, I used the BoMac bovine macrophage 
cell line to determine the apoptosis pathways modulated by Mb1. The BoMac cell line has been 
previously used to study M. bovis co-infection with bovine viral diarrhoea virus in bovine 
macrophages (Burgi et al., 2018). In the present study, I demonstrate the ability of M. bovis strain 
Mb1 but not Mb304 to delay STS-induced apoptosis in BoMac. I also show that M. bovis strain 
Mb1 activates the NF-kβ pathway and induces up-regulation of pro-survival genes Bcl-2 and Bcl-
XL; and inhibits the activity of caspases 3, 6, and 9, reduces ROS production and DNA 
fragmentation upon infection. Our data continue to support observations that M. bovis inhibit 
apoptosis for survival to potentially facilitate bacterial survival, replication and transmission. 
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4.2. Materials and Methods 
Bacteria strains and culture conditions 
The experiments were conducted using M. bovis strain Mb1, which was previously isolated from 
the synovial fluid of a calf exhibiting signs of arthritis (Perez-Casal and Prysliak, 2007), and the 
M. bovis strain Mb304 obtained from bison lung tissue (Suleman et al., 2016a). Cultures were 
grown in modified Hayflick’s medium at 37°C in a 5% CO2 atmosphere. Bacterial cells were 
collected by centrifugation (5,500 x g for 15 min) at the exponential phase of growth and then 
washed with minimum essential medium (MEM; Invitrogen, Burlington, ON, Canada). Bacteria 
were suspended to a cell density of 1x108 cfu/ml in MEM supplemented with 30% glycerol and 
stored at -70°C until use. 
BoMac cell line 
The bovine peritoneal macrophage cell line (BoMac) was obtained as a gift from Dr. Matthias 
Schweizer (Universität Bern, Switzerland) and cultured in D-MEM supplemented with 1mM 
sodium pyruvate and 10% FBS. The cell line was grown to near confluence and split every third-
day using trypsin/EDTA. The cell viability was evaluated by the trypan-blue exclusion assay as 
described earlier (van der Merwe et al., 2010). 
Mycoplasma bovis invasion and survival in BoMac cells 
The assay was carried out as previously described with a few modifications (Burgi et al., 2018; 
Hegde et al., 2014; Suleman et al., 2016a; van der Merwe et al., 2010). Briefly, 5 x 106/per well 
BoMac cells were infected with a range of MOIs (BoMac: M. bovis) of 1:0.1 and 1:5, using 5 x 
106 cfu/ml and 2.5 x 107 cfu/ml respectively. After 3h incubation, the cells were washed and 
cultured in medium containing 400µg/ml Gm (Gibco®, Sigma Inc, St Louis, MO, USA) for 2h to 
kill any extracellular bacteria. Cells were washed twice with warm D-MEM, suspended in D-
MEM and incubated for 2, 6, and 18h treatment as shown in the scheme (Fig. 4.1a). Cells were 
cultured in the presence or absence of Gm to ensure that the use of Gm did not interfere with the 
recovery of viable intracellular bacteria. The culture supernatant was collected at each time point 
and the adherent cells harvested and washed with PBS before lysis. The culture supernatant and 
lysed BoMac cells from each time point were plated in duplicates as 10-fold serial dilutions on 
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Hayflick’s agar plates and incubated for 4 days at 37°C in a 5% CO2 atmosphere, to determine 
the number of extracellular and intracellular viable bacteria respectively. 
Apoptosis assay  
Apoptosis was detected using the Alexa Fluor®488 annexin V/Dead Cell Apoptosis kit 
(Molecular Probes, Life Technologies®, USA). Briefly, cells (5 x 106/per well) were infected with 
both strains of M. bovis (alive and dead) using 2.5 x 107 cfu/ml of M. bovis at a MOI of 1:5 
(BoMac: M. bovis) for 24h and incubated in D-MEM medium in the presence or absence of STS 
(2µg/ml for 6h). To assess if live cells were needed to modulate apoptosis, Mb1 and Mb304 were 
killed with Gm (400µg/ml) for 2h and washed once with warm D-MEM medium prior to the 
apoptosis assay. STS (2µg/ml for 6h) was used as positive control, and the negative control 
included untreated cells grown in the same culture conditions. The cells were harvested using 
trypsin/EDTA buffer and suspended at 2x106 cells/ml in annexin V binding buffer. For every 
100µl aliquot of cells, 5µl of annexin V- Alexa Fluor®488 and 1µl of 100µg/ml propidium iodide 
(PI) were added and incubated for 15min in the dark. Finally, 400µl of annexin V binding buffer 
was added to each tube, mixed gently and the cells immediately analysed by flow cytometry (BD 
FACSCaliburTM, San Jose, CA) using Kaluza® software (Beckman Coulter, Indianapolis, US). 
Caspase assay 
BoMac cells were independently infected with both strains at a MOI of 1:5 (BoMac: M. bovis) 
for 24h in the presence or absence of STS. Controls included cells treated with STS (2 µg/ml for 
6h) or with V-ZAD-FMK, an apoptosis inhibitor (40µM, for 24h), after which the cells were 
lysed for 10min in chilled lysis buffer. The cell debris was removed by centrifugation and the 
cytosolic fraction transferred into a new tube. The protein concentration was adjusted to 
200µg/ml with the cell lysis buffer provided in the colorimetric kit (Abcam, Cambridge, United 
Kingdom). Aliquots of 50µl of the cleared lysate were placed into a 96-well round-bottom 
microtiter plate, Costar™ (Thermo Fisher Scientific, Massachusetts, US) before addition of 50µl 
of the 2x reaction buffer and 5µl of the substrates for caspases 3, 6, or 9. After incubation at 37°C 
for 2h in the dark, the samples were read in a microplate reader (xMark microplate 
spectrophotometer; Bio-Rad, Philadelphia, USA) at 405nm with a 490nm reference filter. 
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ROS measurement 
Intracellular reactive oxygen species (ROS) was measured using the ROS-ID™ Total ROS 
Detection kit (Enzo Life Sciences, Inc., Plymouth Meeting, PA) following the manufacturer’s 
instructions. BoMac cells (5 x 106/per well) were infected with both strains of M. bovis using 2.5 
x 107 cfu/ml at a MOI of 1:5 (BoMac: M. bovis) in the presence and absence of 50µM pyocyanin, 
a ROS inducer. Pyocyanin-treated cells were used as a positive control and untreated cells as a 
negative control. After 30min of incubation at 37°C with 5% CO2 atmosphere intracellular ROS 
production was immediately assessed by measuring intracellular green fluorescence at excitation 
490nm/emission520nm using flow cytometry (BD FACSCaliburTM, San Jose, CA) and data 
analyzed with Kaluza® software (Beckman Coulter, Indianapolis, US). 
Cytochrome C assay 
The cytochrome C releasing assay was carried out following the manufacturer’s instructions 
(Abcam, Cambridge, United Kingdom). Briefly, BoMac cells (5 x 106/per well) were either un-
infected or infected with both strains of M. bovis using 2.5 x 107 cfu/ml at a MOI of 1:5 (BoMac 
cells: M. bovis) for 24h in the presence or absence of STS (6h) and harvested in ice-cold PBS. 
Cells were collected by centrifugation and the pelleted cells were suspended in buffer A on ice 
for 10min. The cells were homogenized with 40 passes by using a Kontes douncer tissue grinder. 
The homogenates were centrifuged and the supernatants saved as the cytosol fractions. The 
pellets were suspended in buffer B, vortexed for 10s and kept as the mitochondrial fractions. 
These two fractions were separated on 12% polyacrylamide gel and subjected to western blotting 
using a bovine cytochrome C antibody (Abcam, Cambridge, United Kingdom) and an IRDye® 
800CW goat anti-mouse IgG (LI-COR ®, Lincoln, US). 
DNA fragmentation 
The DNA fragmentation assay was adopted from (Dumont et al., 1999). Cells were infected 
with both strains of M. bovis for 3h in the presence or absence of STS (2µg/ml). Cells treated 
with STS alone (2 µg/ml, 6h) were used as control. Cells were harvested using trypsin/EDTA 
buffer. Cells were washed twice in phosphate-buffered saline and lysed with 0.5xTBE (25 mM 
TRIS, 25 mM boric acid and 0.5 mM EDTA) containing 0.25% (v/v) NP-40). RNAse H 
(0.5 mg/ml) was added and samples incubated for 45min at 37°C followed by addition of 
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proteinase K (0.5mg/ml, Sigma Inc, St. Louis, MO, USA) with continued incubation for 
another 45min at 37°C. The cell debris was removed by centrifugation at 14 000 rpm at 4°C 
for 10min. The supernatant was transferred into a new Eppendorf tube and, the DNA 
fragments were separated on a 1.5% (w/v) agarose gel (50 V for 2h), stained with ethidium 
bromide in TBE buffer and visualized under ultraviolet light. 
NF-kβ p65 nuclear translocation assay  
This assay was carried out as previously described (Mulongo et al., 2014). Briefly, both strains of 
M. bovis were used to infect 5 x 106/per well BoMac cells using 2.5 x 107 cfu/ml at a MOI of 1:5 
(BoMac: M. bovis) and incubated for 24h. The controls included 1µg/well of Escherichia 
coli LPS (Sigma Inc, St. Louis, MO, USA) for 24h, 2µg/well of STS for 6h and untreated cells 
for 24h. The NF-kβ activation kit (Five Photon Biochemicals, San Diego, CA) was used to 
separate the cytoplasmic and nuclear fractions. The fractions were separated on a 12% SDS-
PAGE and transferred to a nitrocellulose membrane. Western blots were performed using the 
bovine anti-P65 and Alexa 680 anti-rabbit antibodies provided in the kit. The only 
modification was that no Tween-20 was added in the blocking step as the image was taken using 
the LI-COR ®Odyssey® Imager. 
Quantitative real-time PCR 
Total RNA was extracted from BoMac cells using Trizol® (Life Technologies, Inc., Plymouth 
Meeting, PA) from five independent experiments. Treatments included cells infected with both 
strains of M. bovis, treated with STS, and un-infected cells as control. RNA quantity was 
determined using a Nanodrop spectrophotometer and integrity was assessed using denaturing 
agarose gel electrophoresis. Reverse transcription was performed using primers in Table 4.1; they 
all had a primer efficiency of above 90%. qPCR was carried out using the RT² SYBR Green 
Fluor (Qiagen, CA, USA) fast method performed on an iCycler i5 system. The reactions were 
carried out in duplicate using 5ng of cDNA. The melting curve analysis suggested a single 
amplicon product. The data are expressed as fold changes as calculated using the 2-ΔΔCT method 
relative to the geometric mean of two stable housekeeping genes, GAPDH and β-actin. 
Table 4. 1: Primers used in this study. 
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Gene Sequences (5`- 3`) 
Amplicon 
size (bp) Origin 
BAX 
F: 
GCTGCAGAGGATGATCGCAGCTGTG 
R: ATCAACTCGGGCACCTTGGTGCA 
174 
 
(Buhler et al., 
2016) 
Bcl-2 
F: ACGGAGGCTGGGACGCCTTT 
R: AGGGTGATGCAAGCGCCCAC 
121 
 
(Buhler et al., 
2016) 
Bcl-xL 
 
F: CACTGTGCGTGGAAAGCGTA 
R: AAAGTGTCCCAGCCGCC 
127 
 
(Valdez et al., 
2005) 
GAPDH 
 
F: TTCAACGGCACAGTCAAGG 
R: ACATACTCAGCACCAGCATCAC 
119 This thesis 
β-actin. 
F: AGGCATCCTGACCCTCAAGTA 
R: GCTCGTTGTAGAAGGTGTGGT 
95 This thesis 
The sequences of apoptotic gene primers used in the study. F: Forward primer and R: Reverse primer. 
Statistical Analysis 
Prism 7.0c (GraphPad Software, La Jolla, CA, USA) was used for data analysis. The analyses of 
caspase activity, relative percentages of cell death and differential gene expression were carried 
out by using one-way analysis of variance (ANOVA) for multiple-groups analysis. Differences 
were considered significant it the P value was 0.05 or lower. 
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4.3. Results  
M. bovis invades and survives in BoMac cells 
To investigate whether our M. bovis strains Mb1 and Mb304 can invade BoMac cells, a similar 
approach of viable intracellular counts analyzed using the GM resistance assay was used (Burgi 
et al., 2018; Suleman et al., 2016a). The results are shown in figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 1: Invasion and survival of M. bovis strains Mb1 (B) and Mb304 (C) in BoMac cells. Viable 
intracellular bacteria are shown at 2 h, 6 h, and 18 h post-Gm treatment (2h) using an MOI of 1:5. The 
input is the cfu/ml of bacteria used at the beginning of the experiment. The data shown are the mean 
duplicates values of 4 independent experiments in Mb1 and 3 independent experiments in Mb304 and 
standard errors of mean of the individual measurements are indicated as bars. The circle represents 
incubation without gentamicin while the triangle represents incubation in the presence of gentamicin. E: 
extracellular bacteria found in supernatant and I: intracellular bacteria recovered from cell lysate. 
  78 
After 3h post-invasion (PI), both strains were recovered in relatively the same numbers in the cell 
lysate as the input cfu/ml used at the beginning of the experiment (Figs. 4.1a and b). There was 
no growth of bacteria in the culture supernatants following Gm treatment. No differences in 
intracellular bacteria recovery were observed in the presence or absence of Gm in both strains 
(Figs. 4.1a and b). There was recovery of viable intracellular bacteria from both strains 2 and 6h 
after the Gm treatment. In addition, there was no intracellular recovery of the bison isolate 
Mb304 at 18h of incubation (Fig. 4.1b) and no extracellular recovery at any time point suggesting 
that Mb1 is able to survive longer in BoMac cells and Mb304 cannot escape the macrophages. 
These findings indicated that M. bovis is capable of invading and persisting in BoMac cells as 
also shown in other cell types.  
The M. bovis strain Mb1 decreases STS-induced apoptosis of BoMac cells 
I used Alexa Fluor®488 annexin V/PI staining to assess the modulation of apoptosis in BoMac 
cells by both strains of M. bovis. Cells were treated with staurosporine, a known apoptosis 
inducer as a positive control and others left untreated as a negative control. I also selected M. 
bovis Mb304, a bison strain, which did not delay STS-induced apoptosis in bovine primary 
alveolar macrophages (Suleman et al., 2016a). I included live and dead bacterial cells to address 
the question if the delayed apoptosis effect was only observed with live cells. The results are 
shown in figure 4.2. 
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Figure 4. 2: Inhibition of BoMac cells apoptosis by M. bovis isolates from cattle and bison. 
Percentage of BoMac cells undergoing apoptosis after different treatments, live or dead (d) M. bovis 
strains were incubated with cells with or without STS. Controls included untreated cells and STS only 
treated cells. The bars show the mean percentages of apoptotic cells. Each data point is the mean of two 
technical replicates and the bars indicate the mean of three independent experiments. Significant 
differences between the treatments and untreated cells are indicated by * = P<0.05 or ** = P<0.01 and 
significant differences between the treatments and STS are indicated by $$ = P<0.01. 
Compared to untreated cells, there was a significant increase in apoptosis after treatment with 
STS, STS+Mb1 and STS+Mb304 (6% vs. 73, 45, and 68% respectively). Compared to the 
untreated cells, there was no significant increase of apoptotic cells after treatment with dead or 
alive M. bovis Mb1 or Mb304 (Fig. 4.2). Compared to STS-treated cells, there was a 38% 
reduction of STS-induced apoptosis (from 73% to 45%) in BoMac cells treated with live 
Mb1+STS and a significant (P<0.01) 43% reduction after treatment with dead Mb1+STS (From 
73% to 30%). Similar to Mb1, compared to untreated cells there was a 5% decrease (from 73% to 
68%) of apoptotic cells in cells treated with live M. bovis Mb304. Incubation with killed Mb304 
resulted in a 23% reduction of apoptotic cells (from 73% to 50%). Overall, these results are 
consistent with the delay in apoptosis by Mb1 and Mb304 previously observed in primary bovine 
alveolar macrophage (Suleman et al., 2016a). 
M. bovis inhibits the activities of caspases 3, 6 and 9 in BoMac cells 
Given the cardinal role of caspases in apoptosis, I investigated the modulation of BoMac STS-
induced caspase activity following incubation with Mb1 and Mb304 and the results are shown in 
figure 4.1. There was no increase in caspases 3, 6, and 9 activities after infection with both M. 
bovis strains. Incubation with the protease inhibitor Z-VAD-FMK also resulted in no increases in 
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caspases activity (Fig. 4.3). Compared to untreated cells, there was a significant increase in 
caspases 3, 6, and 9 activities in cells treated with STS, Mb1+STS, and Mb304+STS. Compared 
to cells treated with STS, there was a significant reduction of STS-induced caspases 3, 6, and 9 in 
cells treated with Mb1+STS and Mb304+STS. The findings on M. bovis strain Mb1 are 
consistent with those found in bovine monocytes (Mulongo et al., 2014). 
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Figure 4. 3: Effect of M. bovis infection on BoMac cells caspase activity. Cells were treated with STS 
(6h), Mb1 and Mb304 (3 h), in the presence or absence of STS 6h post-infection, and V-ZAD-FMK an 
apoptosis inhibitor (40uM, 24h). Each column represents the average of duplicates of four independent 
experiments for each treatment. The bars represent the standard deviations of individual measurements. 
Significant differences between the treatments and untreated cells are indicated by *** = P<0.001 and 
**** = P≤ 0.0001, significant differences between the treatments and STS are indicated by $$ = P<0.01, 
$$$$ = P<0.0001. 
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M. bovis modulates ROS production 
ROS is crucial in immunological processes both as a component of the killing response of 
immune cells to microbial invasion and an initiator for the intrinsic apoptotic-signalling cascade 
(Fang, 2011; Redza-Dutordoir and Averill-Bates, 2016). I investigated if M. bovis modulated 
pyocyanin-induced ROS production and results are presented in figure 4.4. Compared to 
untreated cells, there was an increase in the production of ROS (P<0.001) after incubation with 
pyocyanin, confirming that ROS is induced in these cells (Fig. 4.4). No changes in ROS 
production were detected upon infection with either of the M. bovis strains alone compared to 
untreated cells. Compared to pyocyanin-treated cells, cells treated with pyocyanin and infected 
with Mb1, (Pyo+Mb1), showed a significant reduction (P<0.001) in ROS production (Fig. 4.4). 
In contrast, compared to pyocyanin-treated cells there was no significant reduction in ROS 
production in cells treated with pyocyanin and infected with Mb304 (Pyo+Mb304) (Fig. 4.4). 
These results indicate that the cattle M. bovis strain Mb1 inhibited pyocyanin-induced ROS 
production but the bison strain Mb304 failed to decrease ROS production in the presence of 
pyocyanin. 
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Figure 4. 4: Decrease in intracellular ROS after M. bovis infection of BoMac cells. BoMac cells were 
treated with both strains of M. bovis in the presence and absence of pyocyanin (Pyo). Pyocyanin alone and 
untreated cells were included as controls. FACS was used to analyse the data. The fluorescence geometric 
mean intensity is shown in the Y axis. Each column represents the average duplicates of two independent 
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experiments. Significant differences between the treatments and untreated cells are indicated by ** = 
P<0.01, *** = P<0.001 and significant differences between the treatments and pyocyanin are indicated by 
$$$ = P<0.001. 
Mitochondrial cytochrome C release to the cytosol is decreased by M. bovis infection of 
BoMac cells 
Cytochrome C translocation from the space between the inner and outer mitochondrial 
membranes to the cytosol allows for detection of changes in the intrinsic apoptotic pathway and 
is required for activation of caspase 9 (Kluck et al., 1997; Wang and Youle, 2009; Wang, 2001; 
Yang et al., 1997). I next asked whether M. bovis anti-apoptotic effects could prevent BoMac 
cytochrome C release to the cytosol during STS-induced apoptosis and the results are shown in 
figure 4.5. By comparing the mitochondrial fractions with that from cytosolic fractions, I found 
that there was decreased translocation of cytochrome C to the cytosol of un-infected and infected 
cells with both mycoplasma strains in the absence or presence of STS as shown in the Western 
blot compared to the increased translocation in STS-treated cells (Fig. 4.5a). These results were 
confirmed by semi quantitative band intensity analysis performed by the Odyssey® CLx Imaging 
System (Fig. 4.5b). This observation suggests that M. bovis decreases the release of cytochrome 
C to the cytosol, a common step required for the intrinsic apoptosis pathway. 
 
 
 
 
 
Figure 4. 5: Western blot analysis of M. bovis inhibition of mitochondrial cytochrome C release 
induced by staurosporine. BoMac cells were treated with both strains of M. bovis in the presence and 
absence of STS as described in Materials and Methods. (A) The cell samples were then fractionated and 
the cytosol fractions analyzed by western blots. 1: untreated cells; 2: STS-treated cells; 3: M. bovis Mb1 
treated cells; 4: M. bovis Mb1+STS treated cells; 5: M. bovis Mb304 treated cells and 6: M. bovis 
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Mb304+STS treated cells. (B) Semi quantitative band intensity analysis performed by the Odyssey® CLx 
Imaging System. 
M. bovis inhibits DNA fragmentation  
The later stage of apoptosis is characterized by DNA fragmentation (Elmore, 2007); hence, I next 
aimed to investigate whether the anti-apoptotic effect of M. bovis on STS-induced apoptosis had 
any effect on decreasing DNA fragmentation and the results are shown in figure 4.6. DNA 
integrity was assayed by agarose gel electrophoresis. As observed in Fig. 4.6, DNA 
fragmentation was not seen in untreated cells (lane 1) and M. bovis-infected cells (lanes 2 and 4). 
There was a slight fragmentation observed in STS-treated cells incubated with Mb1 or Mb304 
(lanes 3 and 5) but significant DNA fragmentation of the STS-treated cells as demonstrated by 
the tailing of the smear (lane 6) due to degradation by nucleases. These results indicate that both 
strains of M. bovis inhibited fragmentation and decreased DNA fragmentation in the presence of 
an apoptosis inducer, STS compared to STS treated cells. 
 
 
 
 
 
 
 
Figure 4. 6: DNA fragmentation analysis by agarose gel electrophoresis. DNA was prepared as 
described in Materials and Methods. DNA integrity was determined by horizontal agarose gel 
electrophoresis followed by staining with ethidium bromide. Lanes: M, molecular mass marker; 1: 
untreated cells; 2: M. bovis Mb1 treated cells; 3: M. bovis Mb1+STS treated cells; 4: M. bovis Mb304 
treated cells; 5: Mb304+STS treated cells; 6: STS-treated cells. 
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NF-kβ -p65 nuclear translocation is activated in BoMac cells infected with M. bovis.  
As previously reported for bovine monocytes cells (Mulongo et al., 2014) incubation with M. 
bovis Mb1 resulted in the translocation into the nucleus of the p65 subunit of NF-kβ. I 
investigated if the effect on NF-kβ was similar in BoMac cells incubated with Mb1 or Mb304 and 
the results are shown in figure 4.7. Western blots show that compared to the untreated cells; there 
was more nuclear translocation of the p65 subunit in LPS- and Mb1-treated BoMac cells (Fig. 
4.7). Similarly, there was more translocation of p65 into the nucleus in cells treated with Mb304 
(Fig. 4.7b). These results were confirmed by semi quantitative band intensity analysis performed 
by the Odyssey® CLx Imaging System (Fig. 4.7 A2-B2). There was no loading control in the 
Mb1 and Mb304 Western blots with LPS treatments (A and B respectively). 
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Figure 4. 7: Translocation of RelA (p65) NF-κB subunit from cytoplasm to the cell nucleus. In panel 
A and B cells were treated with 1 µg/ml LPS and Mb1 (A) and Mb304 (B) for 24 hours, followed by 
lysing of the cells, separation of the cytoplasmic (C) and nuclear (N) fractions, and probing with 
antibodies specific for p65. Untreated cells were used as a control. In panel C, only the nucleic fractions of 
the different treatments of the cells were analyzed with antibodies specific for p65 (65 kDa) and β-Actin 
(45 kDa) to ensure equal loading. Untreated cells (lane 1), cells treated with the apoptosis inducer 1 µg/ml 
STS for 6 h (lane 2), Mb1 24 h (lane 3), STS+Mb1 (lane 4), Mb304 24 h (lane 5) and STS+Mb304 (lane 
6). (A2-C2) Band intensity was visualized by Odyssey® CLx Imaging System. 
 
To determine the effect of STS on translocation of the NF-kβ p65 subunit, I incubated BoMac 
cells with STS, Mb1, STS+Mb1, Mb304 and STS+Mb304. Only the nucleus fractions were 
assayed on the Western blot. Compared to the untreated cells, the band intensities of the p65 
nuclear fractions were higher in STS, Mb1, STS+Mb1, Mb304 and STS+Mb304 (Fig. 4.7C, lanes 
2-6). These results were confirmed by semi quantitative band intensity analysis performed by the 
Odyssey® CLx Imaging System (Fig. 4.7 C2). The results show activation of NF-kβ in BoMac 
cells infected with both strains of M. bovis and simultaneously treated with STS.  
Infection of BoMac cells with M. bovis induces the expression of anti-apoptotic genes, Bcl-
XL and Bcl-2 
Translocation of the NF-kβ p65 protein into the nucleus of the cell results in regulation of 
expression of pro- and anti-apoptotic genes. I tested the effect of M. bovis in STS-treated and 
untreated BoMac cells gene expression of the Bcl-XL and Bcl-2 genes involved in anti-apoptosis 
and the Bax gene involved in the induction of apoptosis at 3h and 24h post-infection with both 
mycoplasma strains. The results are shown in figure 4.8. Relative to the GAPDH and β-actin 
levels, I observed a significant increase in the level of expression of the anti-apoptotic Bcl-2 gene 
compared to the untreated cells in Mb1 (3h)- and Mb304 (3h)-infected cells and also an increase 
in expression at a later time point (24h) and in STS+ M. bovis although not significant compared 
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to the control. Treatment with STS alone showed no apparent differences in Bcl-2 expression 
compared to the control. Similar results were observed with the Bcl-XL gene. There was a 
significant increase of Bcl-XL gene expression in Mb1 (3h), Mb304 (3h), and Mb304 (24h) but 
also an increase in expression after STS + M. bovis although not significant (Fig. 4.8). However, 
there were no significant differences in the expression of pro-apoptotic Bax gene in response to 
infection with either strain of the M. bovis, STS-treated cells and un-stimulated cells (Fig. 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 8: Bcl-XL and Bcl-2 genes are upregulated in BoMac cells infected with M. bovis as 
determined by qPCR. RNA was isolated from BoMac cells infected with both strains in presence or 
absence of STS. Each data point shown represent the average duplicates of five independent 
measurements. Significant differences between the treatments and untreated cells are indicated by * 
P<0.05 and ** P<0.01. 
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4.4. Discussion 
Mycoplasma invasion of the lungs attracts monocytes, macrophages and neutrophils creating an 
inflammatory milieu that attempts to localize and eliminate the infection (Hermeyer et al., 2012a; 
Hermeyer et al., 2011; Howard and Taylor, 1983; Howard et al., 1976). Nonetheless, there is 
evidence of mycoplasma persistence in both normal and diseased lungs, suggesting the existence 
of mechanisms by which the bacterium can evade this inflammatory assault (Hermeyer et al., 
2012a; Hermeyer et al., 2011; Khodakaram-Tafti and Lopez, 2004; Rodriguez et al., 1996). 
Induction (Lancellotti et al., 2009) or inhibition (Faherty and Maurelli, 2008) of apoptosis has 
been reported in different pathogens and cell types and plays a vital role in disease pathogenesis 
(Lancellotti et al., 2009; Faherty and Maurelli, 2008). Our laboratory has previously 
demonstrated delay of apoptosis in all PBMC subsets (van der Merwe et al., 2010), monocytes 
(Mulongo et al., 2014) by M. bovis including primary bovine macrophages (Suleman et al., 
2016a) and the goal of the current study was to use a bovine macrophage cell line to characterize 
the mechanisms underlying this inhibition of apoptosis in order to identify potential pathways 
that could be targeted to achieve macrophage activity against mycoplasma. The bovine 
macrophage cell line (BoMac) is an in vitro differentiated bovine peritoneal macrophage cell line 
(Stabel and Stabel, 1995). It has been used to study infections with bovine herpesvirus-4 (BHV-
4), Map (Langelaar et al., 2005; Souza et al., 2007; Woo et al., 2006) and M. bovis co-infection 
with bovine viral diarrhea virus (Burgi et al., 2018). In these different studies the cell line has 
shown the ability to develop bona fide functions of alveolar macrophages including the ability to 
phagocytize bacteria with and without opsonization, generate reactive oxygen species (ROS), 
produce different cytokines (IL-6, TGFβ-1, TNF-α, IFN-γ, IL1-α) and upregulate genes related to 
apoptosis (Bcl2-1) following activation and infection (Stabel and Stabel, 1995; Tooker et al., 
2002). In a different study using this cell line, Abendaño showed an increased level of expression 
of the apoptotic inhibitor Bcl2-1 and low level of apoptosis and increased TGF-β after infection 
with Map (Abendano et al., 2013). 
I first tested if our strains were capable of invading and surviving in the BoMac cell line at 
different multiplicity of infection (MOI) and with different infection time points using the 
gentamicin protection assay. These findings confirmed that there was recovery of viable 
intracellular Mb1 after 18h post-invasion and Mb304 after 6h post-invasion in presence and 
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absence of gentamicin (Fig. 4.2) at the different MOIs. Consistent with previous observations that 
gentamicin displays minimal eukaryotic cell membrane penetration (Elsinghorst, 1994), this 
antibiotic did not affect the recovery of intracellular bacteria and the viability of the cells 
throughout the experiment. The recovery of viable intracellular mycoplasma demonstrates the 
ability of both M. bovis strains, Mb1 and Mb304 to invade and persist in BoMac cells differently. 
The Mb304 bison strain did not escape the macrophage to the medium, as there was no isolation 
of extracellular (E) viable bacteria in medium without GM in any of the time points. In addition, 
there was less persistence of intracellular (I) Mb304 after 6h compared to Mb1 the cattle strain. 
These discrepancies could be due to the fact that the cell line used is of cattle origin and Mb1 is 
better adapted to it that the bison isolate, Mb304. Previous studies by Pilo’s group also reported 
invasion and survival in BoMac cells of different cattle strains of M. bovis, strains JF4278 and 
L22/93 (Burgi et al., 2018). 
I further explored if both our strains (Mb1 and Mb304) were capable of inhibiting apoptosis in 
BoMac cells as previously demonstrated by our group in primary bovine alveolar macrophages 
(Suleman et al., 2016a). Indeed, as shown previously, the cattle strain M. bovis Mb1 reduced 
STS-induced apoptosis in contrast to the bison strain, M. bovis Mb304 (Fig. 4.3) that did not. On 
the contrary, the study from the co-infection experiment model of M. bovis with bovine viral 
diarrhea virus (BVD) using BoMac cells reported that the M. bovis strain JF4278 caused slight 
apoptosis and delay in STS-induced apoptosis was not observed with the type of test they used 
(Burgi et al., 2018). These discrepancies may also reflect the diversity that exists within M. bovis 
strains as previously described in adherence to various host cell lines that influence virulence 
(Thomas et al., 2003a). 
Successful bacterial pathogens have evolved different strategies to modulate apoptosis of various 
immune cells for survival and replication (Faherty and Maurelli, 2008). I further investigated 
which of the apoptotic pathways in macrophages was affected by infection with M. bovis. 
Different pathogenic bacteria modulate apoptosis by either protecting the mitochondrial integrity 
(Massari et al., 2000; Massari et al., 2003), preventing the release of cytochrome C and inhibition 
of caspase activation (Fan et al., 1998); or activating cell survival pathways by up-regulating 
inhibitors of apoptosis (Abendano et al., 2013; Binnicker et al., 2003; Goebel et al., 2001; 
Sukumaran et al., 2004). 
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Caspases are cysteine proteases that are initially synthesized as inactive pro-caspases that are 
cleaved to an active form upon activation by apoptotic stimuli. Caspases are divided into 
initiators caspases (2, 8, 9, and 10) and executioner caspases (3, 6, and 7) (McIlwain et al., 2013). 
I observed a decrease in protease activity of caspases 3, 6, and 9 STS-treated cells after infection 
with both strains of M. bovis compared to STS-treated cells and reduced activity in a similar trend 
as the caspase inhibitor (Fig. 4.3). In contrast, previous reports show that M. bovis strain Mb1 
inhibits STS-induced apoptosis in monocytes by inhibiting caspase 9 but not 3. The results for 
caspase 6 in monocytes were inconclusive as there were no differences between untreated vs. 
Mb1-treated monocytes and a slight difference in Mb1 vs. STS-treated monocytes (Mulongo et 
al., 2014). The different observations may be attributed to the specific cell types (monocytes vs. 
macrophages) used for the assay. The mechanism of apoptosis of M. bovis has been shown to be 
dependent on caspase 9, an initiator caspase of the mitochondrial apoptosis pathway followed by 
activation of caspases 3 and 6, effector caspases that lead to DNA fragmentation and eventually 
cell death. Upon receiving an apoptosis signal, caspases 3 and 6 exert their effects downstream of 
initiator caspase 9 (Porter and Janicke, 1999), and would be expected to be inactive upon 
inhibition of apoptosis. 
NF-kβ is a transcription factor responsible for gene expression of target genes, the majority of 
which participate in the host immune response and cell death. Defects in NF-κβ signalling result 
in increased susceptibility to apoptosis leading to increased cell death. NF-κβ regulates apoptosis 
by activating the expression of apoptotic or anti-apoptotic genes (Kucharczak et al., 2003). 
Usually, p65 is stored in an inactive form in the cytoplasm as part of the p65-p50 (NF-κβ) 
complex bound to the inhibitory protein IκBα. On activation, IκBα is phosphorylated by the IκB 
kinase leading to ubiquitination and release of the inhibitory protein from the NF-kβ complex. 
This, in turn, exposes nuclear import factors that target p65 to the nucleus where it binds to 
regulatory elements and modulates gene transcription (Rahman and McFadden, 2011). In bovine 
monocytes, NF-kβ activation following in vitro infection with M. bovis was measured by 
detection of accumulated p65 NF-kβ subunit in the nuclear fractions of infected cells compared to 
un-infected cells (Mulongo et al., 2014). Using the same assay, I observed activation of the NF-
kβ signalling in BoMac cells following infection with both M. bovis Mb1 and Mb304 (Fig. 4.7). 
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Apoptosis induced by ROS production, the intrinsic pathway, leads to various events that occur 
in the mitochondria that include the loss of membrane potential (ΔΨm), cytochrome C release, 
and participation of the Bcl-2 homologs (Redza-Dutordoir and Averill-Bates, 2016; Wang and 
Youle, 2009; Wang, 2001). Apoptosis is regulated by two groups of modulators: the anti-
apoptotic Bcl-2-family proteins (such as Bcl-XL and Bcl-2), and pro-apoptotic family of proteins 
(such as Bax and Bak) (Elmore, 2007; Riedl and Shi, 2004; Shi, 2002). The pro-apoptotic 
proteins are mostly found in the cytosol and the anti-apoptotic proteins are localised in the outer 
mitochondrial membrane as heterodimers with apoptotic proteins (Bax and Bad) thus inhibiting 
their apoptotic functions and regulating mitochondrial ΔΨm, cytochrome C release, and caspase 
activation (Cory and Adams, 2002). In the present study, I observed suppression of ROS 
production by M. bovis strain Mb1 (Fig. 4.4) as also shown in leukocytes infected with N. 
gonorrhoeae (Chen and Seifert, 2011). These findings agree with previous findings that observed 
no increase in neutrophil intracellular ROS levels upon stimulation with M. bovis (Gondaira et 
al., 2017; Mitiku et al., 2018; Redza-Dutordoir and Averill-Bates, 2016; Thomas et al., 1991). 
Host cells generate ROS as part of the oxidative burst during an infection to control microbial 
infection and its role in DNA damage during apoptosis is described in the literature (Simon et al., 
2000; Wang and Youle, 2009). In addition to inhibition of ROS, I also report reduced 
translocation of cytochrome C from the mitochondrial intermembrane space to the cytosol of 
infected BoMac cells (Fig. 4.5). Again, our results are consistent with previous reports in N. 
gonorrhoeae (Chen and Seifert, 2011), suggesting that M. bovis inhibits apoptosis in BoMac cells 
by preventing mitochondrial depolarization. The anti-apoptotic Bcl-2 family of proteins, maintain 
the ΔΨm of the mitochondria, and prevent cytochrome C release to the cytoplasm and hence, 
inhibit activation of initiator caspase 9 that exerts its effects upstream of executioner caspases 3 
and 6 (Sukumaran et al., 2004). I subsequently report an up-regulation of the anti-apoptotic 
genes, Bcl-XL and Bcl-2 by both strains in BoMac cells (Fig. 4.8). These results are consistence 
with a study that reported up-regulation of the Bcl-2 gene in BoMac cells infected with Map 
(Abendano et al., 2013). In E. coli infection of RAW 264.7 cell line induces the expression of 
Bcl-XL (Sukumaran et al., 2004), and with Toxoplasma gondii infection of U937 cells induces 
expression of Mcl-1, another anti-apoptotic protein of the Bcl-2 family (Goebel et al., 2001) and 
in Neisseria spp they reported up-regulation of c-IAP-2, and Mcl-1 in primary human urethral 
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epithelial cells (Binnicker et al., 2003). Hence, I cannot exclude the involvement of additional 
anti-apoptotic member of the Bcl-2 protein family and IAPs. 
4.5. Conclusion 
Taken together, our findings suggest novel mechanisms that M. bovis strain Mb1 reduces STS-
induced apoptosis via the intrinsic pathway in a caspase dependent manner by inhibition of 
caspases 3, 6, and 9; decreased cytochrome C release; activation of NF-β with anti-apoptotic 
consequences of increased up-regulation of the anti-apoptotic survival genes Bcl-XL and Bcl-2 
and absence of DNA fragmentation. With the bison strain, M. bovis Mb304 I observed similar 
results except for the STS-induced apoptosis assay where Mb304 induced significantly less 
reduction in apoptosis reported in this thesis (Fig. 4.2) and in primary alveolar macrophages 
(Suleman et al., 2016a). These discrepancies between the two isolates (cattle isolate Mb1 and 
bison isolate Mb304) can be attributed to the difference in strain specific variations and 
evolutionary adaptation to the different host. 
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CHAPTER 5. General discussion and conclusions  
5.1. Summary 
The general purpose of this thesis was to study host-pathogen interactions specifically, the 
modulation of macrophages effector functions and apoptosis, following infection by M. bovis. 
Since mycoplasmosis is highly dependent on the M. bovis ability to subvert the macrophage 
innate immune response I sought to characterize the interaction between M. bovis and bovine 
macrophages. As outlined in this thesis, Mb1 has evolved multiple strategies to survive and 
disseminate within the bovine host. 
There are several studies (including this, Chapter 4) that outline invasion and survival of M. bovis 
in bovine macrophages as an immune evasion tactic in vitro (Burgi et al., 2018; Maina et al., 
2018; Suleman et al., 2016a) and in vivo (Adegboye et al., 1995; Kleinschmidt et al., 2013). 
Evidence of M. bovis as an intracellular bacterium allows it to hide from humoral mediated 
immune responses and some antimicrobial therapy. The ability of the immune cells to move 
within the host also allows an interesting way for pathogens to disseminate systemically inside 
their host to various tissues such as, synovial membrane (Haines et al., 2001b), liver (Adegboye 
et al., 1995), and kidneys (Hermeyer et al., 2012b). 
Other strategies for immune evasion by M. bovis include manipulation of macrophage effector 
functions such as cytokine production by eliciting an anti-inflammatory IL-10-skewed cytokine 
profile at the expense of the pro-inflammatory TNF-α cytokine profile. IL-10 is known to affect 
the APCs by inhibiting their ability to release pro-inflammatory cytokines and can also directly 
affect T-cells by suppressing proliferation and production of cytokines (Couper et al., 2008b). 
These results are consistent with the earlier observation in monocytes where there was reduced 
production of TNF-α and IFN-γ and an increase in IL-10 cytokine (Mulongo et al., 2014). 
Production of pro-inflammatory cytokine causes infiltration of leucocytes and other immune cells 
in the lungs, which eventually contributes to the elimination of the pathogen, but if left 
unchecked can also cause clinical pathology. 
In this thesis, I also explored the modulation of nitric oxide production by infected primary 
BAMs as an immune evasion strategy. NO is an efficient way of controlling intracellular 
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pathogens by phagocytic cells by direct NO action or as a key pro-inflammatory signalling 
molecule. I showed that M. bovis strain Mb1was able to reduce production of NO in primary 
BAMs. In other bacteria such as intracellular Salmonella, Type 3 secretion system is used to 
mediate the NO modulation (Chakravortty and Hensel, 2003). In this thesis, I did not investigate 
the mechanism by which M. bovis attenuates iNOS expression and NO production. 
While apoptosis is considered important in to host defence mechanism bacteria have evolved 
strategies to manipulate host cell death mechanisms for their survival, multiplication as well as 
dissemination (Renehan et al., 2001). The ability of bacteria to induce or inhibit apoptosis can 
profoundly alter the immune response resulting in successful host invasion. Hence, I also 
explored in this thesis the effect of M. bovis strain Mb1 on macrophages apoptosis and the 
mechanism of inhibition for survival in the host. Indeed, in this thesis, I was able to show the 
different mechanisms of apoptosis that are modulated during inhibition of apoptosis (Chapter 4). 
As a result of these studies, I have proposed a novel mechanism by which M. bovis prolongs the 
life of infected bovine alveolar macrophages by inhibiting the intrinsic apoptosis pathway. Mb1 
is able to inhibit activation of caspases 3, 6, and 9, protecting the mitochondrial integrity by 
preventing the release of cytochrome C, inhibiting DNA fragmentation, activation of NF-β and 
activating cell survival pathways by up-regulating anti-apoptotic survival genes Bcl-XL and Bcl-2. 
By prolonging the life of the immune cell, the bacterium ensures survival and systemic 
dissemination in the host. 
It is also now apparent that different strains of M. bovis differ in their invasion, pathogenicity and 
immune modulation in various cell types (Burgi et al., 2018; Thomas et al., 2003a). Herein, I 
observed some different effects while using a bison isolate M. bovis strain Mb304 in the 
apoptosis experiment. Mb304 did not decrease STS-induced apoptosis in BoMac cells (Chapter 
4) and primary cattle alveolar macrophages (Suleman et al., 2016a) and did not reduce ROS 
production by BoMac cells. 
Understanding the factors that contribute to virulence, dissemination and immune evasion of a 
pathogen is critical knowledge for contemplating new vaccines and therapeutics. 
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5.2. Challenges, limitations and prospects 
The use of primary cells in the earlier studies (chapter 2) was a challenge as the data derived from 
these studies had large dispersion. The cost and logistics associated with large animal studies was 
a limitation and the lack of a small animal model for M. bovis or cell line at that point was a 
challenge. 
Another gap in the mycoplasma field is the shortage of genetic tools like those found for other 
bacteria, but there have been some current improvements. In respect to M. bovis the development 
of fluorescence expression tools to study host-mycoplasma interactions resulted in the 
construction of two strains expressing the mNeonGreen and mCherry proteins (Bonnefois et al., 
2016). In addition, genetic manipulation using the transposon Tn4001 (Chopra-Dewasthaly et al., 
2005) and plasmids for gene expression (Li et al., 2015; Sharma et al., 2015) have been 
developed. 
In the future, more studies are needed to assay for modulation of other BAMs effector functions 
such as receptor-mediated phagocytosis with the aid of new technologies such as the use of 
fluorescence mycoplasma cell-labelling already developed for investigating cell invasion. To 
produce the mNeonGreen and mCherry high-expression mycoplasma strains they also used 
transposon mutagenesis with a Tn4001-derivative mini-transposon (Bonnefois et al., 2016). To 
understand cell invasion, real-time cell infections can now also be investigated, and multiple 
fluorescent markers can be used to tag different mycoplasmas, strains or species to analyse mixed 
infections. This technology is not limited to in vitro use but it is also ideally suited for use in vivo 
by direct imaging of small animal models or hosts as reported in other bacteria (Zelmer et al., 
2012). 
More needs to be understood about M. bovis pathogenesis. I used in this thesis the cattle isolate 
M. bovis strain Mb1. Other strains with different virulence properties or field isolates need to be 
used for comparison studies. The disparate finding highlighted in the apoptosis study in chapter 4 
between the cattle and bison isolate (Mb1 and Mb304 respectively) shows the need for further 
comparisons of field isolates. Also In chapter 4, there was a limitation in the lack of a loading 
control of the western blots assay performed for both NF-kβ P56 molecule and cytochrome C 
translocation to ensure accurate loading of the proteins in the gel and the assay should have been 
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repeated severally to allow semi quantification of the band intensity analysis using the 
Odyssey® CLx Imaging System. 
In chapter 3, I investigated the ability of infected primary BAMs to present antigens to T-cells. In 
that study, I was not able to prove that the calves were infected and did not use any other known 
antigens. Further investigations are required to provide detailed information on how possible 
differences on infectious dose, choice of recall antigen, host susceptibility, route of infection, 
infection timeframe, breeds and age of the calves could affect reproducibility of the disease 
model. Also, an increase in the experimental sample size should be considered. 
The genome sequence of M. bovis Mb1 is unknown. The availability of genome sequences of 
different M. bovis isolates will, in turn, improve diagnostics and epidemiological traceability of 
the pathogen through comparative genomic studies. Very few studies in M. bovis correlate 
specific genes with pathogenicity (Rasheed et al., 2017), and so far to date, no gene has been 
identified that influences in vivo virulence of any M. bovis isolate. 
Furthermore, dissecting the molecular mechanisms behind inhibition of apoptosis and modulation 
of T-cell proliferation in the host may also allow us to predict the factors that interfere with the 
host-pathogen interactions, leading to increased persistence, infection and disease. The biological 
significance of the data generated in my thesis on apoptosis remains to be tested in an animal 
model. In the future, the unique adaptations by M. bovis that have been identified in this thesis 
can be tested in a relevant model. Further studies are needed to investigate if inhibition of 
apoptosis is associated with less or more virulent strains of M. bovis as shown in Mycobacterium 
spp. The virulent strains were shown to inhibit apoptosis while attenuated strains enhanced 
apoptosis in macrophages. These findings led to mutation of different virulennce genes and an 
increase of macrophage apoptosis was observed (Velmurugan et al., 2007). Hence, if the genetic 
formation of a bacterium influenced the mechanism of apoptosis then, this would make a huge 
contribution in creating attenuated vaccine strains. The discovery of genes responsible for 
apoptosis modulation by M. bovis would provide an opportunity to understand the host-pathogen 
interaction further and inform the pathogenesis of the disease. 
Manipulation of the macrophage activation response to M. bovis involving pathogenesis aspects 
has been proposed as a promising new avenue for effective development of vaccines strategies 
  96 
and treatment of infection. We demonstrated (I as a co-author) that when we blocked the PD-
1/PD-L1 immune checkpoint with a blocking anti PD-1 antibody we restored proliferation of 
Mb1-infected PBMC (Suleman et al., 2018), while other studies demonstrated restoration of IFN-
γ production in PBMCs in bovine mycoplasmosis (Goto et al., 2017). Thus, these findings can be 
used as a supplement to regular vaccine as antibody-mediated therapy to prevent disease 
progression. 
Just as a kinome array was used previously to study bovine monocytes and M. bovis interactions 
(Mulongo et al., 2014) other robust techniques such as RNA‐seq (Wang et al., 2009) for host-
pathogen interactions should be explored in the future. This would provide information about 
significantly up- or down‐regulated genes involved in the host-pathogen interactions as carried 
out in infection of sheep mammary glands with M. agalactiae (Chopra-Dewasthaly et al., 2017). 
Further studies are needed to determine the best approach to prevent or arrest M. bovis ability to 
manipulate macrophage effector functions and enable better methods to combat mycoplasmosis. 
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Appendix  
Appendix A: Tables 
Table A. 1: List and concentration of coupled beads, standards and antibodies used in the Bioplex 
ELISA. 
Cytokine standards 
 
Cytokine Catalogue number Concentration (ng/ml) 
IL-10 Kingfisher 10 
IL-1 Cyanamid 0.5 
IL-12 Kingfisher RP0077B-005 20 
IL-17 Kingfisher RP0056B-005 2 
IL-6 Kingfisher RP0014B-005 10 
IL-13 Kingfisher RP0002B-005 10 
IFN -α In house 0.5 
IFN-γ In house 1 
IL-2 Cyanamid PRCB52692 20 
IL-4 Biorad PBP006 0.1 
IL-8 Kingfisher RP0023B-005 1 
Coupled beads 
  
Cytokine Catalogue number Bead region 
IL-10 Serotec MCA2110 26 
IL-1 Serotec AHP851Z 62 
IL-12 Serotec MCA1782EL 37 
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IL-17 Kingfisher PB0274B-100 43 
IL-6 Kingfisher KP0652B-100 29 
IL-13 Kingfisher PB0120B-100 52 
IFN -α In house 1C6+adh IgG 45 
IFN-γ In house 2-2-1A IgG 65 
IL-2 VMRD clone 14.1 36 
IL-4 Biorad MCA2371 55 
IL-8 Kingfisher PB1164B-100 28 
Detection antibodies (all biotinylated) 
Cytokine Catalogue number Concentration (µg/ml) 
IL-10 Serotec MCA 2111B 2.5 
IL-1 Serotec AHP851B 1 
IL-12 Serotec MCA2173B 2.5 
IL-17 Kingfisher PBB0277B-050 0.2 
IL-6 Kingfisher KPB0653B-050 1 
IL-13 Kingfisher PBB0153B-050 0.1 
IFN-γ In house 92-133 1/250 
IFN -α In house 92-131 or 92-132 1/2000 
IL-2 R&D baf2465 0.1 
IL-4 Biorad MCA2372B 2 
IL-8 Kingfisher PBB1165B-050 0.1 
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Table A. 2: Antibodies dilutions used in the flow cytometry assay of BAMs surface marker.  
Antibodies Dilution Company 
Mouse anti human macrophage APC 1/200 Serotec/Biorad 
Mouse anti bovine CD40-RPE 1/200 Serotec/Biorad 
Mouse anti bovine CD80-RPE 1/100 Serotec/Biorad 
Mouse anti pig CD163-PE 1/100 Serotec/Biorad 
Mouse anti bovine CD86-FITC 1/100 Serotec/Biorad 
Mouse anti bovine CD205-FITC, 1/100 Serotec/Biorad 
Mouse anti bovine CD11b-FITC 1/200 Serotec/Biorad 
MHC class II DR isotype IgG1 1/100 VMRD/Kingfisher 
Secondary antibody IgG1-PE 1/100 Serotec/Biorad 
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Appendix B: Co-authored papers and my contributions 
Title: Mycoplasma bovis-induced inhibition of bovine peripheral blood mononuclear cell 
proliferation is ameliorated after blocking the immune-inhibitory programmed death 1 
receptor 
Copyright  
Copyright © 2018 American Society for Microbiology. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are 
credited.  
Citation  
Suleman, M., Cyprian, F.S., Jimbo, S., Maina, T., Prysliak, T., Windeyer, C., Perez-Casal, J., 
2018. Mycoplasma bovis-Induced Inhibition of Bovine Peripheral Blood Mononuclear 
Cell Proliferation Is Ameliorated after Blocking the Immune-Inhibitory Programmed 
Death 1 Receptor. Infection and Immunity 86. 
My contributions  
I contributed in the sample and data collection and analysis on BAMs, and participated in 
manuscript review. 
Modified abstract 
We have previously shown that down-regulation of lymphocyte proliferation is another important 
immunosuppression strategy of M. bovis infection (Mulongo et al., 2013; Prysliak et al., 2013; 
van der Merwe et al., 2010; Vanden Bush and Rosenbusch, 2003). We suggested that the 
expression of PD-1 and PD-L1 played a role in the impairment of antigen-specific T-cell 
responses. The PD-1 receptor is expressed on activated T-cells and recognizes its ligand, PD-L1 
expressed on activated dendritic and macrophages cells and engagement of both leads to poor 
immune responses. In the study, we used EBTr cells, EBL cells, and BAMs cells to investigate 
modulation of PD-L1 after M. bovis infection and the PD-1-related immune exhaustion of T-cells 
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during M. bovis infection. We showed an increase in the expression of the PD-1 receptor on total 
PBMCs specifically CD4+ and CD8+ positive cells and increased PD-L1 expression on purified 
lung lavage macrophages after Mb1 infection. We also blocked PD-1 receptors on PBMCs using 
anti-PD-1 antibody at the beginning of infection and demonstrated restoration of M. bovis 
infected PBMCs proliferation (Suleman et al., 2018). 
 
Title: Effect of Mycoplasma bovis on bovine neutrophils 
Citation  
Jimbo, S., Suleman, M., Maina, T., Prysliak, T., Mulongo, M., Perez-Casal, J., 2017. Effect of 
Mycoplasma bovis on bovine neutrophils. Veterinary Immunology and Immunopathology 
188, 27-33. 
Copyright  
Copyright © 2017 Elsevier B.V. All rights reserved. Not an open-access article. 
My contributions  
I generated the nitric oxide assay data and participated in manuscript review. 
Modified abstract 
We know that activation of macrophages leads to the recruitment of neutrophils to the site of 
infection (Gagea et al., 2006b). The aim of the study was to investigate the modulation of specific 
neutrophil activities such as oxidative bursts after infection with Mb1. We hypothesised that Mb1 
modulates neutrophil functions and apoptosis to support its persistence and systemic 
dissemination. We showed that Mb1 had no effect on pro-inflammatory cytokines, IL-12 and 
TNF-α production; there was an increase in elastase production, induction of apoptosis and an 
inhibition of NO production. These results show different mechanisms by which M. bovis 
infections persist systemically and in the bovine lung (Jimbo et al., 2017). 
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Title: Status of the development of a vaccine against Mycoplasma bovis 
Citation  
Perez-Casal, J., Prysliak, T., Maina, T., Suleman, M., Jimbo, S., 2017. Status of the development 
of a vaccine against Mycoplasma bovis. Vaccine 35, 2902-2907. 
Copyright  
Copyright © 2017 Elsevier Ltd. All rights reserved. Not an open-access article. 
My contributions  
I participated in the manuscript review. 
Modified abstract 
We have reviewed the status of different vaccines used in M. bovis control to-date that include 
bacterin-based vaccines, protein-based and live-attenuated vaccines. Additionally, we also 
highlighted the gaps limiting effective vaccines strategies for M. bovis (Perez-Casal et al., 2017). 
 
Title: Th-17 cell mediated immune responses to Mycoplasma bovis proteins formulated with 
Montanide ISA61 VG and curdlan are not sufficient for protection against an experimental 
challenge with Mycoplasma bovis 
Citation  
Prysliak, T., Maina, T., Perez-Casal, J., 2018. Th-17 cell mediated immune responses to 
Mycoplasma bovis proteins formulated with Montanide ISA61 VG and curdlan are not 
sufficient for protection against an experimental challenge with Mycoplasma bovis. 
Veterinary Immunology and Immunopathology 197, 7-14. 
Copyright  
Copyright © 2018 Elsevier B.V. All rights reserved.  
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My contributions  
I assisted in the collection and processing of samples during the animal trial. I also participated in 
the manuscript review 
Modified abstract 
In the literature Th-17 cells have been implicated in protection against respiratory pathogens by 
production of IL-17 and recruiting neutrophils. The aim of the study was to investigate if there 
were any M. bovis antigens that could elicit production of IL-17. The M. bovis antigens included 
recombinant proteins previously published, membrane fractions and whole cell extracts 
formulated in curdlan adjuvant, an inducer of Th-17 responses and Montanide™ ISA 61VG 
adjuvant. We showed significant humoral and cell mediated responses to the antigens; however, 
there was no protection in vaccinated animals against an Mb1 infection (Prysliak et al., 2018).  
 
Title: Analysis of immune responses to recombinant proteins from strains of Mycoplasma 
mycoides subsp. mycoides, the causative agent of contagious bovine pleuropneumonia. 
Citation  
Perez-Casal, J., Prysliak, T., Maina, T., Wang, Y., Townsend, H., Berverov, E., Nkando, I., 
Wesonga, H., Liljander, A., Jores, J., Naessens, J., Gerdts, V., Potter, A., 2015. Analysis 
of immune responses to recombinant proteins from strains of Mycoplasma mycoides 
subsp. mycoides, the causative agent of contagious bovine pleuropneumonia. Veterinary 
Immunology and Immunopathology 168, 103-110. 
Copyright  
Copyright © 2015 Elsevier B.V. All rights reserved. Not an open-access article. 
My contributions  
I assisted in protein expression and purification, vaccine formulation and sterility testing, 
processing of samples as well as analysis of the data and participated in the manuscript review. 
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Modified abstract 
We identified 66 possible vaccine candidates using reverse vaccinology using available 
Mycoplasma mycoides subsp. mycoides (Mmm) genome data. We expressed and purified the 
potential surface exposed protein vaccine candidates. We ranked the proteins based on their 
ability to be recognized by serum from CBPP-positive cattle and vaccinated cattle. We showed 
that the proteins tested were able to elicit good IgG1and IgG2 humoral responses. However, none 
of the recombinant proteins were able to elicit a recall response in PBMCs (Perez-Casal et al., 
2015).  
  105 
REFERENCES 
 
Aachoui, Y., Sagulenko, V., Miao, E.A., Stacey, K.J., 2013. Inflammasome-mediated pyroptotic 
and apoptotic cell death, and defense against infection. Current Opinion in Microbiology 16, 319-
326. 
Abendano, N., Juste, R.A., Alonso-Hearn, M., 2013. Anti-inflammatory and antiapoptotic 
responses to infection: a common denominator of human and bovine macrophages infected with 
Mycobacterium avium subsp. paratuberculosis. BioMed Research International 2013, 908348. 
Adegboye, D.S., Hallbur, P.G., Cavanaugh, D.L., Werdin, R.E., Chase, C.C., Miskimins, D.W., 
Rosenbusch, R.F., 1995. Immunohistochemical and pathological study of Mycoplasma bovis-
associated lung abscesses in calves. Journal of Veterinary Diagnostic Investigation 7, 333-337. 
Aebi, M., Bodmer, M., Frey, J., Pilo, P., 2012. Herd-specific strains of Mycoplasma bovis in 
outbreaks of mycoplasmal mastitis and pneumonia. Veterinary Microbiology 157, 363-368. 
Alberti, A., Addis, M.F., Chessa, B., Cubeddu, T., Profiti, M., Rosati, S., Ruiu, A., Pittau, M., 
2006. Molecular and antigenic characterization of a Mycoplasma bovis strain causing an outbreak 
of infectious keratoconjunctivitis. Journal of Veterinary Diagnostic Investigation 18, 41-51. 
Allen, J.W., Viel, L., Bateman, K.G., Rosendal, S., Shewen, P.E., Physick-Sheard, P., 1991. The 
microbial flora of the respiratory tract in feedlot calves: associations between nasopharyngeal and 
bronchoalveolar lavage cultures. Canadian Journal of Veterinary Research 55, 341-346. 
Alley, M.R., Quinlan, J.R., Clarke, J.K., 1975. The prevalence of Mycoplasma ovipneumoniae 
and Mycoplasma arginini in the respiratory tract of sheep. New Zealand Veterinary Journal 23, 
137-141. 
Arcangioli, M.A., Aslan, H., Tardy, F., Poumarat, F., Le Grand, D., 2012. The use of pulsed-field 
gel electrophoresis to investigate the epidemiology of Mycoplasma bovis in French calf feedlots. 
Veterinary Journal 192, 96-100.
  106 
Arcangioli, M.A., Duet, A., Meyer, G., Dernburg, A., Bezille, P., Poumarat, F., Le Grand, D., 
2008. The role of Mycoplasma bovis in bovine respiratory disease outbreaks in veal calf feedlots. 
Veterinary Journal 177, 89-93. 
Ayling, R.D., Baker, S.E., Peek, M.L., Simon, A.J., Nicholas, R.A., 2000. Comparison of in vitro 
activity of danofloxacin, florfenicol, oxytetracycline, spectinomycin and tilmicosin against recent 
field isolates of Mycoplasma bovis. Veterinary Record 146, 745-747. 
Bai, F., Ni, B., Liu, M., Feng, Z., Xiong, Q., Xiao, S., Shao, G., 2013. Mycoplasma 
hyopneumoniae-derived lipid-associated membrane proteins induce apoptosis in porcine alveolar 
macrophage via increasing nitric oxide production, oxidative stress, and caspase-3 activation. 
Veterinary Immunology and Immunopathology 155, 155-161. 
Banoth, B., Sutterwala, F.S., 2017. Confounding role of tumor necrosis factor in cryopyrin-
associated periodic syndromes. Journal of Clinical Investigation 127, 4235-4237. 
Basu, J., Shin, D.M., Jo, E.K., 2012. Mycobacterial signaling through Toll-like receptors. 
Frontiers in Cellular and Infection Microbiology 2. 
Basu, S., Pathak, S., Banerjee, A., Pathak, S., Bhattacharyya, A., Yang, Z., Talarico, S., Kundu, 
M., Basu, J., 2007. Execution of macrophage apoptosis by PE_PGRS33 of Mycobacterium 
tuberculosis. International Journal of Antimicrobial Agents 29, S67-S67. 
Behrens, A., Heller, M., Kirchhoff, H., Yogev, D., Rosengarten, R., 1994. A family of phase-
variant and size-variant membrane-surface lipoprotein antigens (Vsps) of Mycoplasma bovis. 
Infection and Immunity 62, 5075-5084. 
Behrens, A., Heller, M., Rosenbusch, R., Kirchhoff, H., 1996. Immunoelectron microscopic 
localization of variable proteins on the surface of Mycoplasma bovis. Microbiology 142, 1863-
1871. 
Bendjennat, M., Blanchard, A., Loutfi, M., Montagnier, L., Bahraoui, E., 1997. Purification and 
characterization of Mycoplasma penetrans Ca2+/Mg-2+-dependent endonuclease. Journal of 
Bacteriology 179, 2210-2220. 
  107 
Bennett, R.H., Jasper, D.E., 1977. Immunosuppression of humoral and cell-mediated responses in 
calves associated with inoculation of Mycoplasma bovis. American Journal of Veterinary 
Research 38, 1731-1738. 
Binnicker, M.J., Williams, R.D., Apicella, M.A., 2003. Infection of human urethral epithelium 
with Neisseria gonorrhoeae elicits an upregulation of host anti-apoptotic factors and protects 
cells from staurosporine-induced apoptosis. Cellular Microbiology 5, 549-560. 
Birnbaum, M.J., Clem, R.J., Miller, L.K., 1994. An apoptosis-inhibiting gene from a nuclear 
polyhedrosis-virus encoding a polypeptide with Cys/His sequence motif. Journal of Virology 68, 
2521-2528. 
Blanchard, A., Montagnier, L., 1994. AIDS-associated mycoplasmas. Annual Review of 
Microbiology 48, 687-712. 
Bogdan, C., 2001. Nitric oxide and the regulation of gene expression. Trends Cell Biol 11, 66-75. 
Bonnefois, T., Vernerey, M.S., Rodrigues, V., Totte, P., Puech, C., Ripoll, C., Thiaucourt, F., 
Manso-Silvan, L., 2016. Development of fluorescence expression tools to study host-
mycoplasma interactions and validation in two distant mycoplasma clades. Journal of 
Biotechnology 236, 35-44. 
Booker, C.W., Abutarbush, S.M., Morley, P.S., Jim, G.K., Pittman, T.J., Schunicht, O.C., Perrett, 
T., Wildman, B.K., Fenton, R.K., Guichon, P.T., Janzen, E.D., 2008. Microbiological and 
histopathological findings in cases of fatal bovine respiratory disease of feedlot cattle in Western 
Canada. Canadian Veterinary Journal 49, 473-481. 
Booker, C.W., Guichon, P.T., Jim, G.K., Schunicht, O.C., Harland, R.J., Morley, P.S., 1999. 
Seroepidemiology of undifferentiated fever in feedlot calves in western Canada. Canadian 
Veterinary Journal 40, 40-48. 
Boothby, J.T., Jasper, D.E., Thomas, C.B., 1986. Experimental intramammary inoculation with 
Mycoplasma bovis in vaccinated and unvaccinated cows: effect on milk production and milk 
quality. Canadian Journal of Veterinary Research 50, 200-204. 
  108 
Boothby, J.T., Jasper, D.E., Thomas, C.B., 1987. Experimental intramammary inoculation with 
Mycoplasma bovis in vaccinated and unvaccinated cows: effect on local and systemic antibody 
response. Can J Vet Res 51, 121-125. 
Boothby, J.T., Schore, C.E., Jasper, D.E., Osburn, B.I., Thomas, C.B., 1988. Immune responses 
to Mycoplasma bovis vaccination and experimental infection in the bovine mammary gland. 
Canadian Journal of Veterinary Research 52, 355-359. 
Briken, V., Miller, J.L., 2008. Living on the edge: inhibition of host cell apoptosis by 
Mycobacterium tuberculosis. Future Microbiology 3, 415-422. 
Buchenau, I., Poumarat, F., Le Grand, D., Linkner, H., Rosengarten, R., Hewicker-Trautwein, 
M., 2010. Expression of Mycoplasma bovis variable surface membrane proteins in the respiratory 
tract of calves after experimental infection with a clonal variant of Mycoplasma bovis type strain 
PG45. Research in Veterinary Science 89, 223-229. 
Buhler, S., Frahm, J., Tienken, R., Kersten, S., Meyer, U., Huber, K., Danicke, S., 2016. 
Influence of energy level and nicotinic acid supplementation on apoptosis of blood leukocytes of 
periparturient dairy cows. Veterinary Immunology and Immunopathology 179, 36-45. 
Burgi, N., Josi, C., Burki, S., Schweizer, M., Pilo, P., 2018. Mycoplasma bovis co-infection with 
bovine viral diarrhea virus in bovine macrophages. Veterinary Research Communications 49. 
Burki, S., Gaschen, V., Stoffel, M.H., Stojiljkovic, A., Frey, J., Kuehni-Boghenbor, K., Pilo, P., 
2015. Invasion and persistence of Mycoplasma bovis in embryonic calf turbinate cells. Veterinary 
Research Communications 46-53, 53. 
Bustin, S.A., Benes, V., Garson, J.A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, 
T., Pfaffl, M.W., Shipley, G.L., Vandesompele, J., Wittwer, C.T., 2009. The MIQE guidelines: 
minimum information for publication of quantitative real-time PCR experiments. Clinical 
Chemistry 55, 611-622. 
Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H., Freeman, G.J., 2007. Programmed death-1 
ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. 
Immunity 27, 111-122. 
  109 
Cabral, G.R.A., Wang, Z.T., Sibley, L.D., DaMatta, R.A., 2018. Inhibition of nitric oxide 
production in activated macrophages caused by Toxoplasma gondii Infection occurs by distinct 
mechanisms in different mouse macrophage cell lines. Frontiers in Microbiology 9, 1936. 
Case, C.L., Kohler, L.J., Lima, J.B., Strowig, T., de Zoete, M.R., Flavell, R.A., Zamboni, D.S., 
Roy, C.R., 2013. Caspase-11 stimulates rapid flagellin-independent pyroptosis in response to 
Legionella pneumophila. Proceedings of the National Academy of Sciences of the United States 
of America 110, 1851-1856. 
Cassell, G.H., Davis, J.K., Waites, K.B., Rudd, P.T., Talkington, D., Crouse, D., Horowitz, S.A., 
1987. Pathogenesis and significance of urogenital mycoplasmal infections. Advances in 
Experimental Medicine and Biology 224, 93-115. 
Castillo-Alcala, F., Bateman, K.G., Cai, H.Y., Schott, C.R., Parker, L., Clark, M.E., McRaild, P., 
McDowall, R.M., Foster, R.A., Archambault, M., Caswell, J.L., 2012. Prevalence and genotype 
of Mycoplasma bovis in beef cattle after arrival at a feedlot. American Journal of Veterinary 
Research 73, 1932-1943. 
Caswell, J.L., Archambault, M., 2007. Mycoplasma bovis pneumonia in cattle. Animal Health 
Research Reviews 8, 161-186. 
Caswell, J.L., Bateman, K.G., Cai, H.Y., Castillo-Alcala, F., 2010. Mycoplasma bovis in 
respiratory disease of feedlot cattle. Veterinary Clinics of North America. Food Animal Practice 
26, 365-379. 
Chakravortty, D., Hensel, M., 2003. Inducible nitric oxide synthase and control of intracellular 
bacterial pathogens. Microbes and Infection 5, 621-627. 
Chang, X.X., Wang, L.L., Wang, Z.C., Wu, S., Zhu, X.M., Hu, S.P., Wang, Y., Yu, J.Y., Chen, 
G.Z., 2017. TRADD mediates the tumor necrosis factor-induced apoptosis of L929 cells in the 
absence of RIP3. Scientific Reports 7. 
Chen, A., Seifert, H.S., 2011. Neisseria gonorrhoeae-mediated inhibition of apoptotic signalling 
in polymorphonuclear leukocytes. Infection and Immunity 79, 4447-4458. 
  110 
Chen, S., Hao, H., Zhao, P., Gao, P., He, Y., Ji, W., Wang, Z., Lu, Z., Liu, Y., Chu, Y., 2017. 
Complete Genome Sequence of Mycoplasma bovis Strain 08M. Genome Announcements 5. 
Chopra-Dewasthaly, R., Korb, M., Brunthaler, R., Ertl, R., 2017. Comprehensive RNA-Seq 
Profiling to Evaluate the Sheep Mammary Gland Transcriptome in Response to Experimental 
Mycoplasma agalactiae Infection. PLoS One 12, e0170015. 
Chopra-Dewasthaly, R., Zimmermann, M., Rosengarten, R., Citti, C., 2005. First steps towards 
the genetic manipulation of Mycoplasma agalactiae and Mycoplasma bovis using the transposon 
Tn4001mod. International Journal of Medical Microbiology 294, 447-453. 
Christodoulides, A., Gupta, N., Yacoubian, V., Maithel, N., Parker, J., Kelesidis, T., 2018. The 
role of lipoproteins in Mycoplasma-mediated immunomodulation. Frontiers in Microbiology 9, 
1682. 
Clothier, K.A., Jordan, D.M., Thompson, C.J., Kinyon, J.M., Frana, T.S., Strait, E.L., 2010. 
Mycoplasma bovis real-time polymerase chain reaction assay validation and diagnostic 
performance. Journal of Veterinary Diagnostic Investigation 22, 956-960. 
Cohen, G.M., 1997. Caspases: the executioners of apoptosis. Biochemical Journal 326, 1-16. 
Cookson, B.T., Brennan, M.A., 2001. Pro-inflammatory programmed cell death. Trends in 
Microbiology 9, 113-114. 
Cooper, A.M., Pearl, J.E., Brooks, J.V., Ehlers, S., Orme, I.M., 2000. Expression of the nitric 
oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the 
murine lung. Infection and Immunity 68, 6879-6882. 
Cory, S., Adams, J.M., 2002. The Bcl2 family: regulators of the cellular life-or-death switch. 
Nature Reviews Cancer 2, 647-656. 
Cottew, G.S., Yeats, F.R., 1978. Subdivision of Mycoplasma mycoides subsp. mycoides from 
cattle and goats into two types. Australian Veterinary Journal 54, 293-296. 
  111 
Couper, K.N., Blount, D.G., Riley, E.M., 2008a. IL-10: the master regulator of immunity to 
infection. J Immunol 180, 5771-5777. 
Couper, K.N., Blount, D.G., Riley, E.M., 2008b. IL-10: the master regulator of immunity to 
infection. Journal of Immunology 180, 5771-5777. 
Cowley, S.C., Myltseva, S.V., Nano, F.E., 1996. Phase variation in Francisella tularensis 
affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production. 
Molecular Microbiology 20, 867-874. 
Cusack, P.M., McMeniman, N., Lean, I.J., 2003. The medicine and epidemiology of bovine 
respiratory disease in feedlots. Australian Veterinary Journal 81, 480-487. 
Dahl, J., 1993. The role of cholesterol in mycoplasma membranes. Subcellular Biochemistry 20, 
167-188. 
DeDonder, K.D., Apley, M.D., 2015. A literature review of antimicrobial resistance in pathogens 
associated with bovine respiratory disease. Animal Health Research Reviews 16, 125-134. 
Deghmane, A.E., Veckerle, C., Giorgini, D., Hong, E., Ruckly, C., Taha, M.K., 2009. 
Differential Modulation of TNF-alpha-Induced Apoptosis by Neisseria meningitidis. PloS 
Pathogens 5. 
Diaz, L.F., Chiong, M., Quest, A.F., Lavandero, S., Stutzin, A., 2005. Mechanisms of cell death: 
molecular insights and therapeutic perspectives. Cell Death and Differentiation 12, 1449-1456. 
Donofrio, G., van Santen, V.L., 2001. A bovine macrophage cell line supports bovine 
herpesvirus-4 persistent infection. Journal of General Virology 82, 1181-1185. 
Du, C.Y., Fang, M., Li, Y.C., Li, L., Wang, X.D., 2000. Smac, a mitochondrial protein that 
promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-
42. 
  112 
Dudek, K., Bednarek, D., Ayling, R.D., Kycko, A., Szacawa, E., Karpinska, T.A., 2016. An 
experimental vaccine composed of two adjuvants gives protection against Mycoplasma bovis in 
calves. Vaccine 34, 3051-3058. 
Dumont, A., Hehner, S.P., Hofmann, T.G., Ueffing, M., Droge, W., Schmitz, M.L., 1999. 
Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of 
mitochondria-derived reactive oxygen species and the activation of NF-kappa B. Oncogene 18, 
747-757. 
Duprez, L., Wirawan, E., Vanden Berghe, T., Vandenabeele, P., 2009. Major cell death pathways 
at a glance. Microbes and Infection 11, 1050-1062. 
Dyer, N., Hansen-Lardy, L., Krogh, D., Schaan, L., Schamber, E., 2008. An outbreak of chronic 
pneumonia and polyarthritis syndrome caused by Mycoplasma bovis in feedlot bison (Bison 
bison). Journal of Veterinary Diagnostic Investigation 20, 369-371. 
Dyer, N., Register, K.B., Miskimins, D., Newell, T., 2013. Necrotic pharyngitis associated with 
Mycoplasma bovis infections in American bison (Bison bison). Journal of Veterinary Diagnostic 
Investigation 25, 301-303. 
Edinger, A.L., Thompson, C.B., 2004. Death by design: apoptosis, necrosis and autophagy. 
Current Opinion in Cell Biology 16, 663-669. 
El Kasmi, K.C., Qualls, J.E., Pesce, J.T., Smith, A.M., Thompson, R.W., Henao-Tamayo, M., 
Basaraba, R.J., Konig, T., Schleicher, U., Koo, M.S., Kaplan, G., Fitzgerald, K.A., Tuomanen, 
E.I., Orme, I.M., Kanneganti, T.D., Bogdan, C., Wynn, T.A., Murray, P.J., 2008. Toll-like 
receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular 
pathogens. Nature Immunology 9, 1399-1406. 
Elmore, S., 2007. Apoptosis: a review of programmed cell death. Toxicologic Pathology 35, 495-
516. 
Elsinghorst, E.A., 1994. Measurement of invasion by gentamicin resistance. Methods in 
Enzymology 236, 405-420. 
  113 
Fan, T., Lu, H., Hu, H., Shi, L., McClarty, G.A., Nance, D.M., Greenberg, A.H., Zhong, G., 
1998. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome 
c release and caspase activation. Journal of Experimental Medicine 187, 487-496. 
Fang, F.C., 2011. Antimicrobial actions of reactive oxygen species. MBio 2. 
Fawthrop, D.J., Boobis, A.R., Davies, D.S., 1991. Mechanisms of cell-death. Archives of 
Toxicology 65, 437-444. 
Feldner, J., Gobel, U., Bredt, W., 1982. Mycoplasma pneumoniae adhesin localized to tip 
structure by monoclonal antibody. Nature 298, 765-767. 
Fernandez, D.J., Lamkanfi, M., 2015. Inflammatory caspases: key regulators of inflammation and 
cell death. Biological Chemistry 396, 193-203. 
Fulda, S., Gorman, A.M., Hori, O., Samali, A., 2010. Cellular stress responses: cell survival and 
cell death. International Journal of Biochemistry & Cell Biology 2010, 214074. 
Furuse, M., Nonoguchi, N., Kawabata, S., Miyatake, S.I., Kuroiwa, T., 2015. Delayed brain 
radiation necrosis: pathological review and new molecular targets for treatment. Medical 
Molecular Morphology 48, 183-190. 
Gagea, M.I., Bateman, K.G., Shanahan, R.A., van Dreumel, T., McEwen, B.J., Carman, S., 
Archambault, M., Caswell, J.L., 2006a. Naturally occurring Mycoplasma bovis-associated 
pneumonia and polyarthritis in feedlot beef calves. J Vet Diagn Invest 18, 29-40. 
Gagea, M.I., Bateman, K.G., Shanahan, R.A., van Dreumel, T., McEwen, B.J., Carman, S., 
Archambault, M., Caswell, J.L., 2006b. Naturally occurring Mycoplasma bovis-associated 
pneumonia and polyarthritis in feedlot beef calves. Journal of Veterinary Diagnostic Investigation 
18, 29-40. 
Galluzzi, L., Baehrecke, E.H., Ballabio, A., Boya, P., Bravo-San Pedro, J.M., Cecconi, F., Choi, 
A.M., Chu, C.T., Codogno, P., Colombo, M.I., Cuervo, A.M., Debnath, J., Deretic, V., Dikic, I., 
Eskelinen, E.L., Fimia, G.M., Fulda, S., Gewirtz, D.A., Green, D.R., Hansen, M., Harper, J.W., 
Jaattela, M., Johansen, T., Juhasz, G., Kimmelman, A.C., Kraft, C., Ktistakis, N.T., Kumar, S., 
  114 
Levine, B., Lopez-Otin, C., Madeo, F., Martens, S., Martinez, J., Melendez, A., Mizushima, N., 
Munz, C., Murphy, L.O., Penninger, J.M., Piacentini, M., Reggiori, F., Rubinsztein, D.C., Ryan, 
K.M., Santambrogio, L., Scorrano, L., Simon, A.K., Simon, H.U., Simonsen, A., Tavernarakis, 
N., Tooze, S.A., Yoshimori, T., Yuan, J., Yue, Z., Zhong, Q., Kroemer, G., 2017. Molecular 
definitions of autophagy and related processes. EMBO Journal 36, 1811-1836. 
Galluzzi, L., Vitale, I., Aaronson, S.A., Abrams, J.M., Adam, D., Agostinis, P., Alnemri, E.S., 
Altucci, L., Amelio, I., Andrews, D.W., Annicchiarico-Petruzzelli, M., Antonov, A.V., Arama, 
E., Baehrecke, E.H., Barlev, N.A., Bazan, N.G., Bernassola, F., Bertrand, M.J.M., Bianchi, K., 
Blagosklonny, M.V., Blomgren, K., Borner, C., Boya, P., Brenner, C., Campanella, M., Candi, 
E., Carmona-Gutierrez, D., Cecconi, F., Chan, F.K.M., Chandel, N.S., Cheng, E.H., Chipuk, J.E., 
Cidlowski, J.A., Ciechanover, A., Cohen, G.M., Conrad, M., Cubillos-Ruiz, J.R., Czabotar, P.E., 
D'Angiolella, V., Dawson, T.M., Dawson, V.L., De Laurenzi, V., De Maria, R., Debatin, K.M., 
DeBerardinis, R.J., Deshmukh, M., Di Daniele, N., Di Virgilio, F., Dixit, V.M., Dixon, S.J., 
Duckett, C.S., Dynlacht, B.D., El-Deiry, W.S., Elrod, J.W., Fimia, G.M., Fulda, S., Garcia-Saez, 
A.J., Garg, A.D., Garrido, C., Gavathiotis, E., Golstein, P., Gottlieb, E., Green, D.R., Greene, 
L.A., Gronemeyer, H., Gross, A., Hajnoczky, G., Hardwick, J.M., Harris, I.S., Hengartner, M.O., 
Hetz, C., Ichijo, H., Jaattela, M., Joseph, B., Jost, P.J., Juin, P.P., Kaiser, W.J., Karin, M., 
Kaufmann, T., Kepp, O., Kimchi, A., Kitsis, R.N., Klionsky, D.J., Knight, R.A., Kumar, S., Lee, 
S.W., Lemasters, J.J., Levine, B., Linkermann, A., Lipton, S.A., Lockshin, R.A., Lopez-Otin, C., 
Lowe, S.W., Luedde, T., Lugli, E., MacFarlane, M., Madeo, F., Malewicz, M., Malorni, W., 
Manic, G., Marine, J.C., Martin, S.J., Martinou, J.C., Medema, J.P., Mehlen, P., Meier, P., 
Melino, S., Miao, E.A., Molkentin, J.D., Moll, U.M., Munoz-Pinedo, C., Nagata, S., Nunez, G., 
Oberst, A., Oren, M., Overholtzer, M., Pagano, M., Panaretakis, T., Pasparakis, M., Penninger, 
J.M., Pereira, D.M., Pervaiz, S., Peter, M.E., Piacentini, M., Pinton, P., Prehn, J.H.M., 
Puthalakath, H., Rabinovich, G.A., Rehm, M., Rizzuto, R., Rodrigues, C.M.P., Rubinsztein, 
D.C., Rudel, T., Ryan, K.M., Sayan, E., Scorrano, L., Shao, F., Shi, Y.F., Silke, J., Simon, H.U., 
Sistigu, A., Stockwell, B.R., Strasser, A., Szabadkai, G., Tait, S.W.G., Tang, D.L., Tavernarakis, 
N., Thorburn, A., Tsujimoto, Y., Turk, B., Vanden Berghe, T., Vandenabeele, P., Heiden, 
M.G.V., Villunger, A., Virgin, H.W., Vousden, K.H., Vucic, D., Wagner, E.F., Walczak, H., 
Wallach, D., Wang, Y., Wells, J.A., Wood, W., Yuan, J.Y., Zakeri, Z., Zhivotovsky, B., Zitvogel, 
  115 
L., Melino, G., Kroemer, G., 2018. Molecular mechanisms of cell death: recommendations of the 
Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation 25, 486-541. 
Gaur, U., Roberts, S.C., Dalvi, R.P., Corraliza, I., Ullman, B., Wilson, M.E., 2007. An effect of 
parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. Journal of 
Immunology 179, 8446-8453. 
Gobert, A.P., McGee, D.J., Akhtar, M., Mendz, G.L., Newton, J.C., Cheng, Y., Mobley, H.L., 
Wilson, K.T., 2001. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic 
cells: a strategy for bacterial survival. Proceedings of the National Academy of Sciences of the 
United States of America 98, 13844-13849. 
Godinho, K.S., Wolf, R.M., Sherington, J., Rowan, T.G., Sunderland, S.J., Evans, N.A., 2005. 
Efficacy of tulathromycin in the treatment and prevention of natural outbreaks of bovine 
respiratory disease in European cattle. Veterinary Therapeutics 6, 122-135. 
Goebel, S., Gross, U., Luder, C.G.K., 2001. Inhibition of host cell apoptosis by Toxoplasma 
gondii is accompanied by reduced activation of the caspase cascade and alterations of poly(ADP-
ribose) polymerase expression. Journal of Cell Science 114, 3495-3505. 
Goh, M.S., Gorton, T.S., Forsyth, M.H., Troy, K.E., Geary, S.J., 1998. Molecular and 
biochemical analysis of a 105 kDa Mycoplasma gallisepticum cytadhesin (GapA). Microbiology 
144 ( Pt 11), 2971-2978. 
Gondaira, S., Higuchi, H., Iwano, H., Nishi, K., Nebu, T., Nakajima, K., Nagahata, H., 2018. 
Innate immune response of bovine mammary epithelial cells to Mycoplasma bovis. Journal of 
Veterinary Science 19, 79-87. 
Gondaira, S., Higuchi, H., Nishi, K., Iwano, H., Nagahata, H., 2017. Mycoplasma bovis escapes 
bovine neutrophil extracellular traps. Veterinary Microbiology 199, 68-73. 
Gonzalez, Y.R.C., Bascunana, C.R., Bolske, G., Mattsson, J.G., Molina, C.F., Johansson, K.E., 
1995. In vitro amplification of the 16s ribosomal-RNA genes from Mycoplasma bovis and 
Mycoplasma agalactiae by PCR. Veterinary Microbiology 47, 183-190. 
  116 
Gonzalez-Juarbe, N., Bradley, K.M., Shenoy, A.T., Gilley, R.P., Reyes, L.F., Hinojosa, C.A., 
Restrepo, M.I., Dube, P.H., Bergman, M.A., Orihuela, C.J., 2017. Pore-forming toxin-mediated 
ion dysregulation leads to death receptor-independent necroptosis of lung epithelial cells during 
bacterial pneumonia. Cell Death and Differentiation 24, 917-928. 
Gordon, S., 2003. Alternative activation of macrophages. Nature Reviews Immunology 3, 23-35. 
Gordon, S., 2007. The macrophage: Past, present and future. European Journal of Immunology 
37, S9-S17. 
Goto, S., Konnai, S., Okagawa, T., Nishimori, A., Maekawa, N., Gondaira, S., Higuchi, H., 
Koiwa, M., Tajima, M., Kohara, J., Ogasawara, S., Kato, Y., Suzuki, Y., Murata, S., Ohashi, K., 
2017. Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-gamma production 
via PD-1/PD-L1 blockade in bovine mycoplasmosis. Immunity, Inflammation and Disease 5, 
355-363. 
Gourlay, R.N., Leach, R.H., 1970. A new mycoplasma species isolated from pneumonic lungs of 
calves (Mycoplasma dispar sp. nov.). Journal of Medical Microbiology 3, 111-123. 
Green, D.R., 2011. Means to an end : Apoptosis and other cell death mechanisms. Cold Spring 
Harbor (N.Y.) : Cold Spring Harbor laboratory press. 
Green, D.R., Llambi, F., 2015. Cell death signaling. Cold Spring Harbor Perspectives in Biology 
7. 
Green, D.R., Victor, B., 2012. The pantheon of the fallen: why are there so many forms of cell 
death? Trends in Cell Biology 22, 555-556. 
Guerardel, Y., Maes, E., Briken, V., Chirat, F., Leroy, Y., Locht, C., Strecker, G., Kremer, L., 
2003. Lipomannan and lipoarabinomannan from a clinical isolate of Mycobacterium kansasii - 
Novel structural features and apoptosis-inducing properties. Journal of Biological Chemistry 278, 
36637-36651. 
Haines, D.M., Martin, K.M., Clark, E.G., Jim, G.K., Janzen, E.D., 2001a. The 
immunohistochemical detection of Mycoplasma bovis and bovine viral diarrhea virus in tissues of 
  117 
feedlot cattle with chronic, unresponsive respiratory disease and/or arthritis. Can Vet J 42, 857-
860. 
Haines, D.M., Martin, K.M., Clark, E.G., Jim, G.K., Janzen, E.D., 2001b. The 
immunohistochemical detection of Mycoplasma bovis and bovine viral diarrhea virus in tissues of 
feedlot cattle with chronic, unresponsive respiratory disease and/or arthritis. Canadian Veterinary 
Journal 42, 857-860. 
Halder, P., Kumar, R., Jana, K., Chakraborty, S., Ghosh, Z., Kundu, M., Basu, J., 2015. Gene 
expression profiling of Mycobacterium tuberculosis Lipoarabinomannan-treated macrophages: A 
role of the Bcl-2 family member A1 in inhibition of apoptosis in mycobacteria-infected 
macrophages. Iubmb Life 67, 726-736. 
Hames, C., Halbedel, S., Hoppert, M., Frey, J., Stulke, J., 2009. Glycerol metabolism is important 
for cytotoxicity of Mycoplasma pneumoniae. Journal of Bacteriology 191, 747-753. 
Hanedan, B., Kirbas, A., Kandemir, F.M., Aktas, M.S., Yildiz, A., 2017. Evaluation of arginase 
activity, nitric oxide and oxidative stress status in sheep with contagious agalactia. Acta 
Veterinaria Hungarica 65, 394-401. 
Hayden, M.S., West, A.P., Ghosh, S., 2006. NF-kappaB and the immune response. Oncogene 25, 
6758-6780. 
Hegde, S., Hegde, S., Spergser, J., Brunthaler, R., Rosengarten, R., Chopra-Dewasthaly, R., 
2014. In vitro and in vivo cell invasion and systemic spreading of Mycoplasma agalactiae in the 
sheep infection model. International Journal of Medical Microbiology 304, 1024-1031. 
Hermeyer, K., Buchenau, I., Thomasmeyer, A., Baum, B., Spergser, J., Rosengarten, R., 
Hewicker-Trautwein, M., 2012a. Chronic pneumonia in calves after experimental infection with 
Mycoplasma bovis strain 1067: characterization of lung pathology, persistence of variable surface 
protein antigens and local immune response. Acta Veterinaria Scandinavica 54, 9. 
Hermeyer, K., Jacobsen, B., Spergser, J., Rosengarten, R., Hewicker-Trautwein, M., 2011. 
Detection of Mycoplasma bovis by in-situ hybridization and expression of inducible nitric oxide 
  118 
synthase, nitrotyrosine and manganese superoxide dismutase in the lungs of experimentally-
infected calves. Journal of Comparative Pathology 145, 240-250. 
Hermeyer, K., Peters, M., Brugmann, M., Jacobsen, B., Hewicker-Trautwein, M., 2012b. 
Demonstration of Mycoplasma bovis by immunohistochemistry and in situ hybridization in an 
aborted bovine fetus and neonatal calf. Journal of Veterinary Diagnostic Investigation 24, 364-
369. 
Hochreiter-Hufford, A., Ravichandran, K.S., 2013. Clearing the dead: apoptotic cell sensing, 
recognition, engulfment, and digestion. Cold Spring Harbor Perspectives in Biology 5, a008748. 
Holscher, C., Arendse, B., Schwegmann, A., Myburgh, E., Brombacher, F., 2006. Impairment of 
alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice. 
Journal of Immunology 176, 1115-1121. 
Hotchkiss, R.S., Strasser, A., McDunn, J.E., Swanson, P.E., 2009. Mechanisms of disease cell 
death. New England Journal of Medicine 361, 1570-1583. 
Howard, C.J., Parsons, K.R., Thomas, L.H., 1986. Systemic and local immune responses of 
gnotobiotic calves to respiratory infection with Mycoplasma bovis. Veterinary Immunology and 
Immunopathology 11, 291-300. 
Howard, C.J., Stott, E.J., Thomas, L.H., Gourlay, R.N., Taylor, G., 1987. Protection against 
respiratory disease in calves induced by vaccines containing respiratory syncytial virus, 
parainfluenza type 3 virus, Mycoplasma bovis and M. dispar. Veterinary record 121, 372-376. 
Howard, C.J., Taylor, G., 1983. Interaction of mycoplasmas and phagocytes. Yale Journal of 
Biology and Medicine 56, 643-648. 
Howard, C.J., Taylor, G., Collins, J., Gourlay, R.N., 1976. Interaction of Mycoplasma dispar and 
Mycoplasma agalactiae subsp. bovis with bovine alveolar macrophages and bovine lacteal 
polymorphonuclear leukocytes. Infection and Immunity 14, 11-17. 
  119 
Inamine, J.M., Loechel, S., Collier, A.M., Barile, M.F., Hu, P.C., 1989. Nucleotide sequence of 
the MgPa (mgp) operon of Mycoplasma genitalium and comparison to the P1 (mpp) operon of 
Mycoplasma pneumoniae. Gene 82, 259-267. 
Into, T., Kiura, K., Yasuda, M., Kataoka, H., Inoue, N., Hasebe, A., Takeda, K., Akira, S., 
Shibata, K., 2004a. Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane 
lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation. 
Cellular Microbiology 6, 187-199. 
Into, T., Kiura, K., Yasuda, M., Kataoka, H., Inoue, N., Hasebe, A., Takeda, K., Akira, S., 
Shibata, K., 2004b. Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane 
lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation. 
Cell. Microbiol. 6, 187-199. 
Iwasaki, A., Medzhitov, R., 2004. Toll-like receptor control of the adaptive immune responses. 
Nature Immunology 5, 987-995. 
Jaffe, J.D., Miyata, M., Berg, H.C., 2004. Energetics of gliding motility in Mycoplasma mobile. 
Journal of Bacteriology 186, 4254-4261. 
Jasper, D.E., Boothby, J.T., Thomas, C.B., 1987. Pathogenesis of bovine mycoplasma mastitis. 
Israel Journal of Medical Sciences 23, 625-627. 
Jimbo, S., Suleman, M., Maina, T., Prysliak, T., Mulongo, M., Perez-Casal, J., 2017. Effect of 
Mycoplasma bovis on bovine neutrophils. Veterinary Immunology and Immunopathology 188, 
27-33. 
Johnson, C., Kannan, T.R., Baseman, J.B., 2009. Characterization of a unique ADP-
ribosyltransferase of Mycoplasma penetrans. Infection and Immunity 77, 4362-4370. 
Jorgensen, I., Miao, E.A., 2015. Pyroptotic cell death defends against intracellular pathogens. 
Immunological Reviews 265, 130-142. 
  120 
Jozefova, J., Ayling, R.D., Zendulkova, D., 2014. Report on investigations into the Mycoplasma 
species present in some clinically sick cattle in the Czech Republic. Medycyna Weterynaryjna-
Veterinary Medicine-Science and Practice 70, 413-416. 
Jungi, T.W., Krampe, M., Sileghem, M., Griot, C., Nicolet, J., 1996. Differential and strain-
specific triggering of bovine alveolar macrophage effector functions by mycoplasmas. Microbial 
Pathogenesis 21, 487-498. 
Kannan, T.R., Baseman, J.B., 2000. Hemolytic and hemoxidative activities in Mycoplasma 
penetrans. Infection and Immunity 68, 6419-6422. 
Kannan, T.R., Baseman, J.B., 2006. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma 
pneumoniae represents unique virulence determinant among bacterial pathogens. Proceedings of 
the National Academy of Sciences of the United States of America 103, 6724-6729. 
Kayagaki, N., Warming, S., Lamkanfi, M., Vande Walle, L., Louie, S., Dong, J., Newton, K., Qu, 
Y., Liu, J., Heldens, S., Zhang, J., Lee, W.P., Roose-Girma, M., Dixit, V.M., 2011. Non-
canonical inflammasome activation targets caspase-11. Nature 479, 117-121. 
Keane, J., Remold, H.G., Kornfeld, H., 2000. Virulent Mycobacterium tuberculosis strains evade 
apoptosis of infected alveolar macrophages. Journal of Immunology 164, 2016-2020. 
Keir, M.E., Butte, M.J., Freeman, G.J., Sharpel, A.H., 2008. PD-1 and its ligands in tolerance and 
immunity. Annual Review of Immunology 26, 677-704. 
Kerr, J.F., Wyllie, A.H., Currie, A.R., 1972. Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics. British Journal of Cancer 26, 239-257. 
Khan, L.A., Miles, R.J., Nicholas, R.A.J., 2005. Hydrogen peroxide production by Mycoplasma 
bovis and Mycoplasma agalactiae and effect of in vitro passage on a Mycoplasma bovis strain 
producing high levels of H2O2. Veterinary Research Communications 29, 181-188. 
Khodakaram-Tafti, A., Lopez, A., 2004. Immunohistopathological findings in the lungs of calves 
naturally infected with Mycoplasma bovis. Journal of Veterinary Medicine. A, Physiology, 
pathology, Clinical Medicine 51, 10-14. 
  121 
Kishore, A., Sodhi, M., Khate, K., Kapila, N., Kumari, P., Mukesh, M., 2013. Selection of stable 
reference genes in heat stressed peripheral blood mononuclear cells of tropically adapted Indian 
cattle and buffaloes. Molecular and Cellular Probes 27, 140-144. 
Kleinschmidt, S., Spergser, J., Rosengarten, R., Hewicker-Trautwein, M., 2013. Long-term 
survival of Mycoplasma bovis in necrotic lesions and in phagocytic cells as demonstrated by 
transmission and immunogold electron microscopy in lung tissue from experimentally infected 
calves. Veterinary Microbiology 162, 949-953. 
Kluck, R.M., Bossy-Wetzel, E., Green, D.R., Newmeyer, D.D., 1997. The release of cytochrome 
c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275, 1132-1136. 
Kucharczak, J., Simmons, M.J., Fan, Y., Gelinas, C., 2003. To be, or not to be: NF-kappaB is the 
answer--role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22, 8961-8982. 
Kumar, A., Verma, A.K., Rahal, A., 2011. Mycoplasma bovis, A multi disease producing 
pathogen: An overview. Asian Journal of Animal and Veterinary Advances 6, 537-546. 
Kumar, S., 2007. Caspase function in programmed cell death. Cell Death and Differentiation 14, 
32-43. 
Lai, J.F., Zindl, C.L., Duffy, L.B., Atkinson, T.P., Jung, Y.W., van Rooijen, N., Waites, K.B., 
Krause, D.C., Chaplin, D.D., 2010. Critical role of macrophages and their activation via MyD88-
NFkappaB signaling in lung innate immunity to Mycoplasma pneumoniae. PLoS One 5, e14417. 
Langelaar, M.F.M., Hope, J.C., Rutten, V.P.M.G., Noordhuizen, J.P.T.M., van Eden, W., Koets, 
A.P., 2005. Mycobacterium avium ssp paratuberculosis recombinant heat shock protein 70 
interaction with different bovine antigen-presenting cells. Scandinavian Journal of Immunology 
61, 242-250. 
Laskin, D.L., 2009. Macrophages and inflammatory mediators in chemical toxicity: A battle of 
forces. Chemical Research in Toxicology 22, 1376-1385. 
  122 
Lavric, M., Bencina, D., Kothlow, S., Kaspers, B., Narat, M., 2007. Mycoplasma synoviae 
lipoprotein MSPB, the N-terminal part of VlhA haemagglutinin, induces secretion of nitric oxide, 
IL-6 and IL-1beta in chicken macrophages. Veterinary Microbiology 121, 278-287. 
Le Grand, D., Calavas, D., Brank, M., Citti, C., Rosengarten, R., Bezille, P., Poumarat, F., 2002. 
Serological prevalence of Mycoplasma bovis infection in suckling beef cattle in France. 
Veterinary Record 150, 268-273. 
LeBlanc, D.J., Lee, L.N., Inamine, J.M., 1991. Cloning and nucleotide base sequence analysis of 
a spectinomycin adenyltransferase AAD(9) determinant from Enterococcus faecalis. 
Antimicrobial Agents and Chemotherapy 35, 1804-1810. 
Lee, K.I., Choi, H.G., Son, Y.J., Whang, J., Kim, K., Jeon, H.S., Park, H.S., Back, Y.W., Choi, 
S., Kim, S.W., Choi, C.H., Kim, H.J., 2016. Mycobacterium avium MAV2052 protein induces 
apoptosis in murine macrophage cells through Toll-like receptor 4. Apoptosis 21, 459-472. 
Ley, D.H., Avakian, A.P., Berkhoff, J.E., 1993. Clinical Mycoplasma gallisepticum infection in 
multiplier breeder and meat turkeys caused by F strain: identification by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, restriction endonuclease analysis, and the polymerase chain 
reaction. Avian Diseases 37, 854-862. 
Li, J., Zhang, J., Zhang, N., Zhang, Y., Wu, W., Li, J., 2015. Development of a replicative 
plasmid for gene expression in Mycoplasma bovis. Journal of Microbiological Methods 108, 12-
18. 
Li, L.Y., Luo, L., Wang, X.D., 2001. Endonuclease G is an apoptotic DNase when released from 
mitochondria. Nature 412, 95-99. 
Li, X.C., Raghavan, M., 2010. Structure and function of major histocompatibility complex class I 
antigens. Current Opinion in Organ Transplantation 15, 499-504. 
Li, Y., Zheng, H., Liu, Y., Jiang, Y., Xin, J., Chen, W., Song, Z., 2011. The complete genome 
sequence of Mycoplasma bovis strain Hubei-1. PLoS One 6, e20999. 
  123 
Locksley, R.M., Killeen, N., Lenardo, M.J., 2001. The TNF and TNF receptor superfamilies: 
integrating mammalian biology. Cell 104, 487-501. 
Lohmann-Matthes, M.L., Steinmuller, C., Franke-Ullmann, G., 1994. Pulmonary macrophages. 
Eur. Respir. J. 7, 1678-1689. 
Lysnyansky, I., Rosengarten, R., Yogev, D., 1996. Phenotypic switching of variable surface 
lipoproteins in Mycoplasma bovis involves high-frequency chromosomal rearrangements. Journal 
of Bacteriology 178, 5395-5401. 
Lysnyansky, I., Sachse, K., Rosenbusch, R., Levisohn, S., Yogev, D., 1999. The vsp locus of 
Mycoplasma bovis: gene organization and structural features. Journal of Bacteriology 181, 5734-
5741. 
MacDonald, C., 1990. Development of new cell lines for animal cell biotechnology. Critical 
Reviews in Biotechnology 10, 155-178. 
MacMicking, J., Xie, Q.W., Nathan, C., 1997a. Nitric oxide and macrophage function. Annual 
Review of Immunology 15, 323-350. 
MacMicking, J.D., North, R.J., LaCourse, R., Mudgett, J.S., Shah, S.K., Nathan, C.F., 1997b. 
Identification of nitric oxide synthase as a protective locus against tuberculosis. Proceedings of 
the National Academy of Sciences of the United States of America 94, 5243-5248. 
Maeda, T., Shibahara, T., Kimura, K., Wada, Y., Sato, K., Imada, Y., Ishikawa, Y., Kadota, K., 
2003. Mycoplasma bovis-associated suppurative otitis media and pneumonia in bull calves. 
Journal of Comparative Pathology 129, 100-110. 
Mah, T.F.C., O'Toole, G.A., 2001. Mechanisms of biofilm resistance to antimicrobial agents. 
Trends in Microbiology 9, 34-39. 
Maina, T., Prysliak, T., Perez-Casal, J., 2019. Mycoplasma bovis delay in apoptosis of 
macrophages is accompanied by increased expression of anti-apoptotic genes, reduced 
cytochrome C translocation and inhibition of DNA fragmentation. Veterinary Immunology and 
Immunopathology 208, 16-24. 
  124 
Maiti, D., Bhattacharyya, A., Basu, J., 2001. Lipoarabinomannan from Mycobacterium 
tuberculosis promotes macrophage survival by phosphorylating Bad through a 
phosphatidylinositol 3-kinase/Akt pathway. Journal of Biological Chemistry 276, 329-333. 
Manso-Silvan, L., Dupuy, V., Lysnyansky, I., Ozdemir, U., Thiaucourt, F., 2012. Phylogeny and 
molecular typing of Mycoplasma agalactiae and Mycoplasma bovis by multilocus sequencing. 
Veterinary Microbiology 161, 104-112. 
Manso-Silvan, L., Vilei, E.M., Sachse, K., Djordjevic, S.P., Thiaucourt, F., Frey, J., 2009. 
Mycoplasma leachii sp nov as a new species designation for Mycoplasma sp bovine group 7 of 
Leach, and reclassification of Mycoplasma mycoides subsp mycoides LC as a serovar of 
Mycoplasma mycoides subsp capri. International Journal of Systematic and Evolutionary 
Microbiology 59, 1353-1358. 
Mantegazza, A.R., Magalhaes, J.G., Amigorena, S., Marks, M.S., 2013. Presentation of 
phagocytosed antigens by MHC Class I and II. Traffic 14, 135-152. 
Massari, P., Ho, Y., Wetzler, L.M., 2000. Neisseria meningitidis porin PorB interacts with 
mitochondria and protects cells from apoptosis. Proceedings of the National Academy of 
Sciences of the United States of America 97, 9070-9075. 
Massari, P., King, C.A., Ho, A.Y., Wetzler, L.M., 2003. Neisserial PorB is translocated to the 
mitochondria of HeLa cells infected with Neisseria meningitidis and protects cells from 
apoptosis. Cellular Microbiology 5, 99-109. 
Matsumura, H., Shimizu, Y., Ohsawa, Y., Kawahara, A., Uchiyama, Y., Nagata, S., 2000. 
Necrotic death pathway in Fas receptor signaling. Journal of Cell Biology 151, 1247-1256. 
Maunsell, F.P., Donovan, G.A., 2009. Mycoplasma bovis Infections in young calves. Veterinary 
Clinics of North America. Food Animal Practice 25, 139-177, vii. 
Maunsell, F.P., Woolums, A.R., Francoz, D., Rosenbusch, R.F., Step, D.L., Wilson, D.J., Janzen, 
E.D., 2011. Mycoplasma bovis infections in cattle. Journal of veterinary internal medicine / 
American College of Veterinary Internal Medicine 25, 772-783. 
  125 
Mbulu, R.S., Tjipura-Zaire, G., Lelli, R., Frey, J., Pilo, P., Vilei, E.M., Mettler, F., Nicholas, 
R.A., Huebschle, O.J., 2004. Contagious bovine pleuropneumonia (CBPP) caused by vaccine 
strain T1/44 of Mycoplasma mycoides subsp. mycoides SC. Veterinary Microbiology 98, 229-
234. 
McAuliffe, L., Ellis, R.J., Miles, K., Ayling, R.D., Nicholas, R.A., 2006. Biofilm formation by 
mycoplasma species and its role in environmental persistence and survival. Microbiology 152, 
913-922. 
McGowin, C.L., Ma, L., Martin, D.H., Pyles, R.B., 2009. Mycoplasma genitalium-encoded 
MG309 activates NF-kappaB via Toll-like receptors 2 and 6 to elicit proinflammatory cytokine 
secretion from human genital epithelial cells. Infect. Immun. 77, 1175-1181. 
McIlwain, D.R., Berger, T., Mak, T.W., 2013. Caspase functions in cell death and disease. Cold 
Spring Harbor Perspectives in Biology 5. 
Menzies, M., Ingham, A., 2006. Identification and expression of Toll-like receptors 1-10 in 
selected bovine and ovine tissues. Veterinary Immunology and Immunopathology 109, 23-30. 
Mitiku, F., Hartley, C.A., Sansom, F.M., Coombe, J.E., Mansell, P.D., Beggs, D.S., Browning, 
G.F., 2018. The major membrane nuclease MnuA degrades neutrophil extracellular traps induced 
by Mycoplasma bovis. Veterinary Microbiology 218, 13-19. 
Mosser, D.M., 2003. The many faces of macrophage activation. Journal of Leukocyte Biology 
73, 209-212. 
Mosser, D.M., Edwards, J.P., 2008. Exploring the full spectrum of macrophage activation. Nature 
Reviews Immunology 8, 958-969. 
Muhlradt, P.F., Frisch, M., 1994. Purification and partial biochemical-characterization of a 
Mycoplasma Fermentans-derived substance that activates macrophages to release nitric-oxide, 
tumor-necrosis-factor, and Interleukin-6. Infection and Immunity 62, 3801-3807. 
  126 
Muhlradt, P.F., Kiess, M., Meyer, H., Sussmuth, R., Jung, G., 1997. Isolation, structure 
elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans 
acting at picomolar concentration. Journal of Experimental Medicine 185, 1951-1958. 
Mulongo, M., Prysliak, T., Perez-Casal, J., 2013. Vaccination of feedlot cattle with extracts and 
membrane fractions from two Mycoplasma bovis isolates results in strong humoral immune 
responses but does not protect against an experimental challenge. Vaccine 31, 1406-1412. 
Mulongo, M., Prysliak, T., Scruten, E., Napper, S., Perez-Casal, J., 2014. In vitro infection of 
bovine monocytes with Mycoplasma bovis delays apoptosis and suppresses production of gamma 
interferon and tumor necrosis factor alpha but not interleukin-10. Infection and Immunity 82, 62-
71. 
Nair, P., Lu, M., Petersen, S., Ashkenazi, A., 2014. Apoptosis initiation through the cell-extrinsic 
pathway. Regulated Cell Death Pt A: Apoptotic Mechanisms 544, 99-128. 
Naot, Y., Tully, J.G., Ginsburg, H., 1977. Lymphocyte-activation by various Mycoplasma strains 
and species. Infection and Immunity 18, 310-317. 
Nicholas, R., Ayling, R., McAuliffe, L., 2008. Bovine respiratory disease. Mycoplasma Diseases 
of Ruminants, 132-168. 
Nicholas, R.A., Ayling, R.D., 2003. Mycoplasma bovis: disease, diagnosis, and control. Research 
in Veterinary Science 74, 105-112. 
Nicholas, R.A., Ayling, R.D., Stipkovits, L.P., 2002. An experimental vaccine for calf pneumonia 
caused by Mycoplasma bovis: clinical, cultural, serological and pathological findings. Vaccine 
20, 3569-3575. 
Nicholas, R.A.J., 2011. Bovine mycoplasmosis: silent and deadly. Veterinary Record 168, 459-
462. 
Nicolet, J., 1996. Animal mycoplasmoses: A general introduction. Revue Scientifique Et 
Technique De L Office International Des Epizooties 15, 1233-1240. 
  127 
Niu, H., Kozjak-Pavlovic, V., Rudel, T., Rikihisa, Y., 2010. Anaplasma phagocytophilum Ats-1 
Is Imported into Host Cell Mitochondria and Interferes with Apoptosis Induction. PloS Pathogens 
6. 
Nkando, I., Perez-Casal, J., Mwirigi, M., Prysliak, T., Maina, T., Townsend, H., Berverov, E., 
Liljander, A., Jores, J., Kuria, J., J., M., Soi, R., Gerdts, V., Potter, A., Naessens, J., Wesonga, H., 
2016. Recombinant Mycoplasma mycoides proteins elicit protective immune responses against 
contagious bovine pleuropneumonia Vet. Immunol. Immunopathol. 171, 103-114. 
O'Neill, L.A.J., Hardie, D.G., 2013. Metabolism of inflammation limited by AMPK and pseudo-
starvation. Nature 493, 346-355. 
Odegaard, J.I., Chawla, A., 2011. Alternative macrophage activation and metabolism. Annu Rev 
Pathol 6, 275-297. 
Parandhaman, D.K., Narayanan, S., 2014. Cell death paradigms in the pathogenesis of 
Mycobacterium tuberculosis infection. Frontiers in Cellular and Infection Microbiology 4. 
Parker, A.M., Sheehy, P.A., Hazelton, M.S., Bosward, K.L., House, J.K., 2018. A review of 
mycoplasma diagnostics in cattle. Journal of Veterinary Internal Medicine 32, 1241-1252. 
Perez-Casal, J., Prysliak, T., 2007. Detection of antibodies against the Mycoplasma bovis 
glyceraldehyde-3-phosphate dehydrogenase protein in beef cattle. Microbial Pathogenesis 43, 
189-197. 
Perez-Casal, J., Prysliak, T., Maina, T., Suleman, M., Jimbo, S., 2017. Status of the development 
of a vaccine against Mycoplasma bovis. Vaccine 35, 2902-2907. 
Perez-Casal, J., Prysliak, T., Maina, T., Wang, Y., Townsend, H., Berverov, E., Nkando, I., 
Wesonga, H., Liljander, A., Jores, J., Naessens, J., Gerdts, V., Potter, A., 2015. Analysis of 
immune responses to recombinant proteins from strains of Mycoplasma mycoides subsp. 
mycoides, the causative agent of contagious bovine pleuropneumonia. Veterinary Immunology 
and Immunopathology 168, 103-110. 
  128 
Pfutzner, H., 1990. Epizootiology of the Mycoplasma bovis Infection of Cattle. Recent Advances 
in Mycoplasmology 20, 394-399. 
Pich, O.Q., Burgos, R., Ferrer-Navarro, M., Querol, E., Pinol, J., 2006. Mycoplasma genitalium 
mg200 and mg386 genes are involved in gliding motility but not in cytadherence. Molecular 
Microbiology 60, 1509-1519. 
Pilo, P., Vilei, E.M., Peterhans, E., Bonvin-Klotz, L., Stoffel, M.H., Dobbelaere, D., Frey, J., 
2005. A metabolic enzyme as a primary virulence factor of Mycoplasma mycoides subsp 
mycoides small colony. Journal of Bacteriology 187, 6824-6831. 
Pitcher, D.G., Nicholas, R.A., 2005. Mycoplasma host specificity: fact or fiction? Veterinary 
Journal 170, 300-306. 
Porter, A.G., Janicke, R.U., 1999. Emerging roles of caspase-3 in apoptosis. Cell Death and 
Differentiation 6, 99-104. 
Prysliak, T., Maina, T., Perez-Casal, J., 2018. Th-17 cell mediated immune responses to 
Mycoplasma bovis proteins formulated with Montanide ISA61 VG and curdlan are not sufficient 
for protection against an experimental challenge with Mycoplasma bovis. Veterinary 
Immunology and Immunopathology 197, 7-14. 
Prysliak, T., Van der Merwe, J., Lawman, Z., Wilson, D., Townsend, H., van Drunen Littel-van 
den Hurk, S., Perez-Casal, J., 2011. Respiratory disease caused by Mycoplasma bovis is enhanced 
by exposure to Bovine Herpes Virus 1 (BHV-1) and not to Bovine Viral Diarrhoea Virus 
(BVDV) type 2 Canadian Veterinary Journal 52, 1195-1202. 
Prysliak, T., van der Merwe, J., Perez-Casal, J., 2013. Vaccination with recombinant 
Mycoplasma bovis GAPDH results in a strong humoral immune response but does not protect 
feedlot cattle from an experimental challenge with M. bovis. Microbial Pathogenesis 55, 1-8. 
Qi, J., Guo, A., Cui, P., Chen, Y., Mustafa, R., Ba, X., Hu, C., Bai, Z., Chen, X., Shi, L., Chen, 
H., 2012. Comparative geno-plasticity analysis of Mycoplasma bovis HB0801 (Chinese isolate). 
PLoS One 7, e38239. 
  129 
Radi, Z.A., Caverly, J.M., Dixon, R.A., Brogden, K.A., Ackermann, M.R., 2001. Effects of the 
synthetic selectin inhibitor TBC1269 on tissue damage during acute Mannheimia haemolytica-
induced pneumonia in neonatal calves. American Journal of Veterinary Research 62, 17-22. 
Rahman, M.M., McFadden, G., 2011. Modulation of NF-kappaB signalling by microbial 
pathogens. Nature Reviews Microbiology 9, 291-306. 
Rappuoli, R., 2000. Reverse vaccinology. Current Opinion in Microbiology 3, 445-450. 
Rasheed, M.A., Qi, J.J., Zhu, X.F., He, C.F., Menghwar, H., Khan, F.A., Gang, Z., Zubair, M., 
Hu, C.M., Chen, Y.Y., Chen, H.C., Guo, A.Z., 2017. Comparative genomics of Mycoplasma 
bovis strains reveals that decreased virulence with Increasing passages might correlate with 
potential virulence-related factors. Frontiers in Cellular and Infection Microbiology 7. 
Razin, S., Hayflick, L., 2010. Highlights of mycoplasma research-An historical perspective. 
Biologicals 38, 183-190. 
Razin, S., Jacobs, E., 1992. Mycoplasma Adhesion. Journal of General Microbiology 138, 407-
422. 
Razin, S., Yogev, D., Naot, Y., 1998. Molecular biology and pathogenicity of mycoplasmas. 
Microbiology and Molecular Biology Reviews 62, 1094-1156. 
Redza-Dutordoir, M., Averill-Bates, D.A., 2016. Activation of apoptosis signalling pathways by 
reactive oxygen species. Biochimica et Biophysica Acta 1863, 2977-2992. 
Register, K.B., Thole, L., Rosenbush, R.F., Minion, F.C., 2014. Multilocus sequence typing of 
Mycoplasma bovis reveals host-specific genotypes in cattle versus bison. Veterinary 
Microbiology. 
Register, K.B., Woodbury, M.R., Davies, J.L., Trujillo, J.D., Perez-Casal, J., Burrage, P.H., 
Clark, E.G., Windeyer, M.C., 2013. Systemic mycoplasmosis with dystocia and abortion in a 
North American bison (Bison bison) herd. Journal of Veterinary Diagnostic Investigation 25, 
541-545. 
  130 
Renehan, A.G., Booth, C., Potten, C.S., 2001. What is apoptosis, and why is it important? BMJ 
322, 1536-1538. 
Riedl, S.J., Shi, Y., 2004. Molecular mechanisms of caspase regulation during apoptosis. Nature 
Reviews Molecular Cell Biology 5, 897-907. 
Robinson, K.S., Aw, R., 2016. The commonalities in bacterial effector inhibition of apoptosis. 
Trends in Microbiology 24, 665-680. 
Rodriguez, F., Bryson, D.G., Ball, H.J., Forster, F., 1996. Pathological and immunohistochemical 
studies of natural and experimental Mycoplasma bovis pneumonia in calves. Journal of 
Comparative Pathology 115, 151-162. 
Rodriguez, F., Castro, P., Poveda, J.B., Afonso, A.M., Fernandez, A., 2015. 
Immunohistochemical labelling of cytokines in calves infected experimentally with Mycoplasma 
bovis. Journal of Comparative Pathology 152, 243-247. 
Rosales, R.S., Churchward, C.P., Schnee, C., Sachse, K., Lysnyansky, I., Catania, S., Iob, L., 
Ayling, R.D., Nicholas, R.A.J., 2015. Global multilocus sequence typing analysis of Mycoplasma 
bovis isolates reveals two main population clusters. Journal of Clinical Microbiology 53, 789-
794. 
Rosengarten, R., Behrens, A., Stetefeld, A., Heller, M., Ahrens, M., Sachse, K., Yogev, D., 
Kirchhoff, H., 1994. Antigen heterogeneity among Isolates of Mycoplasma bovis Is generated by 
high-frequency variation of diverse membrane-surface proteins. Infection and Immunity 62, 
5066-5074. 
Ross, R.F., 1973. Pathogenicity of swine Mycoplasmas. Annals of the New York Academy of 
Sciences 225, 347-368. 
Rossetti, B.C., Frey, J., Pilo, P., 2010. Direct detection of Mycoplasma bovis in milk and tissue 
samples by real-time PCR. Molecular and Cellular Probes 24, 321-323. 
Rottem, S., 2003. Interaction of mycoplasmas with host cells. Physiological Reviews 83, 417-
432. 
  131 
Ruhl, S., Broz, P., 2016. The gasdermin-D pore: Executor of pyroptotic cell death. Oncotarget 7, 
57481-57482. 
Sachse, K., Grajetzki, C., Rosengarten, R., Hanel, I., Heller, M., Pfutzner, H., 1996. Mechanisms 
and factors involved in Mycoplasma bovis adhesion to host cells. Zentralblatt Fur Bakteriologie-
International Journal of Medical Microbiology Virology Parasitology and Infectious Diseases 
284, 80-92. 
Sachse, K., Helbig, J.H., Lysnyansky, I., Grajetzki, C., Muller, W., Jacobs, E., Yogev, D., 2000. 
Epitope mapping of immunogenic and adhesive structures in repetitive domains of Mycoplasma 
bovis variable surface lipoproteins. Infection and Immunity 68, 680-687. 
Sachse, K., Pfutzner, H., Hotzel, H., Demuth, B., Heller, M., Berthold, E., 1993. Comparison of 
various diagnostic methods for the detection of Mycoplasma bovis. Revue Scientifique Et 
Technique De L Office International Des Epizooties 12, 571-580. 
Sachse, K., Salam, H.S.H., Diller, R., Schubert, E., Hoffmann, B., Hotzel, H., 2010. Use of a 
novel real-time PCR technique to monitor and quantitate Mycoplasma bovis infection in cattle 
herds with mastitis and respiratory disease. Veterinary Journal 186, 299-303. 
Saelens, X., Festjens, N., Vande Walle, L., van Gurp, M., van Loo, G., Vandenabeele, P., 2004. 
Toxic proteins released from mitochondria in cell death. Oncogene 23, 2861-2874. 
Scheidereit, C., 2006. IkappaB kinase complexes: gateways to NF-kappaB activation and 
transcription. Oncogene 25, 6685-6705. 
Schott, C., Cai, H., Parker, L., Bateman, K.G., Caswell, J.L., 2014. Hydrogen peroxide 
production and free radical-mediated cell stress in Mycoplasma bovis pneumonia. Journal of 
Comparative Pathology 150, 127-137. 
Schwartz, S.M., Bennett, M.R., 1995. Death by any other name. American Journal of Pathology 
147, 229-234. 
  132 
Sharma, S., Citti, C., Sagne, E., Marenda, M.S., Markham, P.F., Browning, G.F., 2015. 
Development and host compatibility of plasmids for two important ruminant pathogens, 
Mycoplasma bovis and Mycoplasma agalactiae. PLoS One 10, e0119000. 
Sharma, S., Markham, P.F., Browning, G.F., 2014. Genes found essential in other Mycoplasmas 
are dispensable in Mycoplasma bovis. PLoS One 9. 
Shi, J., Gao, W., Shao, F., 2017. Pyroptosis: Gasdermin-mediated programmed necrotic cell 
death. Trends in Biochemical Sciences 42, 245-254. 
Shi, Y., 2002. Mechanisms of caspase activation and inhibition during apoptosis. Molecular Cell 
9, 459-470. 
Shimizu, T., Kida, Y., Kuwano, K., 2005. A dipalmitoylated lipoprotein from Mycoplasma 
pneumoniae activates NF-kappa B through TLR1, TLR2, and TLR6. J. Immunol. 175, 4641-
4646. 
Shimizu, T., Kida, Y., Kuwano, K., 2008. A triacylated lipoprotein from Mycoplasma genitalium 
activates NF-kappaB through Toll-like receptor 1 (TLR1) and TLR2. Infect Immun 76, 3672-
3678. 
Sica, A., Allavena, P., Mantovani, A., 2008. Cancer related inflammation: The macrophage 
connection. Cancer Letters 267, 204-215. 
Silke, J., Meier, P., 2013. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and 
inflammation. Cold Spring Harbor Perspectives in Biology 5. 
Simon, H.U., Haj-Yehia, A., Levi-Schaffer, F., 2000. Role of reactive oxygen species (ROS) in 
apoptosis induction. Apoptosis 5, 415-418. 
Slee, E.A., Adrain, C., Martin, S.J., 2001. Executioner caspase-3,-6, and-7 perform distinct, non-
redundant roles during the demolition phase of apoptosis. Journal of Biological Chemistry 276, 
7320-7326. 
  133 
Snowder, G.D., Van Vleck, L.D., Cundiff, L.V., Bennett, G.L., 2006. Bovine respiratory disease 
in feedlot cattle: environmental, genetic, and economic factors. Journal of Animal Science 84, 
1999-2008. 
Sodhi, M., Kishore, A., Khate, K., Kapila, N., Mishra, B.P., Kataria, R.S., Mohanty, A.K., 
Varshney, N., Mukesh, M., 2013. Evaluating suitable internal control genes for transcriptional 
studies in heat-stressed mammary explants of buffaloes. Journal of Animal Breeding and 
Genetics 130, 106-117. 
Soehnlen, M.K., Aydin, A., Lengerich, E.J., Houser, B.A., Fenton, G.D., Lysczek, H.R., Burns, 
C.M., Byler, L.I., Hattel, A.L., Wolfgang, D.R., Jayarao, B.M., 2011. Blinded, controlled field 
trial of two commercially available Mycoplasma bovis bacterin vaccines in veal calves. Vaccine 
29, 5347-5354. 
Somerson, N.L., Purcell, R.H., Taylorro.D, Chanock, R.M., 1965. Hemolysin of Mycoplasma 
Pneumoniae. Journal of Bacteriology 89, 813-&. 
Souza, C.D., Evanson, O.A., Sreevatsan, S., Weiss, D.J., 2007. Cell membrane receptors on 
bovine mononuclear phagocytes involved in phagocytosis of Mycobacterium avium subsp 
paratuberculosis. American Journal of Veterinary Research 68, 975-980. 
Srinivasula, S.M., Ashwell, J.D., 2008. IAPs: What's in a name? Molecular Cell 30, 123-135. 
Stabel, J.R., Stabel, T.J., 1995. Immortalization and characterization of bovine peritoneal-
macrophages transfected with Sv40 plasmid DNA. Veterinary Immunology and 
Immunopathology 45, 211-220. 
Stein, M., Keshav, S., Harris, N., Gordon, S., 1992. Interleukin-4 potently enhances murine 
macrophage mannose receptor activity - a marker of alternative immunological macrophage 
activation. Journal of Experimental Medicine 176, 287-292. 
Sukumaran, S.K., Selvaraj, S.K., Prasadarao, N.V., 2004. Inhibition of apoptosis by Escherichia 
coli K1 is accompanied by increased expression of BClXL and blockade of mitochondrial 
cytochrome c release in macrophages. Infection and Immunity 72, 6012-6022. 
  134 
Suleman, M., Cyprian, F.S., Jimbo, S., Maina, T., Prysliak, T., Windeyer, C., Perez-Casal, J., 
2018. Mycoplasma bovis-Induced Inhibition of bovine peripheral blood mononuclear cell 
proliferation Is ameliorated after blocking the immune-inhibitory programmed death 1 receptor. 
Infection and Immunity 86-77. 
Suleman, M., Prysliak, T., Clarke, K., Burrage, P.H., Windeyer, M.C., Perez-Casal, J., 2016a. 
Mycoplasma bovis isolates recovered from cattle and bison (Bison bison) show differential in 
vitro effects on PBMC proliferation, alveolar macrophage apoptosis and invasion of epithelial 
and immune cells. Veterinary Microbiology 186, 28-36. 
Suleman, M., Prysliak, T., Windeyer, C., Perez-Casal, J., 2016b. In vitro antimicrobial 
susceptibility of Mycoplasma bovis clinical isolates recovered from bison (Bison bison). 
Canadian Journal of Microbiology 62, 272-278. 
Sun, P., Luo, H., Zhang, X., Xu, J., Guo, Y., He, S., 2018. Whole-genome sequence of 
mycoplasma bovis strain ningxia-1. Genome Announcements 6. 
Sundberg, E.J., Deng, L., Mariuzza, R.A., 2007. TCR recognition of peptide/MHC class II 
complexes and superantigens. Seminars in Immunology 19, 262-271. 
Sweeney, S., Jones, R., Patyk, K., LoSapio, C. 2013. Mycoplasma bovis-An emerging pathgen in 
ranched bison (United States Department of Agriculture). 
Tait, S.W.G., Ichim, G., Green, D.R., 2014. Die another way - non-apoptotic mechanisms of cell 
death. Journal of Cell Science 127, 2135-2144. 
Taylor, J.D., Fulton, R.W., Lehenbauer, T.W., Step, D.L., Confer, A.W., 2010. The epidemiology 
of bovine respiratory disease: What is the evidence for predisposing factors? Canadian Veterinary 
Journal-Revue Veterinaire Canadienne 51, 1095-1102. 
Ten Broeke, T., Wubbolts, R., Stoorvogel, W., 2013. MHC class II antigen presentation by 
dendritic cells regulated through endosomal sorting. Cold Spring Harbor Perspectives in Biology 
5-21. 
  135 
Teng, X.C., Hardwick, J.M., 2014. Apoptosis: the extrinsic pathway. Molecular Oncology: 
Causes of Cancer and Targets for Treatment, 353-366. 
Thiaucourt, F., Aboubakar, Y., Wesonga, H., Manso-Silvan, L., Blanchard, A., 2004. Contagious 
bovine pleuropneumonia vaccines and control strategies: recent data. Developmental Biology 
119, 99-111. 
Thiaucourt, F., Bolske, G., 1996. Contagious caprine pleuropneumonia and other pulmonary 
mycoplasmoses of sheep and goats. Revue Scientifique Et Technique De L Office International 
Des Epizooties 15, 1397-1414. 
Thomas, A., Dizier, I., Trolin, A., Mainil, J., Linden, A., 2002. Comparison of sampling 
procedures for isolating pulmonary mycoplasmas in cattle. Veterinary Research Communications 
26, 333-339. 
Thomas, A., Sachse, K., Dizier, I., Grajetzki, C., Farnir, F., Mainil, J.G., Linden, A., 2003a. 
Adherence to various host cell lines of Mycoplasma bovis strains differing in pathogenic and 
cultural features. Veterinary Microbiology 91, 101-113. 
Thomas, A., Sachse, K., Farnir, F., Dizier, I., Mainil, J., Linden, A., 2003b. Adherence of 
Mycoplasma bovis to bovine bronchial epithelial cells. Microbial Pathogenesis 34, 141-148. 
Thomas, C.B., Mettler, J., Sharp, P., Jensen-Kostenbader, J., Schultz, R.D., 1990. Mycoplasma 
bovis suppression of bovine lymphocyte response to phytohemagglutinin. Veterinary 
Immunology and Immunopathology 26, 143-155. 
Thomas, C.B., Van Ess, P., Wolfgram, L.J., Riebe, J., Sharp, P., Schultz, R.D., 1991. Adherence 
to bovine neutrophils and suppression of neutrophil chemiluminescence by Mycoplasma bovis. 
Veterinary Immunology and Immunopathology 27, 365-381. 
Thomas, L.H., Howard, C.J., Stott, E.J., Parsons, K.R., 1986. Mycoplasma bovis infection in 
gnotobiotic calves and combined infection with respiratory syncytial virus. Veterinary Pathology 
23, 571-578. 
  136 
Timsit, E., Arcangioli, M.A., Bareille, N., Seegers, H., Assie, S., 2012. Transmission dynamics of 
Mycoplasma bovis in newly received beef bulls at fattening operations. Journal of Veterinary 
Diagnostic Investigation 24, 1172-1176. 
Tooker, B.C., Burton, J.L., Coussens, P.M., 2002. Survival tactics of M. paratuberculosis in 
bovine macrophage cells. Veterinary Immunology and Immunopathology 87, 429-437. 
Uenoyama, A., Kusumoto, A., Miyata, M., 2004. Identification of a 349-kilodalton protein 
(Gli349) responsible for cytadherence and glass binding during gliding of Mycoplasma mobile. 
Journal of Bacteriology 186, 1537-1545. 
Valdez, K.E., Cuneo, S.P., Turzillo, A.M., 2005. Regulation of apoptosis in the atresia of 
dominant bovine follicles of the first follicular wave following ovulation. Reproduction 130, 71-
81. 
van der Merwe, J., Prysliak, T., Gerdts, V., Perez-Casal, J., 2011. Protein chimeras containing the 
Mycoplasma bovis GAPDH protein and bovine host-defence peptides retain the properties of the 
individual components. Microbial Pathogenesis 50, 269-277. 
van der Merwe, J., Prysliak, T., Perez-Casal, J., 2010. Invasion of bovine peripheral-blood 
mononuclear cells and erythrocytes by Mycoplasma bovis. Infection and Immunity 78, 4570-
4578. 
Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., Vandenabeele, P., 2014. 
Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nature 
Reviews Molecular Cell Biology 15, 134-146. 
Vanden Bush, T.J., Rosenbusch, R.F., 2002. Mycoplasma bovis induces apoptosis of bovine 
lymphocytes. FEMS Immunology and Medical Microbiology 32, 97-103. 
Vanden Bush, T.J., Rosenbusch, R.F., 2003. Characterization of the immune response to 
Mycoplasma bovis lung infection. Veterinary Immunology and Immunopathology 94, 23-33. 
Vasconcelos, A.T., Ferreira, H.B., Bizarro, C.V., Bonatto, S.L., Carvalho, M.O., Pinto, P.M., 
Almeida, D.F., Almeida, L.G., Almeida, R., Alves-Filho, L., Assuncao, E.N., Azevedo, V.A., 
  137 
Bogo, M.R., Brigido, M.M., Brocchi, M., Burity, H.A., Camargo, A.A., Camargo, S.S., Carepo, 
M.S., Carraro, D.M., de Mattos Cascardo, J.C., Castro, L.A., Cavalcanti, G., Chemale, G., 
Collevatti, R.G., Cunha, C.W., Dallagiovanna, B., Dambros, B.P., Dellagostin, O.A., Falcao, C., 
Fantinatti-Garboggini, F., Felipe, M.S., Fiorentin, L., Franco, G.R., Freitas, N.S., Frias, D., 
Grangeiro, T.B., Grisard, E.C., Guimaraes, C.T., Hungria, M., Jardim, S.N., Krieger, M.A., 
Laurino, J.P., Lima, L.F., Lopes, M.I., Loreto, E.L., Madeira, H.M., Manfio, G.P., Maranhao, 
A.Q., Martinkovics, C.T., Medeiros, S.R., Moreira, M.A., Neiva, M., Ramalho-Neto, C.E., 
Nicolas, M.F., Oliveira, S.C., Paixao, R.F., Pedrosa, F.O., Pena, S.D., Pereira, M., Pereira-
Ferrari, L., Piffer, I., Pinto, L.S., Potrich, D.P., Salim, A.C., Santos, F.R., Schmitt, R., Schneider, 
M.P., Schrank, A., Schrank, I.S., Schuck, A.F., Seuanez, H.N., Silva, D.W., Silva, R., Silva, S.C., 
Soares, C.M., Souza, K.R., Souza, R.C., Staats, C.C., Steffens, M.B., Teixeira, S.M., Urmenyi, 
T.P., Vainstein, M.H., Zuccherato, L.W., Simpson, A.J., Zaha, A., 2005. Swine and poultry 
pathogens: the complete genome sequences of two strains of Mycoplasma hyopneumoniae and a 
strain of Mycoplasma synoviae. Journal of Bacteriology 187, 5568-5577. 
Velmurugan, K., Chen, B., Miller, J.L., Azogue, S., Gurses, S., Hsu, T., Glickman, M., Jacobs, 
W.R., Porcelli, S.A., Briken, V., 2007. Mycobacterium tuberculosis nuoG is a virulence gene that 
inhibits apoptosis of infected host cells. PloS Pathogens 3, 972-980. 
Vivona, S., Gardy, J.L., Ramachandran, S., Brinkman, F.S., Raghava, G.P., Flower, D.R., 
Filippini, F., 2008. Computer-aided biotechnology: from immuno-informatics to reverse 
vaccinology. Trends In Biotechnology 26, 190-200. 
Wang, C.X., Youle, R.J., 2009. The role of mitochondria in apoptosis. Annual Review of 
Genetics 43, 95-118. 
Wang, X.D., 2001. The expanding role of mitochondria in apoptosis. Genes and Development 15, 
2922-2933. 
Wang, Y., Taylor, D.E., 1990. Chloramphenicol resistance in Campylobacter coli: nucleotide 
sequence, expression, and cloning vector construction. Gene 94, 23-28. 
  138 
Wang, Y.P., Gao, W.Q., Shi, X.Y., Ding, J.J., Liu, W., He, H.B., Wang, K., Shao, F., 2017. 
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547, 
99-103. 
Wang, Z., Gerstein, M., Snyder, M., 2009. RNA-Seq: a revolutionary tool for transcriptomics. 
Nature Reviews Genetics 10, 57-63. 
Wesonga, H.O., Thiaucourt, F., 2000. Experimental studies on the efficacy of T1sr and T1 44 
vaccine of Mycoplasma mycoides subsp. mycoides (small colony) against a field isolate causing 
contagious bovine pleuropneumonia in Kenya - effect of a revaccination. Reveue d elevage et de 
medicine veterinarie des pays tropicaux 53, 313-318. 
Westberg, J., Persson, A., Holmberg, A., Goesmann, A., Lundeberg, J., Johansson, K.E., 
Pettersson, B., Uhlen, M., 2004. The genome sequence of Mycoplasma mycoides subsp. mycoides 
SC type strain PG1T, the causative agent of contagious bovine pleuropneumonia (CBPP). 
Genome Research 14, 221-227. 
Wherry, E.J., 2011. T cell exhaustion. Nature Immunology 12, 492-499. 
Wiggins, M.C., Woolums, A.R., Hurley, D.J., Sanchez, S., Ensley, D.T., Donovan, D., 2011. The 
effect of various Mycoplasma bovis isolates on bovine leukocyte responses. Comparative 
Immunology Microbiology and Infectious Diseases 34, 49-54. 
Wise, K.S., Calcutt, M.J., Foecking, M.F., Roske, K., Madupu, R., Methe, B.A., 2011. Complete 
genome sequence of Mycoplasma bovis type strain PG45 (ATCC 25523). Infection and Immunity 
79, 982-983. 
Woese, C.R., Maniloff, J., Zablen, L.B., 1980. Phylogenetic analysis of the mycoplasmas. 
Proceedings of the National Academy of Sciences of the United States of America 77, 494-498. 
Woo, S.R., Sotos, J., Hart, A.P., Barletta, R.G., Czuprynski, C.J., 2006. Bovine monocytes and a 
macrophage cell line differ in their ability to phagocytose and support the intracellular survival of 
Mycobacterium avium subsp paratuberculosis. Veterinary Immunology and Immunopathology 
110, 109-120. 
  139 
Wu, G., Chai, J.J., Suber, T.L., Wu, J.W., Du, C.Y., Wang, X.D., Shi, Y.G., 2000. Structural 
basis of IAP recognition by Smac/DIABLO. Nature 408, 1008-1012. 
Yaneva, R., Schneeweiss, C., Zacharias, M., Springer, S., 2010. Peptide binding to MHC class I 
and II proteins: new avenues from new methods. Molecular Immunology 47, 649-657. 
Yang, J., Liu, X., Bhalla, K., Kim, C.N., Ibrado, A.M., Cai, J., Peng, T.I., Jones, D.P., Wang, X., 
1997. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. 
Science 275, 1129-1132. 
Yilmaz, R., Cangul, I.T., Onat, K., Akkoc, A., Ozyigit, M.O., Akdesir, E., 2016. 
Histopathological, immunohistochemical and bacteriological characterization of Mycoplasma 
bovis pneumonia in cattle. Pakistan Veterinary Journal 36, 316-321. 
Zelmer, A., Carroll, P., Andreu, N., Hagens, K., Mahlo, J., Redinger, N., Robertson, B.D., Wiles, 
S., Ward, T.H., Parish, T., Ripoll, J., Bancroft, G.J., Schaible, U.E., 2012. A new in vivo model 
to test anti-tuberculosis drugs using fluorescence imaging. Journal of Antimicrobial 
Chemotherapy 67, 1948-1960. 
Zhang, R., Han, X., Chen, Y., Mustafa, R., Qi, J., Chen, X., Hu, C., Chen, H., Guo, A., 2014. 
Attenuated Mycoplasma bovis strains provide protection against virulent infection in calves. 
Vaccine 32, 3107-3114. 
Zhuang, H., Tian, W., Li, W., Zhang, X., Wang, J., Yang, Y., Liu, X., Xia, Z., Feng, D., Zhang, 
L., 2016. Autophagic cell death and apoptosis jointly mediate cisatracurium besylate-induced cell 
Injury. International Journal of Molecular Sciences 17, 515. 
 
